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Abstract
Modern computational biology is awash in large-scale data mining problems. Several
high-throughput technologies have been developed that enable us, with relative ease
and little expense, to evaluate the coordinated expression levels of tens of thousands
of genes, evaluate hundreds of thousands of single-nucleotide polymorphisms, and
sequence individual genomes. The data produced by these assays has provided the
research and commercial communities with the opportunity to derive improved clini-
cal prognostic indicators, as well as develop an understanding, at the molecular level,
of the systemic underpinnings of a variety of diseases.
Aside from the statistical methods used to evaluate these assays, another, more
subtle challenge is emerging. Despite the explosive growth in the amount of data
being generated and submitted to the various publicly available data repositories,
very little attention has been paid to managing the phenotypic characterization of
their samples (i.e., managing class labels in a controlled fashion). If sense is to be
made of the underlying assay data, the samples' descriptive metadata must first be
standardized in a machine-readable format.
In this thesis, we explore these issues, specifically within the context of curat-
ing and analyzing a large DNA microarray database. We address three main chal-
lenges. First, we acquire a large subset of a publicly available microarray repository
and develop a principled method for extracting phenotype information from free-
text sample labels, then use that information to generate an index of the sample's
medically-relevant annotation. The indexing method we develop, Concordia, in-
corporates pre-existing expert knowledge relating to the hierarchical relationships
between medical terms, allowing queries of arbitrary specificity to be efficiently an-
swered. Second, we describe a highly flexible approach to answering the question:
"Given a previously unseen gene expression sample, how can we compute its sim-
ilarity to all of the labeled samples in our database, and how can we utilize those
similarity scores to predict the phenotype of the new sample?" Third, we describe a
method for identifying phenotype-specific transcriptional profiles within the context
of this database, and explore a method for measuring the relative strength of those
signatures across the rest of the database, allowing us to identify molecular signa-
tures that are shared across various tissues ad diseases. These shared fingerprints
may form a quantitative basis for optimal therapy selection and drug repositioning
for a variety of diseases.
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Chapter 1
Introduction
Modern biology is awash in data mining problems, many of a high-dimensional na-
ture. Several high-throughput technologies have been developed that enable us, with
relative ease and little expense, to evaluate the coordinated expression levels of tens
of thousands of genes [24, 33], evaluate hundreds of thousands of single-nucleotide
polymorphisms [6], and sequence individual genomes [30]. The data produced by
these assays has provided the research and commercial communities with the op-
portunity to derive improved clinical prognostic indicators, as well as develop an
understanding, at the molecular level, of the systemic underpinnings of a variety of
diseases.
Although several of these technologies have been available for a number of years,
there were relatively few samples available, with respect to the number of features
assayed. This is beginning to change, with several government-funded biological data
repositories boasting sample collections numbering in the hundreds of thousands [82,
14]. The accessibility of such large and phenotypically diverse data resources should
eventually enable large-scale data-driven hypothesis generation and testing. This
will necessitate, however, a new generation of data mining techniques that are tuned
to the specific signals generated by these assays, and aware of their inherent technical
and biological noise properties.
Aside from the statistical methods used to evaluate the assays themselves, an-
other, more subtle challenge is emerging. Despite the explosive growth in the amount
of data being generated and submitted to the various publicly-available biological
data repositories (or perhaps because of that growth), very little work has gone into
managing the phenotypic characterization of their samples. If sense is to be made of
the underlying assay data, something must first be done to standardize the descrip-
tive nomenclature used to annotate each sample and data set. If we are to bring
data mining and machine learning methods to bear on these resources, the sam-
ple labeling, which is at present largely based on free-text, must be made machine
readable.
In this thesis, we explore these issues, specifically within the context of curating
and analyzing a large DNA microarray database [83].
1.1 Microarrays
There are three main classes of macromolecules that form the information and phys-
ical superstructures required for life: deoxyribonucleic acid (DNA), ribonucleic acid
(RNA), and proteins [4]. The "central dogma of molecular biology" [27] asserts a
model of information flow between these molecules that closely reflects the biome-
chanical operation of the cell. DNA contains all of the fundamental instructions
required to form a living organism. Those instructions, encoded primarily as genes,
are passed along, via gene transcription, through messenger RNA (mRNA) molecules
that inform the synthesis of proteins, via translation. Those protein end-products
are the organic polymers responsible for directing nearly all of the activity within
living cells.
This arrangement is loosely comparable to that of a modern computer executing
a program. DNA can be seen as the rough (although inexact) analog to a program's
source code: it provides a predefined set of instructions for running a set of algorithms
in response to input. Consequently, the state of the machine's memory is fully
determined by the combination of that source code along with the input supplied to
the program - as the mRNA messages observable at any point in time in a cell are
largely the result of the instructions provided by DNA in response to the environment.
Thus, quantification of mRNA concentrations has become a popular mechanism
for characterizing the molecular state of a cell [5]. Modern DNA microarrays are
capable of measuring the relative expression intensities of tens of thousands of genes
simultaneously. A thorough explanation of microarray technology is beyond the
scope of this thesis, but can readily be found elsewhere [47]. Briefly, microarrays
consist of a set of DNA "probes" bound to a solid substrate over which flourescence-
tagged cDNA copy of the sample RNA is hybridized. After sample hybridization, the
array is scanned, and the relative flourescence of each probe is recorded. Gene-level
transcription levels are then inferred, based on the sequences of the array's probes.
Acceptance of this "high-throughput" technique was inhibited early-on by sev-
eral high-profile studies citing reproducibility problems [88, 61]. Subsequently, how-
ever, many of these inconsistencies were associated with the differences in the cited
array technologies and designs, post-processing normalization and statistical analy-
ses [48, 99, 15, 12], and a number of studies have successfully demonstrated biological
consistency between molecular phenotype signatures derived from high-throughput
array technologies [91].
1.2 Thesis Overview
This thesis addresses three main challenges. First, we acquire a large subset of a
publicly-available microarray repository and develop a principled method for extract-
ing phenotype information from free-text sample labels, then use that information
to generate an index of the sample's medically-relevant annotation. The indexing
method we develop, Concordia, incorporates pre-existing expert knowledge relating
to the hierarchical relationships between medical terms, allowing queries of arbitrary
specificity to be efficiently answered. Second, we describe a highly-flexible approach
to answering the question: "Given a previously unseen gene expression sample, how
can we compute its similarity to all of the labeled samples in our database, and how
can we utilize those similarity scores to predict the phenotype of the new sample?"
Third, we describe a method for identifying phenotype-specific transcriptional pro-
files within the context of this database, and explore a method for measuring the
relative strength of those signatures across the rest of the database.
Chapter 2 discusses generically the problems presented by free-text bio-medical
annotations, and details our approach to building a standardized queryable database
from them. Chapter 3 describes the application of that framework specifically to
the data resources explored in the remainder of this thesis, namely the transcrip-
tional profiles available from NCBI's Gene Expression Omnibus. Chapter 4 presents
a method for using the curated database in a nearest-neighbors-like approach to at-
tribute phenotype to new samples. Chapter 5 describes the relationship between
normal tissue, malignant tissues and stem cells, from the perspective of a highly-
conserved stem cell expression profile derived from our database. Due to the diverse
nature of the content in this thesis, related and previous works are presented inline
with each topic, rather than together in one section.
Chapter 2
Concordia: A UMLS-based Index
of Free-text Documents
The widespread adoption of electronic storage media throughout the medical and
biomedical research communities presents significant new challenges and opportuni-
ties. Current estimates place United States healthcare IT spending in the range of
$7 billion per year [39]. Recent publications have emphasized the utility of these
data resources for genomic research, as well as patient care [46, 100, 65]. By recent
estimates however, only 17% of doctors and 10% of hospitals are currently utilizing
such systems [18]. A variety of programs recently enacted by the US government are
intended to motivate doctors and hospitals to adopt technologies that interoperate
with other parts of the healthcare system by 2015, or face financial penalty in sub-
sequent years [18]. The volume of data generated by this mandate over the coming
years will be tremendous.
In addition to the imminent proliferation of electronic medical records, a variety
of high-throughput biomedical assays have been refined over the past decade, and
more continue to be developed today. It is expected that the data derived from these
assays will eventually be brought to bear on clinical diagnostics as well as therapeutic
drug design. The volume of data available from some of these sources (e.g., NCBIs
Gene Expression Omnibus repository [14]) has already outstripped our ability to
perform large-scale, automated discovery of relevant patterns among records with
shared phenotype. At the time of writing, GEO contained over 600,000 samples, each
associated with a variety of free-text medical and biological descriptions. Moreover,
at present, there exist no systems capable of associating these assay records in a
standardized and meaningful way with relevant EHRs or other clinical narrative.
Such cross-pollenization would enable sophisticated quantitative clinical diagnostic
systems, as well as accelerate the pace of therapeutic innovation.
To our knowledge, there are no open, scalable, standardized systems for cataloging
and searching large volumes of medical data that leverage existing expert knowledge.
Many institutions have developed proprietary in-house solutions that tend to be ad
hoc, lack portability between problem domains (e.g., systems designed for retrieving
medical records cannot be easily adapted to the task of retrieving medical literature)
and require a major technical undertaking. The applications that consume such
services must interact with several different systems that cannot interoperate with
one another in any natural, meaningful way.
One of the main contributions of this thesis is a data indexing system that ad-
dresses these challenges, called Concordia. Concordia is a scalable standards-based
infrastructure for searching multiple disparate textual databases by mapping their
contents onto a structured ontology of medical concepts. This framework can be
leveraged against any database where free-text attributes are used to describe the
constituent records (for example, medical images might be associated with a short
description). While our main focus will remain on indexing the metadata associated
with a large gene expression database (NCBI's GEO), we will mention several other
use cases for such a system.
This system may be used to form the cornerstone backend search tool required to
build portable applications that leverage the wide variety of data-rich resources that
are becoming available. Outside the realm of searching biological sample reposito-
ries this may also help address one of the core challenges in personalized healthcare
practice: identifying clinically distinct subgroups to which a particular patient be-
longs [45].
The remainder of this chapter will consist of a brief description of the conceptual
methods underlying Concordia, and then a brief discussion of implementation details.
2.1 Designing an ontology-based indexing system
Two major challenges arise when indexing free-text medical literature as it appears
in electronic medical records, medical reference volumes or other medical docu-
ments: resolving synonyms and identifying conceptual relationships between medical
terms. We suggest that both of these challenges can be addressed by building a
system around the National Library of Medicines Unified Medical Language System
(UMLS) [?, 66]. UMLS is an ontological organization of medical concepts, built from
various thesauri, such as SNOMED [73], MeSH [51], and RxNorm [53]. Concordia
works by mapping both source documents and user queries into UMLS hierarchically
structured space of medical concepts.
2.1.1 Resolving multiple synonymous terms to unified con-
cepts
Multiple synonymous phrases are often used to describe one common medical or bi-
ological concept. For example, the terms malignant neoplasm of the lung and lung
carcinoma both describe the same medical concept, but there is no agreement on
which term should be used to describe the one underlying concept, a malignant can-
cerous growth appearing in the lung. To see where this becomes a challenge, consider
searching a database for the phrase lung carcinoma where all of the constituent doc-
uments refer to malignant neoplasm of the lung: Searching the database by simple
string matching will fail to find the documents related to the query.
We address this problem by mapping the text content of each entity in the
database to a controlled vocabulary, the UMLS. The UMLS consists of a series of
"biomedical vocabularies developed by the US National Library of Medicine" [66,
19].The purpose of these expert-curated vocabularies is to provide a set of thesauri
that map multiple synonymous phrases to a single unified concept. The collection of
these mappings is called the UMLS Metathesaurus. MetaMap [7], a program that
generates these thesaurus correspondences from free text, is available from the Na-
tional Library of Medicine (NLM), and is the standard tool for such tasks. MetaMap
matches simple syntactic noun phrases from an input text to UMLS concepts, effec-
tively standardizing the text to a set of unique concepts.
In our setting, applying MetaMap to the database entities allows us to alleviate
the problem of resolving synonymous but textually disparate phrases. One of the
major contributions of our approach is the concept that when we later query the
database, we can apply the same standardization to the input query as was used
to transform the original source text, allowing us to search for database entities
matching the query in the structured space of standardized UMLS concepts rather
than free-text. In addition, when the practitioner later wishes to perform large-scale
data mining on such a database, we can treat the UMLS concepts associated with
the database entities as a discrete labeling thereof, without applying ad-hoc text
searches to identify groups of related records.
2.1.2 Mapping documents and queries onto UMLS ontology
of medical concepts
UMLS provides a hierarchical organization of the concepts that it contains. For ex-
ample, the concepts "white blood cell abnormality," "thrombosis," "anemia," and
"hemorrhage" are all among the descendants of the concept "hematological diseases"
in the UMLS hierarchy. Concordia processes free-text user queries with the same
NLP-driven UMLS mapping tool that we use to process the source documents, thus
translating the query task into the simpler job of identifying documents associated
with the concept(s) to which it maps (see Figure 2-2). Continuing the above ex-
ample, any query that maps to the hematological diseases concept should return
documents related to any one (or several) of these four subordinate concepts, even
though the NLP mapping of the documents source text may not have directly hit
hematological diseases. We exploit the expert knowledge encoded in this structure
by storing references to the source documents (e.g., medical records, diagnostic tests,
medical literature) on top of the UMLS hierarchy.
The ontology is manifested as a directed acyclic graph. Each vertex in this graph
stores a pointer to the documents that reference it. This hierarchical structure allows
us to efficiently traverse the ontology and retrieve records related to a particular
concept and its subordinates. For each concept that a query string maps to, we can
thus efficiently (running time proportional to the number of vertices in the subgraph)
return both all of the source documents whose text directly mapped to that concept,
as well as those whose text mapped to some subordinate concept.
In scenarios where traversing each subgraph presents a prohibitive impact on sys-
tem performance, we have also developed a "pre-processing" procedure that enables
faster query response. This procedure first creates a hash table mapping each con-
cept to a list of all of its descendants, as well as another hash table mapping each
concept to a list of all of its ancestors. These hash tables are then used to generate
two additional hash tables: one that maps each concept to a list of all documents
referenced by it or one of its subordinates; and another that maps each document to
a list of the concepts and their ancestor concepts that are hit by the document. Using
these data structures, the query running time for a single concept is constant, rather
than dependent on the size of the UMLS subgraph below it. Of course, this comes
at the expense of the time required to completely traverse the subgraph reachable
from each vertex, as well as the storage space required to persist the results of those
graph traversals.
Figure 2-1: Free text source documents are processed with NLP software that maps them to unified medical
concepts. Queries against those documents are similarly processed with NLP, reducing the query procedure to
matching concepts from the query string against the standardized database.
Utilizing these data structures, we have developed a mechanism in Concordia
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that can efficiently aggregate documents that match arbitrarily complex logical com-
binations of UMLS concepts. We have implemented a standard stack-based algo-
rithm [68] for evaluating infix set logic expressions. Here, the operands are the
set operators (INTERSECTION, UNION, DIFFERENCE) and the arguments are
UMLS concepts. Conceptually, the algorithm works by replacing the stack entry for
each UMLS concept in the expression with the set of database records that reference
it, then proceeding with the logical evaluation as usual. This enables us to perform
free-text queries such as "anemia and cancer" or "lung cancer and metastasis but
not smoking" against the library of documents.
2.2 Concordia implementation details
Traditional relational database systems are typically regarded as more flexible than
hierarchical databases. Such systems index their records based on lexicographical
ordering of key values, irrespective of conceptual relationships that exist between
these keys [26]. Here, however, every query (or precomputed traversal) performed
against the UMLS index will require a traversal of the UMLS topology similar to
the one described in the above. Thus, a hierarchically structured database is more
appropriate than a relational model when indexing documents based on an ontology
such as UMLS.
We designed software for maintaining the persistent hierarchical database in Java,
utilizing Oracles BerkeleyDB JE package. This package allowed us to easily serialize
the in-core data structures manipulated by our search algorithms without the com-
munication overhead incurred when interacting with an out-of-core database service.
To make our Concordia databases accessible to a wide variety of applications, we
implemented both SOAP [90] and XML-RPC [97] services that wrap the Concordia
functionality. These APIs expose two main pieces of functionality: they present the
topology of the UMLS ontology to the client, and present the concept / document
associations to the client. API procedures for reporting all ancestor and descendant
concepts relative to a particular query concept (as well as their respective minimum
hop distance in the UMLS graph), reporting all indexed documents (including those
related to descendant concepts) related to a specified query string, and reporting
all concepts (including ancestors) related to a particular document are implemented
in the current version of the system. We have also implemented an interface be-
tween Concordia and the R statistical programming environment [101] via the rJava
package [102], avoiding the network-induced overhead of the XML-based APIs.
The XML-based APIs (SOAP, XML-RPC) enable out-of-core queries to non-
Java applications. In addition, they allow the database the be hosted on dedicated
hardware, freeing client applications to run anywhere the network protocols allow.
The R API presents a convenient interface to the popular statistical environment.
While rJava is JNI-dependent [40], the overhead incurred therein is less than the
XML-based APIs. For this reason, the R API is preferred when performance is at a
premium, but it is not feasible to develop the entire analysis workflow solely in Java.
In addition, this design, with standards-based APIs surrounding the Concordia
system, allows for a great deal of scalability through data federation. Similar in spirit
to Googles MapReduce methodology [28], queries may be initially processed by a
head node which in turn requests that multiple worker nodes perform the database
search in parallel . Each of these worker nodes would be capable of searching a
separate portion of the database. Results would then be returned to the head node,
aggregated, and returned to the client.
This infrastructure enables us to scale to meet future needs by simply adding
additional worker nodes. Throughput, scalability and fault tolerance may all be
improved by a variety of striping schemes [81]. Although the particular application
of Concordia described in this thesis does not directly rely on this functionality, we





Figure 2-2: The Concordia APIs enable naive data federation to support both fault tolerance and improved total
throughput. A query node serves as an intermediary between the client applications and the data-storing nodes
that each run a separate Concordia instance. That is, each data-storing "worker" node is responsible for storing a
specific subset of the total database. The query node processes client requests and requests that each worker node
process the portion of the query representing the data that it is responsible for managing. Each worker node returns
its portion of the response, and the multiple worker responses are aggregated at the query node, where they are
assembled to be returned to the client application.
2.3 Applications of Concordia
In addition to the database constructed from NCBI's Gene Expression Omnibus that
is described in detail later in this thesis, we note several other likely applications.
NCBI maintains a database of gene-centric annotation data [60]. These annota-
tions explicitly connect each annotated gene to both biological processes and medical
concepts. We have experimented with using Concordia to index these annotations.
Such a resource may be valuable for gene set enrichment-type analyses [95], where
one wishes to understand the broad-stroke disease and tissue concepts most strongly
associated with a predetermined set of genes. We propose replacing the commonly-
used Gene Ontology [8] (or GO) terms in these analyses with UMLS concepts whose
associated genes are learned from the application of Concordia described above.
Data mining electronic health records is becoming an increasingly popular method
for performing pharmacovigilance [100] and genetic studies [46]. By standardizing
the nomenclature of disparate data sources across healthcare IT infrastructure and
research databases, Concordia may enable larger-scale studies to be performed with
minimal overhead.
Concordia is not limited to generating its index based solely on the UMLS on-
tology. The system has been designed to be easily reconfigured to generate an index
over any ontology or acyclic graph. The possible applications of this technology,
therefore span beyond the realm of medical language and knowledge, and it may
prove a useful backend datastore for implementing semantic web applications [41].
Chapter 3
Making NCBI's Gene Expression
Omnibus Machine Readable with
Concordia
This chapter presents a brief overview of NCBI's Gene Expression Omnibus, and
describes how we applied the Concordia framework to construct a machine-readable
index of it. In addition, we will also discuss the handling of GEO's underlying gene
expression intensity data, which will be used throughout the remainder of this thesis.
3.1 Motivation
Our analyses will require a large volume of gene expression (microarray) data ac-
quired from samples spanning a wide range of clinically relevant biological condi-
tions. We have assembled this database from NCBIs Gene Expression Omnibus
(GEO) [13]. GEO contains tens of thousands of human microarray samples derived
from extremely diverse experimental conditions. While the sheer volume of data
available to the public is promising, bringing these resources to bear on structured
analyses presents several challenges [22]. First, the quantitative measurements ac-
quired from the microarrays need to be normalized to be comparable to one another
across data sets [47]. Second, because NCBI has not enforced any organization on
GEOs free-text description fields, significant work must be done to decipher the
relevant phenotype of each sample [22].
3.2 Metadata
GEO serves as a public repository of gene expression microarray data. Each submit-
ted microarray hybridization is, in GEO terminology, called a sample. Each sample
has a set of gene expression intensities associated with it, along with a variety of meta-
data describing the sample phenotype and any relevant treatment information. All
of this metadata is free-text. Samples are grouped into data series, which represent
a collection of related samples, typically derived from the same study / publication.
Further, each sample may be assigned to zero or more data sets, providing an addi-
tional level of phenotypic classification. For example, a researcher publishing a paper
on colon tumors might submit a series to GEO containing colon cancer samples along
with non-malignant colon biopsies to serve as a control (the series metadata would
describe the overall experiment design, and the sample-level annotations would be
expected to provide malignant vs. non-malignant phenotype). Continuing the exam-
ple, a data set might be composed over a subset of these samples, comprising only
those samples derived from patients with a history of inflammatory bowel disease
(this phenotype classification might only be represented at the data set level).
The goal of our automated processing of GEO was to obtain as comprehensive
picture of phenotype as possible for each sample. As such, we associated all of the
relevant free text (sample-, series- and data set-level) available to each sample.
We then removed erroneous phenotype associations caused by this overly-optimistic
strategy manually (see section 3.2.1).
One of the greatest challenges that needs to be addressed when utilizing loosely-
curated resources such as GEO is the lack of standardized nomenclature (see Chapter
2). Specifically, our analyses (described later in this thesis) will seek to cast the activ-
ity of both individual genes and coupled gene modules within the context of multiple
disease and tissue conditions. GEO's samples are described by free-text descriptions
relating to the experimental setup and phenotype of the biological material. In order
to utilize this data for our analyses, we need to construct an index into it based on a
standardized biomedical nomenclature. We employed the previously described Con-
cordia framework to address this challenge. The UMLS thesauri used to construct
the Concordia index were MeSH [51] and SNOMED [73].
3.2.1 Generating high-confidence phenotype labelings
The NLP software that was used to map the samples into the UMLS hierarchy tends
to be overly sensitive [63], picking up unintended text-to-concept associations. For
example, it frequently mistakes certain abbreviations used in a sample's description
for concepts that the author hadn't intended (e.g., any text containing the abbrevi-
ation "mg." gets mapped by MMTx to the concept that represents "Madagascar",
even when the context of the document suggests the author intended it as an abbre-
viation for "milligram"). These are challenges that can be overcome only by training
an NLP algorithm on domain-specific patterns. As a consequence, the concept as-
sociations produced by MMTx represent a good first-pass filter on the text, but
are hardly reliable enough to drive analyses where we require data relating to very
specific phenotypes. Rather than attempting to refine the NLP procedure, we took
a simpler data-driven approach to constructing a high-confidence set of reference
samples.
In addition to these homonym errors, the inclusion of high-level descriptive meta-
data is often a source of false concept associations. For example, the summary text
for GEO series GSE9187 reads:
Transcriptional profiling of human breast cancer cell line LM2, a sub-
line of MDA-MB-231 highly metastatic to lung when injected to nude
mice, to identify the genes that are regulated after the metastasis gene
metadherin is knocked down. Keywords: Genetic modification
Because the NLP software identifies tissue concepts related to both the terms
"breast cancer" and "lung", we need to filter out the unintended association (in this
case lung, since the cell line is actually breast cancer).
In order to assist with the task of manual data curation, we developed a graphical
user interface that allows domain experts to examine the NLP results and both verify
the concept associations, as well as add new ones that MMTx missed altogether. This
tool allows a user to quickly examine and annotate a large number of samples by
grouping samples based on their MMTx-derived annotation. Thus, repeat errors are
easily caught and corrected. Nevertheless, the process of generating a high-confidence
reference set in this manner is tedious.
This tool presents the user with a list of the GEO samples in the database,
grouped by GEO series. The user may select one of these sample identifiers, populat-
ing the remaining UI elements, including fields derived from the sample's associated
series, fields derived from the samples' associated data sets and fields derived from
the sample-level annotations. The UI presents the user with the UMLS concepts as-
sociated with various text fragments from each level of metadata, allowing each one
to be manually verified (see Figure 3-1). A total of 3030 samples (listed in section
7.1) were manually verified. Those samples comprise the data used throughout the
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Figure 3-1: A screen shot of the software designed to allow manual validation of the Concordia-derived UMLS annotation. On the extreme left-hand
side of the interface, there is a list of the CEO samples in the database, grouped by CEO series. The user may select one of these, populating the
remaining fields on the form. the next column to the right contains the CEO fields derived from the sample's associated series. To the right of that are
the fields derived from the samples' associated data sets. To the right of the data set entries are the fields derived from the sample-level annotations.
At the bottom of each column, a list of check-boxes allows the user to manually validate the UMLS concepts associated with various text fragments.
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3.3 Expression Intensity Data
The database is presently comprised exclusively of gene expression samples per-
formed on the Affymetrix HGU-133 Plus 2.0 platform. The original CEL files were
downloaded from GEO and Affymetrixs MAS 5.0 normalization procedure [2] was
performed on each sample. The probe-level measurements were subsequently sum-
marized (mean) at the gene level. This summarization step both helps to reduce
probe-specific noise [47] and to make the database interoperable with a wide vari-
ety of gene-level and protein-level analysis tools. The gene-specific measurements
for each sample were then processed to generate both rank normalized values, and
z-scored log2 transformed values. The ranked data is often useful when mining the
database for phenotypic trends across large sets of samples [47] (e.g., clustering sam-
ples related to particular tumor pathologies, and comparing our database to external
resources, such as data acquired from alternative platforms), whereas the z-scored
data can be useful when looking for more subtle gene-level trends [23] (e.g., detecting
tightly-coupled gene modules [10]).
The MAS 5.0 procedure operates on individual samples without explicitly model-
ing any inter-chip relationships, as opposed to, e.g., the loess or RMA procedures [20].
Our approach of rank or z-score normalizing the MAS 5.0 data has proven adequate
for a wide variety of analyses, while also enabling fast and reliable integration of new
samples into the database without the requirement of reprocessing the entire library
of expression values. Because we have generated gene-level data (as opposed to,
say, platform-specific probe-level data), the data are readily interpretable within the
framework of genetic interactions, protein-protein interaction networks, regulatory
models, gene set / pathway analysis, and all of the publicly available data resources
devoted to them.
Chapter 4
Mapping the Transcriptional State
Space of Cell Identity
The material presented in this chapter is the result of collaboration with Patrick R.
Schmid.
This chapter describes a statistical method that uses our curated GEO Concordia
database for phenotype prediction. The central problem we address here is: Given
a previously unseen gene expression sample, how can we compute its similarity to
all of the labeled samples in our Concordia database, and how can we utilize those
similarity scores to predict the phenotype of the new sample?
While microarray experiments have become commonplace, the transcriptional
landscape of tissue and disease still remains poorly understood. A macroscopic anal-
ysis of 3030 human gene expression samples presented here reveals that biologically
related tissues are highly co-localized within the transcriptional state space. From a
transcriptome-wide perspective, the boundaries between these related tissues overlap
to form a smooth continuum of related phenotypes. By systematically focusing on
restricted regions of this landscape, these boundaries become increasingly distinct,
and additional biologically-meaningful organization is revealed. We have developed
an online resource that uses this structure to provide detailed tissue and disease
phenotype enrichment information for user-submitted microarray samples. We also
show that tissue specific marker genes are activated in localized subspaces, and that
tumor samples, while proximal to their unaffected counterparts, exhibit greater re-
spective expression variance. Furthermore, we see that tumor metastases are often
enriched for phenotypes relating to their tissue of origin. In addition, we provide a
specificity measure for the conventional clinical classification of tissue and disease,
and lay the foundation for large-scale automated clinical prognostication and novel
drug-discovery.
4.1 Background and biological motivation
Although the human genetic code has been successfully sequenced, the comprehensive
transcriptome-wide landscape representing similarities between various tissues and
diseases has yet to be deciphered. Even with the hundreds of thousands of expression
arrays available through public repositories such as NCBIs Gene Expression Omnibus
(GEO) [13] and EMBIs ArrayExpress [71], transcriptional analyses have generally
been limited to isolated pockets of this landscape (e.g., comparison of a diseased
tissue class vs. its normal counterpart). While it is known that the activation
or repression of specific genetic modules plays a role in creating the phenotypic
variances that differentiate various tissue and disease states [87], these programs are
frequently shared based on high-level biological similarities [74, 107]. The topology
of the transcriptional space, as defined by the common vs. unique activation of
these modules in various tissues and diseases, remains unclear. Insight into the
organization of this landscape may provide a quantitative basis for drug repositioning
and design, as well as the practice of personalized therapeutics.
Among the principal challenges for large-scale analyses have been the biological
and measurement noise and biases that characterize each data set [85], as well as
the lack of standardized annotations of tissue and disease characteristics for each
sample [22]. Unlike previous efforts such as Oncomine [78], EBIs Human Gene Ex-
pression Map [58], TiGER [54], BODYMAP [69], BioGPS, and TiSGeD [105] that
address these difficulties by providing gene-centric analyses performed using relative
measures of expression, we took a macroscopic view by combining the results from
3030 microarray samples and explored the global transcriptomic landscape.
Indeed, we see that a macroscopic analysis of the human transcriptome shows that
tissues reside as close neighbors in a smooth continuum in the expression landscape.
Although there are relatively gradual transitions between phenotypes, there is a high
degree of localization of individual phenotypes in expression space. A holistic analysis
of the global expression landscape reveals that the expression locality of phenotypes
provides a key insight to prediction accuracies for clinically meaningful categories
using gene expression.
However, the tantalizing goal of leveraging a large, diverse set of data to auto-
matically classify and prognosticate patients based on biological samples, perhaps
along lines even more clinically relevant than current diagnostic classes [56], has
remained distant. The classification of diseases across studies has either used expres-
sion samples from small numbers of data sets [92] or within relatively homogenous
disease classes [78]. To this end, we take a robust statistical approach that allows
users to obtain detailed tissue and disease labels, as well as an enrichment statistic,
for new, unlabeled microarray sample by mapping it to this expression continuum.
By providing a view into this continuum, we see that malignant tumor samples are
co-located with their unaffected counterparts and that tumor metastases are also
mapped to the location of their primary site.
4.2 Multi-resolution analysis of human transcrip-
tional state space
A multi-resolution investigation of the global transcriptome landscape, as represented
by the first two principal components of the gene expression values of 3030 microarray
samples obtained from GEO, reveals that the expression continuum is first divided
into three distinct landmarks: blood, brain, and soft tissue (Figure 4-1A).






























































Figure 4-1: Multi-resolution analysis of the gene expression landscape. (A) The gene expression landscape, as
represented by the first two principal components of the expression values of 3030 microarray samples separates into
three distinct clusters: blood, brain, and soft tissue. The shading of the regions corresponds to the amount of data
located in that particular region of the landscape such that the darker the color, the more data exists at that location.
Interestingly, the area where the soft tissue intersects the blood tissue corresponds to bone marrow samples, and
where it intersects the brain tissue, mostly corresponds to spinal cord tissue samples. (B) There is a clear separation
of genitourinary tissue samples and gastrointestinal samples in the soft tissue cluster. (C) A closer examination of the
genitourinary and gastrointestinal sub-clusters shows clear localization of phenotypes. (D) Cancerous tissue samples
show greater variance in their expression signals while still remaining proximal to their non-cancerous counterparts.
Tissue specific genes were selected by performing permutation based t tests com-
paring, for example, the log-normalized expression values for the blood samples for
a given gene to the log-normalized expression values of the samples associated with
brain and soft tissue. Each permutation run consisted of computing the t statistic
for the actual labeling of the samples and comparing it to the t statistics produced
when the labels were randomly permuted 200 times while keeping the sample size
distribution constant. To counter the potential influence of sampling bias, this entire
procedure was performed 100 times, each time using only a random 75% of the data
for each tissue type. Genes that were deemed significant were those that had a false
discovery rate corrected p-value of 0.05 or lower in all 100 runs. The genes were then
sorted such that a gene that had a larger difference in means between the pheno-
types was ordered before those that had a smaller difference. GO enrichment was
performed on the top 50, 100, and 250 genes for each tissue type using FuncAssociate
2 [17]. We report only the GO terms that had a resampling-based p-value less than
0.05.
As to be expected, when analyzing the tissue specific characteristics of the clusters
for marker genes we see the over-expression of genes such as COL3A1, COL6A3,
KRT19, KRT14, and CADHI in the soft tissue cluster and GFAP, APLP1, GRIA2,
PLP1, and SLC1A2 in the brain cluster (Figures 4-2 - 4-4). GO enrichment analysis
of these tissue specific genes further points to over-enrichment for terms related
to each of the three tissue types (see Supplemental Tables (Chapter 7) 7.2 - 7.4).
Interestingly, many spinal cord tissue samples lie at the intersection of the brain and
soft tissue clusters, while bone and bone marrow samples lie at the intersection of
the blood and soft tissue clusters. Although there have been several reports that
data from different datasets are not comparable as the dataset (aka batch) signal
is dominant [70, 77], we find that the tissue signal is dominant in this macroscopic
view of the transcriptome (see Section 4.4).
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Figure 4-3: Expression intensity distribution of the top 20 overexpressed brain tissue genes. Each plot corresponds
to the kernel density estimate of expression values for the gene named above each plot for the three broad tissue
types, blood, brain, and soft tissue. We see that the expression values of brain specific genes such as GFAP, APLP1,
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Figure 4-4: Expression intensity distribution of the top 20 overexpressed blood gen
es. Each plot corresponds to
the kernel density estimate of expression values for the gene named above each plot for the three broad
 tissue types,
blood, brain, and soft tissue. We see that that the expression value of brain specific genes such as H
BM, PPBP,
VNN2, SELL, and NFE2 are markedly higher in samples corresponding to blood than
 in samples of the other two
types.
Mirroring the properties of the full transcriptome landscape, a multi-resolution
examination of the soft tissue cluster reveals not only that the tissues inhabit distinct
locations in the transcriptome landscape, but also the co-localization of functionally
related tissues. This co-localization of related tissues forms a smooth expression
continuum in which there are phenotypic hotspots but also a gradient where the
tissues mesenchymal in origin are on one side, while the more epithelial tissues are
on the other. As depicted in Figure 4-1B, the tissues from the respiratory system, the
lower gastrointestinal tract, and oral soft tissue together form a distinct sub-region
in the smooth landscape, but also reside in their own confined neighborhoods within
that sub-region. Juxtaposed to the soft lining epithelial tissue, which has relatively
high rates of cell replication, the less mitotically active tissues of the genitourinary
system can be found. Further limiting the investigation to only the soft lining tissue
reveals clear co-localization of related tissue such as colon, intestinal mucosa, and
stomach in one part of the transcriptomic topography, and tongue, esophagus, and
dentition in another.
Unlike phenotypically normal tissue, the genetically altered state of malignant
tissue causes a change in the placement of cancerous tissue in the expression land-
scape within the confines of the three major clusters. Similar to the high-resolution
findings of Lukk et al. [58], we see a shift of the tumorous samples away from the fully
differentiated state of normal tissue. We further find that, for example, cancerous
genitourinary samples no longer are distinctly localized to hotspots at the periphery
of the soft tissue cluster, but rather become intermingled with one another, causing
greater overlap between the phenotypes in the continuum (Figure 4-1C). Indeed, this
lack of specificity is also evident in the decrease in correlation between normal tissue
samples and their corresponding cancerous tissue samples (Table 4.1).
Table 4.1: The change in correlation between normal and cancerous tissue samples. Each value in the table
corresponds to the mean correlation between all samples with the given phenotype. We see that the correlation
between normal tissue samples is generally higher than the corresponding correlation of cancerous tissue pointing
toward a loss of differentiation. This loss of correlation may be attributed to the loss differentiation in tumor tissue
causing a more variance in gene expression.












4.3 Predicting phenotype with the Concordia GEO
database
We developed a principled statistical approach that utilizes the previously discussed
high degree of correlation between samples of similar phenotype to associate previ-
ously unseen gene expression samples with Unified Medical Language System (UMLS) [19]
concepts. In particular, we employ a database of samples that we have previously
labeled with UMLS concepts through both an automated, natural language process-
ing method and hand curation (see Chapter 3). Due to the domain of the data, we
filtered the concepts down to only those that are descendants of either Disease or
Anatomy, resulting in a total of 1489 unique concepts. Our method then calculates
the UMLS concepts most likely to be related to the given input by assessing the
over-enrichment of those concepts in nearby database samples (Figure 4-5).
4.3.1 UMLS concept enrichment score calculation
We use the database of gene expression samples to assess over-enrichment for partic-
ular disease- and tissue-specific signals. Given a new expression profile, for each con-
cept represented in the database, we calculate a statistic that measures the strength
of association between the sample and concept, as implied by its similarity to the
labeled database samples.
We measure the similarity of the new expression profile to those contained in the
database by computing the Spearman rank correlation, p, between the profile and
all database samples. Previous work by Adler et al. [1] shows that using correlation
yields favorable results for finding similar gene expression samples in the context of
computing co-expression. For a particular concept, we then calculate an enrichment
score that measures the difference between the distributions of correlation coefficients
for the database samples that map to the concept versus those that do not map to
the concept. Our enrichment score is similar to the normalized Kolmogorov-Smirnov
statistic that lies at the heart of the Connectivity Map [49] ranking of drug similarities
and the Gene Set Enrichment Analysis procedure [96].
Algorithmically, the statistic is calculated as follows: First, the database con-
sisting of n curated expression samples {Si, s2, s3 , ..., s} is sorted (in decreasing
order) according to each observations Spearman correlation with the new profile.
Let s' , s, -.., s'n represent the samples ordered according to their correlation coef-
ficients Psi', Ps2 1, pS3', , p,1,. For a given concept c in the set C, the set of all UMLS
concepts in our database, let Sc be the set of all database samples associated with
the concept. That is, Sc = {siIsi is associated with c}. We define an ordered list of
x values:
1+p2g/
zi= 2 , when sample si/ is associated with concept c, and
-1
i for all other samples that are not associated with concept c
n - |Sc|
Intuitively, when ssi is associated with the concept in question, the xi value
corresponds to the fraction of total correlation between the new sample and all
database samples associated with the concept. All of the xi values for the concept
hits sum to 1, and all of the xi values for the concept misses sum to -1.
Then we compute a running sum of xi across all n database samples and take the
maximum value achieved by this running sum as our enrichment score (ES) for the
concept in question:
ESe = max zi
1jn1<i<j
This sum across all n samples is zero. We are interested in concepts where there
is strong positive deviation from 0. These are the concepts whose associated samples
are more highly correlated with the new profile than those samples that are not
associated with the concept.
In this manner, we are able to localize new gene expression data in the context of
the existing gene expression landscape. It is noteworthy that no hard boundaries are
drawn when a new input sample is labeled, but rather the concepts pertinent to the
transcriptomic context for the input sample are reported. To illustrate its function,
we provide an online tool that allows users to input their own microarray samples
performed on the Affymetrix HGU-133 Plus 2.0 array and obtain their over-enriched
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Figure 4-5: A user submits a gene expression profile to the database that then computes the similarity to all other
samples in the database. Based on the similarity, an enrichment score is computed for each UMLS concept for which




4.3.2 Quantifying performance of the enrichment strategy
To demonstrate the quality of the concept associations produced, we performed leave-
one-sample-out cross-validation and computed the receiver operating characteristic
(ROC) curve for each of the tissue and disease UMLS concepts. We use the the area
under the ROC curve (AUC) as a summary statistic for each concept represented in
the database. The ROC curves represent the full spectrum of performance charac-
teristics available under a variety of ES thresholds. We compute the ROC curves for
each concept as follows.
For each concept c in the database, we iteratively leave out each sample s, and
compute ss enrichment score for c using the remaining samples in the database. The
samples are then sorted from highest to lowest by their enrichment score for c. By
walking down this list of sorted samples we calculate the running true- and false-
positive counts. The true-positive (TP) count is incremented if the ith sample in
the list is actually labeled with concept c. If the sample is not labeled with concept
c, the false-positive (FP) count is incremented. At each position i, the TP and FP
are divided by the number of known positives and negatives (respectively) to obtain
the true-positive rate (TPR) and false-positive rate (FPR). By plotting the TPR vs.
FPR we obtain the ROC curve. The larger the area under the ROC curve (AUC), the
greater the gene expression signal for that concept, as the samples with the highest
enrichment scores for the concept were truly labeled with that concept.
When using this method to label a new sample, we compute its ES (w.r.t. the
entire database) for each concept. We then report the system's estimated FPR for
each concept at the samples observed concept-specific enrichment score. These FPR
values are derived from the running statistics used to generate the ROC plots: simply
look up the new samples score position in the list of sorted scores, and report the
FPR at that position (or the next-lowest score, i.e., next-worst FPR, if there is not
an exact match among the database scores).
We see an average accuracy of 92.8% (AUC value of 0.928) after restricting the
set of UMLS concepts to the 1209 that have samples from two or more expression
series in GEO to ensure that a diverse set of data is used. Even when we restrict the
concepts to the 450 that have at least 50 distinct samples originating from at least
five different data series, the average accuracy is approximately 89.8%. Table 4.2
contains the performance of a selection of UMLS concepts, along with the number
of samples and series that were associated with that concept, and the depth of that
concept in the UMLS hierarchy. The complete list of performance values can be
found in Supplementary Tables (Chapter 7, Table 7.1) . It is important to note that
many of these concepts are highly correlated and share some or all of the database
samples. As a direct consequence, many of the concepts have similarly high (or low,
respectively) AUC values.
Table 4.2: Area under the curve for selected UMLS concepts.
Concept UMLS AUC Number Number of
Depth of Series Samples
Malignant Neoplasms 3 0.82 74 855
Malignant neoplasm of breast 3 0.97 9 69
Malignant neoplasm of ovary 4 0.99 4 51
Malignant neoplasm of lung 4 0.97 4 98
Leukemia 3 0.99 13 151
Stem cells 2 0.93 19 179
Pluripotent Stem Cells 3 0.996 5 53
Soft Tissue 2 0.69 98 1513
Breast 2 0.93 13 195
Ovary 3 0.95 8 103
Lung 2 0.95 9 131
Inflammatory disorder 1 0.79 13 91
Rheumatoid Arthritis 3 0.93 7 31
Inflammatory Bowel Diseases 4 0.99 2 24
Our approach employs a non-parametric enrichment statistic that only requires
the labeling of the samples in the gene expression database and therefore can be
updated in real-time without having to retrain the database. Moreover, as "normal
control" is hard to define in a clinical setting [57, 64, 75], we also ensured that
this approach does not require case-control type input and, but rather just a single
microarray sample.
We see a significant increase in accuracy of the concept associations as more data
is added to the underlying database. In an effort to quantify this effect, we computed
the classification accuracy of each concept when the number of samples that were used
to compute the enrichment score for that given concept was set to 50%, 60%, 70%,
80%, and 90%. For example, using all 69 samples for "Malignant neoplasm of breast"
yields an accuracy of 96.5%. Then, keeping all else constant, we randomly removed
half of the "Malignant neoplasm of breast" samples and recomputed the enrichment
score. This random re- computation was performed five times for each concept at each
threshold. In the case of "Malignant neoplasm of breast," for instance, the average
accuracy across the five runs using only 34 samples is a mere 37%. We see that the
average accuracy across all concepts drastically increases from 44% to roughly 93%
when increasing the amount of data used (Figure 4-6). It is also noteworthy that
the concepts that are the most susceptible to change are "specific" concepts (e.g.,
"Pluripotent stem cells" [48% to 99% accuracy] and "Myeloid Leukemia" [49% to
99% accuracy]), while the classification accuracy of the broad topics (e.g., "Structure
of soft tissues of abdomen" [27% to 56% accuracy]) never improve drastically, as the
underlying gene expression values are so diverse.
This implies that the power of this type of macroscopic analysis increases with
the amount of underlying data, thereby enabling better biological quantification of
the phenotypic signal, and that a system such as this could be deployed in a clinical
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Figure 4-6: Improvement of accuracy of the enrichment statistic with the increase of data in the database. (A)
Density estimate of the performance of the method over various amounts of data. (B) The average AUC values over
all concepts when varying the amount of data used to compute the enrichment scores. For example, when using only
50% of the data for a given concept, the average AUC drops down to 42%.
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4.4 A discussion on "batch effects"
There have been several reports that data from different datasets are not comparable
as the dataset (aka batch) signal is dominant [70, 77]. While the localization of phe-
notypes as seen in the expression landscape (Figure 4-1), regardless of series of origin,
depicts the lack of a dataset effect in principal component space, the cross-validation
performance shows that this phenomenon holds true when all gene expression data is
considered. Although the area-under-the-curve (AUC) and receiver operating char-
acteristic (ROC) curves are generally used to quantify the performance of classifier,
they can also be used as a proxy to quantify the significance of a batch effect. As
high AUC values can only be attained through accurate identification of phenotypes
in cross-validation, it is a necessary precondition for samples associated with a given
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Figure 4-7: The ROC curve for leukemia depicts a lack of batch effect. The colors plotted along the curve correspond
to the series of origin for each of the samples used to generate the curve. The intermingling of series points to the
robustness of the phenotypic signal: samples with the same phenotype cluster together before all other phenotypes,
and samples from different data series are intermingled within a phenotype.
In addition, by associating the series of origin for each sample used to generate
the ROC plot, we can visually inspect the degree of the batch effect by the clustering
of the samples from these series. For instance, the ROC curve for the concept
"leukemia" (Figure 4-7) shows that: 1) samples with the phenotype, regardless of
dataset, are closer to the other samples with the same phenotype, and 2) samples from
various datasets are intermingled. The leukemia samples were more closely related to
other leukemia samples with a mean intra-phenotype, inter-series correlation of 0.1
higher compared to other samples within their own dataset that were non-leukemia
samples (inter-phenotype, intra-series). We see that this trend is evident in the ROC
curves across all types of phenotypes. Intuitively, if this were not the case, not only
would the AUC values for concepts that have samples from multiple series have to be
substantially lower than those with fewer series, but also the phenotypic localization
evident in the transcriptome landscape would have been overshadowed by dataset
localization.
In an effort to quantify the dataset effect (DE) from the correlation structure of
the gene expression samples used in the construction of the transcriptome landscape,
we compared the mean difference in correlation between all samples in a series with
the phenotype to all other samples in other series with that phenotype to the mean
difference in correlation of samples with a given phenotype in a series against all
other samples in that series without the phenotype. In the event that the signal
from the data series is greater than that of the phenotype, one would expect that
the intra-series correlation between differing phenotypes is greater than the inter-
series correlation between samples corresponding to identical phenotypes. The p-
values were computed by randomly shuffling the phenotype labels on the samples and
computing the dataset effect 100 times for each tissue type. The empirical p-value
was determined by finding the position in the sorted list of sampled dataset effect
values. The majority of the tissues for which sufficient data was available (at least
two series with the phenotype, and at least one series containing both the phenotype
of interest and at least one other phenotype), do not exhibit the existence of a batch
effect. For example, across 6 series with normal prostate tissue, the correlation of
prostate samples to other prostate samples in other series is on average 0.17 higher
than the correlation of those samples to other samples within their own series. In the
few instances where the correlation within the dataset is higher, it generally is due
to the highly similar nature of the samples and that the tissue signal dominates the
disease signal. In the case for the blood series, for instance, normal blood is being
compared to diseased blood. Table 4.3 provides these numbers for all tissues that
are represented in the tissue relationship network such that a negative batch effect
implies that the phenotypic signal dominated the dataset signal
Table 4.3: Area under the curve for selected UMLS concepts.
Tissue Dataset Effect p-value
Spleen -0.22 0
Esophagus -0.2 0
Salivary Glands -0.2 0
Cerebellum -0.18 0
Prostate -0.17 0
Lymph Node -0.17 0
Myometrium -0.14 0
Tongue -0.14 0
Liver and/or Biliary Strue- -0.14 0
ture
Kidney -0.13 0
Skeletal Muscle -0.12 0
Spinal Cord -0.11 0
Stomach -0.11 0
Endometrium -0.11 0
Spinal Nerve Structure -0.1 0
Heart -0.1 0
Brain -0.08 0










Bone Marrow -0.01 0






4.5 Using the Concordia-based phenotype enrich-
ment statistics to identify the primary site of
tumor metastases
By mapping a tumor metastasis tissue sample onto the gene expression landscape, we
provide an unbiased measure of its phenotypic predisposition based on gene expres-
sion. It is commonly known by pathologists that tumor metastasis samples resemble
the tissue of the primary site rather than that of a tissue in the metastasized loca-
tion. Nevertheless, the proper identification of the primary site of a metastasis can
be critical in determining the appropriate clinical treatment plan [21, 42, 43, 103]. In
conjunction with clinical and pathological investigation, the origin of metastatic tu-
mors can currently be identified by immunohistochemistry (IHC), computed tomog-
raphy (CT) scans, and position emission tomography (PET) scans. Various primary
site prediction methods have been proposed including a panel of antibodies [72],
CT and PET scans [76], and other gene expression-based methods. Bridgewater,
et al. [21], for example, proposed an algorithmic method for identifying the origin
of metastases by employing a nearest-neighbor method to look up the five nearest
neighbors of an input gene expression sample in the commercial CupPrint database
(www.agendia.com) for carcinomas with an unknown primary site.
Indeed, we find that even without the use of specially tuned primary site detection
method as proposed by others [21, 84], metastatic tissue samples lie in the vicinity
of their tissue of origin in the global continuum of the gene expression landscape.
For instance, using the metastasized breast cancer samples from Zhang, et al. [108]
(GSE14107), we see that all of the metastases, regardless of whether they were
removed from the lung, brain, or bone, more closely resemble breast tissue than their
biopsy locations (Figure 4-8A). Some of the over-enriched UMLS concepts include
"White Adipose Tissue," "Subcutaneous Fat," "Subcutaneous Tissue," "Lactiferous
duct," "Mammary lobe," and "Glandular structure of breast". 15 of the 17 colorectal
cancer samples from GSE10961 (Figure 4-8B) were all labeled with "Rectum and
sigmoid colon," "Colonic Diseases, Functional," and "Colon carcinoma" with a false
positive rate of below 0.05; the other two samples had a FPR of 0.06 for "Colon
Carcinoma."
Those metastases that were mislabeled provide a measure of the unbiased de-
gree of overlap between these metastases, reflecting the lack of hard boundaries in
the smooth continuum of the transcriptomic landscape. This is particularly evident
within the soft-tissue cluster (bottom left of Figure 4-8A-D), in which the tissue spe-
cific signal can be dwarfed by the larger variances caused by the blood and brain tis-
sue samples. Although the use of a supervised learning approach, such as in Schaner
et al. [84], could mitigate these issues and be used to identify the tissue of origin,
these approaches minimize the significant biological overlap of some of these samples,
which may have implications for therapeutic selection [31]. Thus, for example, our
approach appropriately does not label brain metastasis samples (GSE14108) with
brain descriptors, yet a transcriptome-wide approach such as ours that encompasses
samples ranging from normal tissue to blood samples from autistic patients, cannot
label them with the correct primary epithelial site other than correctly identifying it
as a form of adenocarcinoma (Figure 4-8C). Similarly, due to the close proximity of
breast and ovarian tissue samples in the transcriptomic landscape, we had trouble
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Figure 4-8: Principal component analysis shows that metastatic samples more closely resemble their primary sites.
Along with the concept enrichment, the first two principal components of the gene expression data show that the
gene expression signature of tumor metastases more closely resembles that of their primary site location than that
of their metastasized sties. (A) Breast tumors that metastasized to the lung, brain, and bone still appear to be more
closely related to other breast samples than to their metastasis sites. (B) Colon tumors that metastasized to the liver
lie proximal to colon tissue and are enriched for concepts such as Rectum and sigmoid colon and Colon carcinoma.
(C) While we were not able to correctly identify the exact primary site location, the lung adenocarcinoma samples
that metastasized to the brain look nothing like brain tissue that is located in the top right cluster (see Figure 1).
(D) In the context of the entire transcriptome landscape, there is significant overlap in breast and ovarian tumor and





We have illustrated a detailed map of the relative locations of diseases and tissues
in the smooth continuum of the expression landscape using a publicly-available,
broad and heterogeneous expression data set. Given merely gene expression data,
we are able to recapitulate the biological and medically relevant concepts relating
to the underlying genetic processes. It is also encouraging to see that the power
of macroscopic analysis increases with the size of the data, confirming the value of
maintaining large, public gene expression databases. The topographical structure of
the expression landscape can in and of itself provide key insights into the biomedical
similarity of tissues and diseases and can offer valuable knowledge of topics ranging
from gene expression study design to treatment of diseases. Clinical applications of
this approach could effectively be used to more accurately and consistently annotate
clinical samples and provide an impartial view of the landscape of clinico-pathological
classification. In addition to pointing out differences between tissues and diseases,
our approach provides an unbiased perspective on the overlapping biology of dis-
eases with the attendant implications for therapy selection in personalized medicine.
The ability to use gene expression to automatically classify and prognosticate pa-
tients based on biological samples may be facilitated by a better understanding of
the genetic landscape in relation to the conventional clinical classification of dis-
ease. Although not meant as a replacement for a skilled clinician or pathologist,
this unbiased transcriptome-wide perspective may aid clinicians in identifying the
primary sites of metastases and can provide another possible clinical application of
this system. Alternatively, it could be used to error check human annotations by
analyzing the concordance of the gene expression signatures of the patient with the
textual information provided by the clinician. Since it makes use of an enrichment
statistic that only requires the usual standard of care in the labeling of the sample,
this system could be deployed in a clinical setting with minimal alteration of normal
procedures.
As suggested by some [56], systematic application of molecular pathology mea-
surements will allow a useful shifting of the conventionally employed diagnostic clas-
sification boundaries to include the notion that there are intermediate pathotypes
that cross the boundaries of the conventional medical classifications. These inter-
mediate pathotypes are more closely coupled to the actual underlying pathology,
thus revealing not only shared pathology but also opportunities for development of
shared treatment [31, 35]. It may be the case that the gene expression signatures
of disease provide clues to a disease network [11] other than what classical medical
knowledge dictates, thus providing new insights into relationships between diseases
that previously were unknown. Used as part of a larger diagnostic pipeline that
incorporates environmental, genomic, and phenotypic factors as input, mapping ex-
pression samples onto the transcriptomic landscape can provide genomic contextual
information to the clinician when determining a diagnosis and for developing suitable
therapeutics.
Due to the data-driven nature of the method, changing the scope or domain of
the labels on the gene expression samples in the database allows the method to be
applied in different contexts. Although we have presented the accuracy of the system
across various UMLS concepts as a measure of the performance of the system for
classification, the primary goal of this method is to provide contextual information
of a new gene expression sample. By shifting the current gene expression analysis
paradigm of what makes this sample unique? to what other samples am I similar to
so that similar treatment can be administered, we hope to address one of the key
requirements of the performance and development of personalized medicine.
Chapter 5
Core Stem Cell Transcriptional
Activity and Cancer Signatures
This chapter describes an in-depth transcriptional analysis using the Concordia
framework. We first identify a highly-conserved stem cell transcriptional profile,
then go on to explore the extent to which these expression characteristics are present
in a diverse set of normal tissue and malignancy samples. While these results rep-
resent an example of the type of large-scale analysis that can be performed with
little overhead using the Concordia framework, they also contribute novel biological
insight to the ongoing debate about the role played by stem cells in the progression
of a variety of cancers.
Understanding the fundamental mechanisms of tumorigenesis remains one of the
most pressing problems in modern biology and translational medicine. While the
cancer stem cell hypothesis presents a compelling model of self-renewal and partial
differentiation, the relationship between tumor cells and normal stem cells has re-
mained unclear. Here, we present a comprehensive analysis of the mRNA expression
profiles derived from a heterogeneous set of normal human tissues, cancers and stem
cells. We identify, in an unbiased fashion, transcriptional activity that is associated
with pluripotent stem cells and then use this profile to derive a quantitative measure
of stem cell-like gene expression activity. We show how this signature stratifies a
diverse gene expression dataset according to the samples relative plasticity and dif-
ferentiation, from ES and iPS cells, to partially committed multipotent stem cells
and immortalized cell lines, to solid and hematopoietic cancers, and ultimately fully-
differentiated non-diseased tissue. This stem-like signature also serves as a proxy for
tumor grade in a variety of solid tumors, suggesting potential therapeutic implica-
tions. Our results expand upon the growing link between genes associated with stem
cells and their role in a diverse set of cancers.
5.1 Biological overview and motivation
There have been numerous investigations, from a variety of perspectives, into the re-
lationship between normal organogenesis programs and malignancy, particularly with
respect to the stem cell properties of self-renewal and pluripotentiality [86, 94, 80].
At the molecular level, certain malignant tumors and developing tissues have been
shown to exhibit shared transcription factor activity, regulation of chromatin struc-
ture and signaling characteristics [67]. Stem cell-like enrichment patterns for well-
characterized gene sets have been observed in breast cancers as well as bladder can-
cers and poorly differentiated glioblastomas [16]. Stem cell populations have been
identified that are specific to individual tissues, yet share some of the same gene ex-
pression characteristics of embryonic stem cells. Similarly, diverse malignancies have
been shown to share broad gene expression programming while also maintaining tis-
sue specific characteristics. Multiple controversies continue to circulate around the
role of particular genes in stem cells vs. differentiated tissues (e.g. N-cadherin [50]),
and the extent to which the activation of various stem cell-like programs and path-
ways occurs across various tissues and diseases.
The cancer stem cell hypothesis asserts a model of tumorigenesis that may tie
some of these observations together. The theory suggests that only a small frac-
tion of tumor cells (cancer stem cells) maintain the ability to self renew, with the
majority of a tumors mass composed of the progeny of these stem cells, themselves
lacking proliferative potential [104]. This model implies a hierarchical organization
of tumorigenesis that closely reflects normal tissue development, thus accounting for
the high degree of functional heterogeneity observed in solid tumors [44, 29]. Under
these assumptions, expression profiles derived from resected tumor samples (compris-
ing both the hypothesized cancer stem cells and their progeny) would be expected
to broadly resemble those of the normal tissue of origin, with a degree of stem cell
like activity also apparent.
Originally identified in hematopoietic cancers [36], leukemic stem cells were ob-
served to express several markers in common with normal stem cells. Subsequently,
analogous models have been developed for a number of solid tumors (e.g., brain [89],
breast [3], skin [34], ovarian epithelial [9], prostate [25], bone [38], and colon [79]
cancers), primarily through the identification of a small population (typically < 5%)
of tumor cells that were unique both in their expression of a set of specific surface
markers as well as their ability to induce phenocopies of their original tumors in
xenograft and transplant models.
Although the cancer stem cell model and the experimental approach to identify-
ing cancer stem cell populations have been replicated across a variety of tissues, the
exact molecular signatures derived from the proliferative cells have varied widely.
As yet, the extent to which there exist any molecular fingerprints commonly at-
tributable to multiple types of cancer stem cells remains unclear. For example,
leukemia stem cells have been identified by a CD34+CD38- phenotype shared with
hematopoietic stem cells [55], while brain cancer and colon cancer stem cells have
been isolated among CD133+ cells [89, 79]. Breast cancer stem cells have been de-
fined by a CD44+CD24- phenotype [3], while prostate cancer stem cells have been
isolated from minority CD44+/Ga2 h/CD133+ populations [25]. Bone sarcoma cells
with proliferative potential have been shown to express activated Stat3 [38]. These
cells also expressed a subset of the embryonic stem cell-associated genes (Oct3/4,
Nanog) [106], but again, the degree to which these trends may be apparent across
other populations of cancer stem cells is unknown.
The increasing volume of evidence supporting a pervasive connection between
cancer and stem cells suggests significant therapeutic implications. Current therapies
are evaluated based on their ability to reduce the overall size of a tumor. Regimens
that target cancer stem cells, however, may have more success in preventing long-term
recurrence [104]. Molecular signatures that are capable of grading pluripotentiality
and proliferative potential represent an important step in designing such regimens
and guiding therapeutic procedures.
Indeed, gene expression signatures derived from breast cancer stem cells have
been shown to separate patients with early-stage breast cancer into high-risk and
low-risk groups [52]. Similar methods with broad applicability will pave the way
for individually tailored treatment strategies. Enrichment for stem cell-specific hand
curated gene sets has been demonstrated in aggressive breast tumors, as well as blad-
der carcinomas and glioblastomas [16]. Diverse malignant tissue samples have been
shown to exhibit a broadly similar trend within a large gene expression database [58],
but no specific connection has been made in this context to stem cell-like activity.
Here, we present a structured perspective on a diverse compilation of gene ex-
pression samples that reveals a robust multidimensional continuum from ES / iPS
cells to fully differentiated tissues. Our results indicate that, within this functional
genomic landscape, cancers display a combination of stem cell-like programming and
tissue-specific signatures. We derive a shared molecular measure of pluripotentiality
that may help bridge the gap between the disparate cell-type-specific markers as-
sociated with individual cancer stem cell populations and their shared proliferative
potential. In addition, we demonstrate that our differentiation and pluripotentiality-
centric view of gene expression correlates with classical grading systems for a variety
of solid tumors, suggesting that our results may form a quantitative axis with prac-
tical relevance to personalized medicine.
5.2 Identifying a stem cell gene set
Our first goal was to identify a set of genes whose expression profiles represent a
tightly conserved core of transcriptional programming among stem cells. We call
this set of genes our stem cell gene set (SCGS). We derived SCGS from a high-
quality database called Concordia, representing a significant subset of the NCBIs
Gene Expression Omnibus (GEO). Concordia was constructed using a combination of
automated textual parsing, human curation and normalization methods (see Chapter
3).
In order to identify a set of genes with highly specific stem cell expression inten-
sities, we used this curated database to identify all of the stem cell samples in our
dataset. We then applied a standard signal processing tool, a finite impulse response
filter (FIR) [62], to identify those genes with the most highly-conserved expression
intensities among the stem cell samples. That is, those genes with a range of ex-
pression intensities among the stem cell samples that was most distinct from the
non-stem cell samples scored the highest.
We sought to associate with each gene a measure of how well conserved its expres-
sion intensity was over the stem cell samples. Rather than seeking a strict measure
of constitutive over- or under-expression of the gene among the stem cell population,
our goal was instead to identify individual genes that tightly cluster the stem cell
population anywhere along the spectrum of expression intensities.
The input to the FIR scoring procedure is a list of all of the expression samples,
sorted according to their intensity for a particular gene. The filter then applies a
sliding window to the list and outputs, at each window position, the proportion of
stem cell samples within the frame. The maximal value of this sliding window at
any position in the list is then taken as that genes score. We use a window equal in
size to the total number of stem cell samples in the database, so the interpretation
of the filters maximal output is intuitive: If were looking to find all of the stem cell
samples within one window frame, what is the greatest fraction that we can localize,
given the expression values for this gene across the entire database. Genes with the
highest scores are those with most specific stem cell expression intensities.
Binomial p-values (k=number of stem cell samples in a given window frame;
n=window frame size; p=proportion of stem cell samples in the entire database) are
reported along with these scores.
In contrast to a standard t-test, this approach does not require us to define a
specific control phenotype against which we test for separation, a poorly defined
task when comparing against such a diverse database. Moreover, this method iden-
tifies genes with expression levels that are highly specific in the stem cell samples,
allowing for the diverse population of non-stem cell samples to express these genes at
simultaneously higher and lower levels (something for which a t-test cannot directly
account). For example, the gene DBC1 exhibits a highly specific range of expression
across the stem cell samples, and ranked highly (among the top 0.5% of all stem
cell marker genes) by the described method. However, the non-stem cell samples
demonstrate both higher and lower expression levels of this gene, causing a standard
Students t-test (treating all non-stem cell samples as the control group) to rank this
gene as only the 24.6% strongest marker gene.
We verified the ability of the SCGS to capture a nuanced measure of stem cell-
like gene expression activity by demonstrating the accurate clustering of a series of
developing ES cell populations in mouse. This analysis also shows the concordance
between the SCGS transcriptional profile and cellular state of differentiation.
To verify that our SCGS captures a quantitative transcriptional measure of dif-
ferentiation, we used it to examine the expression dynamics of a set of developing
mouse ES cells over time (data available in GEO Series GSE12550). This data set
consisted of a time course of differentiating mouse ES cells, with gene expression
measured at four time points (ES cells, 4 days of differentiation, 8 days of differ-
entiation and 14 days of differentiation). Human genes were mapped to mouse via
NCBI's Homologene [14]. Human genes that lacked a unique match in mouse were
ignored. Expression intensities were processed in an identical manner to the human
data (see Chapter 3), and again summarized by gene. We computed the dominant
variance among the differentiating mouse cells via PCA. We used each mouse ES
samples coordinates in the first principal basis as a summary value of SCGS gene
expression activity.
The dominant expression signal reflected in these genes accurately sorts the sam-
ples according to their time point, as shown in Figure 5-1. This supports the hy-
pothesis that our SCGS reflects measurable changes in state of differentiation and
pluripotentiality, and reflects the fact that the functional genomic mechanisms asso-
ciated with stem cell activity are at least partially conserved across species.
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Figure 5-1: Distribution of differentiating mouse ES cells over stem cell signature. Each curve represents the
distribution of SCGS summary values for a particular time point. The stem cell signature collocates the four time
points samples and clearly separates the early and late stages of differentiation.
Previous studies [16] have examined the expression patterns of literature-curated
gene sets relating to ES-like activity among a variety of malignancies. In contrast,
we have constructed a gene set that reflects only those transcriptional signals with
C5J
C0
the greatest ability to localize the stem cell samples within the spectrum of human
tissues and diseases.
The genes comprising the SCGS can be found in Table 5.1.
Table 5.1: Genes comprising the SCGS

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3 ES-like signature stratifies a diverse expres-
sion database by pluripotentiality and malig-
nancy
Via principal component analysis (PCA), we examined the transcriptional profile
of the SCGS across the entire collection of normal tissues, cancers and stem cells
assembled from GEO. Performing PCA across only the SCGS genes (including all
samples in the data set) allowed us to measure the extent to which the specific
transcriptional activity observed in the stem cell population was apparent in each of
the other phenotypes.
This analysis revealed a striking trend apparent in the first two principal compo-
nents (PCs) of the gene set: PCi captured a measure of cellular potency, while PC2
reflected the broad transcriptional differences between hematopoietic, neural and ep-
ithelial tissues. These trends are demonstrated in Figure 5-2. Each panel highlights
in color the PCA region occupied by a particular normal tissue population (red) and
its associated malignancies (green), as well as any related precursor cells (orange),
immortalized cell line samples (cyan), multipotent (blue) and pluripotent stem cells
(magenta). The pluripotent stem cells included in this analysis were a combination
of both embryonic stem cells and induced pluripotent stem cells. The locations of
all other samples in the data set are shaded gray to provide context.
The dominant characteristic of PC 1 is its ability to separate the pluripotent stem
cells from the normal tissue samples (e.g., the normal tissues shown in Figure 5-2
blood, breast, brain, colon, shaded red, consistently lie on the extreme left side of the
plots, whereas the pluripotent stem cells, shaded magenta, lie on the extreme right).
Moreover, PCi apparently reflects a finer-grained continuum of cellular potency:
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Figure 5-2: The stem cell signature genes stratify a phenotypically diverse database according to pluripotentiality.
Each panel shows the entire expression database plotted on the principal coordinates defined by the stem cell signature
genes. PCI is represented on the x-axis of each plot, while PC2 is on the y-axis. In each plot, the pluripotent stem
cells (IPS and ES) are clustered on the extreme right-hand side (magenta), followed by mesenchymal stem cells (blue)
and immortalized cell lines (cyan). Each panel demonstrates that, across tissue types, this stem cell signature draws
a coherent picture of pluripotentiality and differentiation. While the distinction between the pluripotent stem cells
and the normal tissues represents the predominant signal (PC1) in the data, the contrast in the expression profiles
of hematopoietic and neural tissues apparently defines the second strongest signal. Even so, both tissues respective
malignancies show a common tendency to exhibit greater stem-like activity, as demonstrated by their closer proximity
to the pluripotent stem cell cluster. A, B, C, D) Blood, breast, brain and colon all demonstrate the same enhanced
stem-like expression activity among their respective malignancies. That is, tumor samples cluster more closely to
the pluripotent stem cells than their associated normals
the multipotent stem cells are clustered near the pluripotent stem cells, with the
hematopoietic progenitors (the only progenitors in our dataset) slightly farther away
(Figure 5-2A).
Further, the hematopoietic, neural and epithelial cancers (shaded green in Figure
5-2A-D) contained in our data all clustered directly between the stem cell populations
and their associated normal non-malignant samples. These results suggest that the
SCGS captures a kernel of stem cell-like transcriptional activity that concurrently
apparent in a variety of malignancies.
5.4 ES-like signature stratifies tumor grade
We used the SCGS to evaluate the transcriptional profiles of several graded tumor
data sets. Our goal was to evaluate whether our molecular marker for tissue-agnostic
stem cell-like transcriptional activity was representative of poor clinical prognosis.
We identified four independent data series containing expression profiles for graded
tumors of various tissue types in GEO (GSE4290, GSE23593, GSE17537, GSE18842)
on Affymetrix HGU 133+ 2.0. Each series was pre-processed (MAS5.0 normalized,
summarized) as previously described. Within each series, the SCGS summary values
were computed, again, via PCA over this gene set, allowing us to associate a value
with each sample indicating its relative stem-like expression activity. For each data
set, we computed PCA over the SCGS to identify the dominant differences between
the samples within the context of the stem cell genes.
Our analysis revealed a unified molecular signature that correlates with tumor
grade for a variety of primary tissues. The first principal component of each data set
revealed a strong separation between the high- and low-grade tumor samples in each
tissue surveyed. Figure 5-3 shows the distribution of SCGS summary values for the
four tissue types graded tumor samples. In each case, the transcriptional activity
of the SCGS defines a clear separation between the high- and low-graded tumors,
while providing a molecular foundation based on stem-like expression for the clinical
difficulty in classifying mid-grade tumors,
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Figure 5-3: Stem cell-like activity correlates with tumor grade in various solid malignancies. Each panel displays
the distribution, within the space of the stem cell genes, of graded tumor samples for one particular tissue type. Our
molecular index of pluripotentiality and proliferative potential consistently separates high-grade tumors from low
grade ones. Based on this transcriptional index, the mid-grade tumors are less well defined.
5.5 Characterizing the functional diversity of the
stem cell gene set
Our final goal was to characterize the functional diversity of the genes comprising
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the SCGS. Hierarchical clustering of these genes transcriptional activity in a popula-
tion of pluripotent stem cells revealed four distinct coexpression modules. For each
module, we then identified a set of over-enriched GO biological processes.
To illustrate the gene expression trends apparent within each gene cluster, Figure
5-4 shows a heatmap of their profiles across pluripotent and partially committed stem
cells, as well as malignant and normal breast samples.
Genes active in DNA replication, cell cycle regulation and RNA transcription
(see Table 7.5 and Table 7.6 for detailed annotations) are most highly expressed
in the pluripotent stem cells, and less so, respectively, through increasing levels of
cellular differentiation / decreasing pluripotentiality. Genes related to metabolism
and hormone signaling (see Table 7.7 for detailed annotations) show peak expression
intensity among the partially committed stem cells, while exhibiting low intensity
among the fully differentiated tissue and tumor samples. Correspondingly, genes
responsible for multicellular signaling and cellular identity (see Table 7.8 for detailed
annotations) are most highly expressed in the fully differentiated tissue and malig-
nant samples. Within each functional module, the tumor samples trend away from
the respective normal tissue, echoing stem cell-like transcriptional activity.
5.5.1 SCGS genes represented in the Figure 5-4
This section lists, in order of appearance, the genes displayed in 5-4.
Genes represented in the DNA replication / cell cycle cluster
DNMT3B, MCM6, CDC25A, PFAS, MCM4, XRCC5, HAUS6, TET1, IGF2BP1,
PLAA, DEPDC1B, TEX1O, CCDC99, MSH2, BUBIB, MSH6, DLGAP5, SKIV2L2,
CENPE, CHEK2, SOHLH2, CCNB1, RRAS2, PRIMI, PAICS, CCNA2, CPSF3,























Figure 5-4: Four distinct expression modules are apparent within the stem cell genes. To demonstrate the
transcriptome-wide implications of these profiles, this figure shows a series of cell types, ranging from fully differ-
entiated (normal breast), through the associated malignancy, partially committed stem cells, and pluripotent stem
cells. Each gene (row) has been independently z-score normalized to improve readability and highlight cluster-specific
trends. Biological significance of each cluster was determined by GO analysis.
ASCC3, FANCB, MCM10, HMGA2, SKP2, TRIM24, ORCIL, HDAC2, HESX1,
Clorfl35, INHBE, C21orf45, DCUN1D5, POLE2, MRPL3, CENPH, MYCN, HAUS1,
4
GDF3
Genes represented in the RNA transcription / protein synthesis cluster
TBCE, RIOK2, BCKDHB, RADi, C5orfl3, ADH5, PLRG1, ROR1, RAB3B, LOC285431,
DBC1, KIF23, DIAPH3, GNL2, FGF2, TARDBP, NMNAT2, ZNF167, KIF20A,
CENPI, DDX1, C3orf2l, GPR176, FBXO22, BBS9, C14orfl66, BOD1, CDC123,
SNRPD3, FAM118B, DPH3, EIF2B3, KDELC1, RPF2, APLP1, DACTI, PDHB,
C14orfl19, DTD1, SAMM50, CCL26, C4orf52, CCDC90B, MED20, UTP6, RARS2,
KIAA0020, ARMCX2, RARS, MTHFD2, DHX15, HTR7, HIST1H4C
Genes represented in the metabolism / hormone signaling cluster
MTHFD1L, ARMC9, XPOT, IARS, HDX, ARPM1, ERCC2, TBC1D16, GARS,
KIF7, UBE2K, SLC25A3, ICMT, UGGT2, ATP11C, SLC24A1, EIF2AK4, GPX8,
ALX1, OSTC, TRPC4, HAS2, FZD2, TRNT1, MMADHC, SNX8, CDH6, HATi,
SEC11A, DIMT1L, TM2D2, FST, GBE1
Genes represented in the multicellular signaling / immune signaling /
cellular identity cluster
MLL3, MXI1, FKSG49, FAM185B, ARRB2, SMARCC2, WASH3P, PILRB, CTSH,
SATI, JUNB, CD53, PECAMI, IL1ORA, RCSD1, ARHGDIB, GIMAP5, GIMAP6,
HLA-DMB, PTPRC, ClOorf128, CMBL, HLA-DRB5, HLA-DPA1, ABCG1, GIMAP7,
HLA-DQA1, TSHZ2, C13orf15, CCR1, NPR3, RSAD2, GIMAPi, TNFSF10, AFTPH,
MALAT1, UBXN2A, PDE4C, GIMAP8, FYB, MS4A7, C5orf56, LOC400931, MLLT6,
CTSS, ZBTB20
5.6 Implications of the stem cell gene set
We have demonstrated conserved stem cell-like transcriptional activity across a wide
variety of hematopoietic and solid cancers through a comprehensive molecular survey
of malignancy, pluripotent stem cells and normal tissues. Our findings echo several
recent developments in the cancer stem cell debate. In particular, our results high-
light transcriptional evidence that, despite individual tissue-specific characteristics,
a wide range of cancers share a common set of functional genomic mechanisms with
each other as well as pluripotent and multipotent stem cells.
The overall landscape of the human transcriptome appears to be organized by a
combination of tissue, cell-type and disease-specific features. Previous studies have
suggested that the primary factors driving the organization of this landscape are
largely attributable to hematopoietic and malignant programming. Our results indi-
cate that while there exists a strong tissue-specific signal, the malignancy signature
is more specifically a reflection of the self-renewal and pluripotentiality common to
both stem cell populations and heterogeneous tumors.
Although our results neither support nor refute the cancer stem cell hypothesis,
they do strongly suggest that there are a large number of stem cell-specific mecha-
nisms observable in heterogeneous tumor samples. Our data indicates the need for
more detailed transcriptional assays comparing proliferative tumor cells to both ES /
iPS cells and bulk heterogeneous tumor cells, as well as normal tissue cells. Our data
suggests the hypothesis that the gene expression patterns observed in heterogeneous
tumor samples may be due to the effect of a small population of cancer stem cells
in combination with a large number of partially differentiated cells. It is plausible
that, while the partially differentiated mass of the tumor behaves transcriptionally
similar to healthy tissue, the small population of proliferative tumor cells push the
observation of the aggregate mRNA back along the spectrum of stem cell like activity
identified in this paper.
Controversy remains as to the exact origin of cancer stem cells, with the data
often supporting contradictory conclusions for different tissues [55]. Some studies
have indicated that cancer stem cells arise from normal pluripotent or multipotent
stem cells that have lost the ability to regulate their proliferative activity, while
others have indicated that cancer stem cells derive from a committed progenitor cell
that has acquired the ability to self renew [104].
Despite these controversies, and what appear to be cell type-specific molecu-
lar characteristics, we have demonstrated a specific, unbiased transcriptional signal
that is shared among a wide variety of solid and hematopoietic cancers. Moreover,
when considered from a transcriptome-wide perspective, this signal is indicative of
stem cell-like activity. We have shown how these gene expression patterns are most
strongly associated with embryonic and induced pluripotent stem cells, and are suc-
cessively less apparent in multipotent stem cells, malignancies, and fully differenti-
ated tissues, respectively. In addition, the genes that comprise this signal also reveal
a stratification of solid tumors that correlates strongly with classical grading systems.
Recent trends in chemotherapy design have focused not only on regulating cy-
totoxicity, but also on affecting the differentiation pathways that are apparently
impaired in malignant cells. For example, Stegmaier et al. have demonstrated the
ability of gefitinib to induce myeloid differentiation in both AML cell lines as well
as patient-derived AML blast cells [93]. Indeed, the phenotypic transformation in-
duced by gefitinib was shown to be observable in both cellular morphology and gene
expression. The ubiquitous stem cell-like expression patterns described in this pa-
per, as well as those specifically tuned to individual tumor subclasses, may prove
useful in screening compounds through the early stages of drug discovery. To these
ends, we have begun investigating the transcriptional effect of known therapeutic
compounds on the SCGS via CMAP-like [49] analyses. Understanding the transcrip-
tional changes wrought by these compounds within the context of pluripotentiality




In this thesis, we have demonstrated how a large set of gene expression samples
can be indexed by phenotype using a combination of natural language processing
tools, expert curation, and an ontology-based hierarchical database. We described
techniques for using the resulting database to characterize the phenotype of new
gene expression samples, and demonstrated the ability of that phenotype enrichment
scoring scheme to recover clinically relevant information about the tissue of origin
for metastasized tumors. Finally, we developed a method that uses our database to
identify expression profiles that are highly conserved within particular phenotypes.
We used that method to characterize the relative extent to which stem cell-like
expression programming is present across the full spectrum of diseases and tissues
represented in our database, and highlighted the clinical relevance of those findings.
6.1 Future Work
There are a number of future directions that we intend to explore. These fall into
two main categories: 1) analyses that utilize the gene expression resources assembled
for this thesis, and 2) future projects that involve repurposing the flexible Concordia
ontology-based indexing system for categorizing data in other domaines (e.g., outside
the scope of gene expression analyses.
6.1.1 Expanding the expression database
Because the manual curation procedure outlined in this thesis is time consuming and
tedious, we have begun developing a set of algorithms that use a reference set such
as the Concordia GEO database described earlier as a starting point to bootstrap a
large database. Inspired by the reinforcement learning paradigm [98], we take the
samples that have been expert labeled, and search for samples that are not already
in the database, but have similar gene expression profiles and whose NLP-derived
concept associations are similar to those in the database. The goal is to prioritize the
introduction of new samples into the database in such a way as to rapidly expand
the coverage for one or more particular phenotypes.
For example, if we require a large number of blood samples from type II diabetic
patients, but such samples are scarce in our existing dataset (because they have not
yet been manually verified), we begin by hand labeling a small number (early cross
validation results indicate that as few as 5-10 samples can serve as a reliable starting
point). We then ask our algorithm to search for samples whose gene expression and
text characteristics are similar to those few initial samples. Using this framework, the
system continuously updates its understanding of each phenotype, and dynamically
ranks the unlabeled samples phenotypic predisposition in accordance with this belief.
In so doing, the user is constantly provided with high-confidence samples related to
their specific interest.
The database, as it is currently constructed, represents a diverse cross-section of
both normal and malignant human tissue samples, but is still only a small fraction
(roughly 10%) of the total number of HGU133+ 2.0 samples for which GEO makes
CEL files available. We intend to use the tools outlined above to expand the breadth
of this data set in order to tailor it specifically to our future analyses.
6.1.2 Therapeutic compound expression profiles
The emergence of such large-scale molecular profiling data sets as the one described
in this thesis has given rise to a series of techniques for computational drug reposi-
tioning [32, 59]. Here, the goal is to search large phenotypically diverse databases for
previously un-exploited molecular signatures that appear to be therapeutic targets
for existing drug compounds. Because our Concordia database represents a compre-
hensive hierarchical characterization of the constituent samples, and affords the user
effortless querying of this structure, we believe that Concordia is a highly attractive
framework for enabling these types of analyses.
In addition, we are also investigating the possibility of assembling a Concordia
database containing transcriptional profiles for a collection of tumor biopsies, and
associating that database with clinical histories, courses of treatment, and outcomes.
We believe that such a resource, if adequate in its breadth and depth, would provide
a clinically-relevant method for pairing new patients with a course of treatment that
has the optimal expected outcome, based on the molecular profile of their particular
tumor.
6.1.3 Adverse drug / event data mining
We have begun early-stage analyses of anonymized patient data to detect adverse
events that coincide with a population of patients being prescribed a particular drug.
Here, we use Concordia to index the patient "event" database, then assess, for every
drug of interest, whether the odds of each event (including those event categorizations
implied by the UMLS hierarchy, but not explicitly defined in the raw data) are
statistically surprising in the patients who were administered the drug vs. those who
were not administered the drug.
6.1.4 Monitoring disease outbreak
The advent of realtime world-wide health monitoring systems like HealthMap [37]
has major implications for how we analyze epidemiological data. We anticipate that
Concordia's ability to summarize the textual information that underlies such services
at arbitrarily specific levels of medical knowledge will prove useful in generating noise-
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GSM175795, GSM46884, GSM175796, GSM175797, GSM170978,
GSM46888, GSM175792, GSM117730, GSM203686, GSM402327,
GSM353935, GSM175799, GSM159011, GSM352110, GSM353933,
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GSM187621, GSM67186, GSM187622, GSM117755,
GSM350288, GSM187629, GSM152679, GSM187627,
GSM187623, GSM187624, GSM175777, GSM175776,
GSM76499, GSM117751, GSM175775, GSM187630,
GSM337198, GSM385721, GSM363411, GSM175789,
GSM175787, GSM325807, GSM175782, GSM175781,
GSM363415, GSM175785, GSM175784, GSM175783,
GSM391367, GSM211122, GSM280847, GSM371106,
GSM325817, GSM85486, GSM325812, GSM361964,
GSM148605, GSM211142, GSM148606, GSM148607,
GSM201235, GSM201236, GSM201237, GSM385383, GSM201238, GSM201239, GSM231876,
GSM231874, GSM46858, GSM238795, GSM238794, GSM238797, GSM238796, GSM238791,
GSM201241, GSM238790, GSM201240, GSM46850, GSM238793, GSM201243, GSM238792,
GSM279753, GSM173679, GSM325787, GSM53033, GSM386413, GSM60985, GSM173684,
GSM317736, GSM279743, GSM173685, GSM173682, GSM173683, GSM306190, GSM173680,
GSM173681, GSM211092, GSM317739, GSM80602, GSM80601, GSM80600, GSM173688,
GSM270809, GSM173689, GSM173686, GSM173687, GSM60972, GSM386403, GSM316693,
GSM238875, GSM238877, GSM238870, GSM211082, GSM238873, GSM280897, GSM279774,
GSM238874, GSM238871, GSM238872, GSM351404, GSM238867, GSM238865, GSM238864,
GSM316683, GSM238868, GSM211072, GSM238860, GSM238861, GSM199307, GSM238862,
GSM279763, GSM238863, GSM66937, GSM325797, GSM360316, GSM238854, GSM238856,
GSM238855, GSM238858, GSM238857, GSM316673, GSM80632, GSM80633, GSM80634,
GSM80635, GSM80630, GSM80631, GSM340514, GSM372286, GSM238851, GSM280877,
GSM372289, GSM372288, GSM372287, GSM238848, GSM401152, GSM238846, GSM238847,
GSM372292, GSM238844, GSM401156, GSM372293, GSM238845, GSM372290, GSM238842,
GSM372291, GSM238843, GSM80629, GSM386453, GSM80626, GSM80625, GSM360329,
GSM80628, GSM80627, GSM80645, GSM80646, GSM80643, GSM75017, GSM80644,
GSM80641, GSM340504, GSM80642, GSM80640, GSM372295, GSM372294, GSM280887,
GSM372297, GSM238841, GSM372296, GSM279784, GSM238840, GSM372299, GSM372298,
GSM401162, GSM238835, GSM238837, GSM238838, GSM401165, GSM279794, GSM238834,
GSM386443, GSM80639, GSM238839, GSM80638, GSM80637, GSM80636, GSM80610,
GSM176306, GSM80611, GSM203716, GSM80612, GSM176304, GSM80613, GSM176305,
GSM176302, GSM176303, GSM352580, GSM176300, GSM176301, GSM238822, GSM280857,
GSM238823, GSM238820, GSM401132, GSM238821, GSM238826, GSM238827, GSM238824,
GSM238825, GSM80604, GSM80603, GSM60960, GSM80606, GSM80605, GSM386433,
GSM80608, GSM80607, GSM80609, GSM176319, GSM179951, GSM80620, GSM179950,
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GSM80623, GSM176315, GSM80624, GSM176316, GSM80621, GSM176317, GSM203706,
GSM80622, GSM176318, GSM176312, GSM176313, GSM176310, GSM238810, GSM280867,
GSM238811, GSM238812, GSM238813, GSM401142, GSM238815, GSM238816, GSM80617,
GSM386423, GSM238817, GSM80616, GSM238818, GSM80615, GSM238819, GSM80614,
GSM80619, GSM80618, GSM152759, GSM152757, GSM187702, GSM350248, GSM238807,
GSM152755, GSM238806, GSM80669, GSM238809, GSM238808, GSM238803, GSM238802,
GSM238805, GSM238804, GSM401112, GSM238801, GSM238800, GSM80671, GSM203732,
GSM80670, GSM176321, GSM176320, GSM117680, GSM176323, GSM203736, GSM176322,
GSM175840, GSM176325, GSM175841, GSM176324, GSM80679, GSM175842, GSM176327,
GSM80678, GSM175843, GSM176326, GSM80677, GSM175844, GSM176329, GSM80676,
GSM175845, GSM176328, GSM80675, GSM175846, GSM80674, GSM175847, GSM179940,
GSM80673, GSM175848, GSM199357, GSM80672, GSM175849, GSM175839, GSM152749,
GSM350258, GSM345187, GSM401122, GSM80680, GSM176332, GSM176331, GSM80682,
GSM176330, GSM80681, GSM176336, GSM175830, GSM176335, GSM176334, GSM176333,
GSM203726, GSM80688, GSM175833, GSM179930, GSM80687, GSM301707, GSM175834,
GSM117690, GSM176339, GSM175831, GSM176338, GSM80689, GSM175832, GSM176337,
GSM80684, GSM175837, GSM80683, GSM175838, GSM199367, GSM80686, GSM175835,
GSM80685, GSM175836, GSM80649, GSM80647, GSM80648, GSM187722, GSM281019,
GSM350268, GSM175860, GSM176345, GSM175861, GSM176344, GSM175862, GSM117660,
GSM176347, GSM203756, GSM175863, GSM176346, GSM176341, GSM176340, GSM176343,
GSM176342, GSM80653, GSM175868, GSM80652, GSM175869, GSM80651, GSM340534,
GSM80650, GSM152739, GSM80657, GSM53093, GSM175864, GSM199377, GSM80656,
GSM175865, GSM80655, GSM175866, GSM80654, GSM175867, GSM179920, GSM80658,
GSM80659, GSM281009, GSM187712, GSM176360, GSM401102, GSM176361, GSM350278,
GSM175851, GSM176358, GSM175852, GSM176357, GSM203746, GSM176356, GSM175850,
GSM117670, GSM176355, GSM176354, GSM176353, GSM80660, GSM176352, GSM179918,
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GSM80662, GSM368398, GSM175859, GSM152729, GSM80661, GSM53083, GSM340524,
GSM80664, GSM175857, GSM80663, GSM175858, GSM80666, GSM175855, GSM80665,
GSM175856, GSM80668, GSM175853, GSM179910, GSM80667, GSM175854, GSM176359,
GSM199387, GSM317794, GSM316663, GSM176370, GSM176372, GSM176371, GSM351424,
GSM175806, GSM350208, GSM175807, GSM175808, GSM175809, GSM179900, GSM175801,
GSM389778, GSM175800, GSM175803, GSM122548, GSM152719, GSM175802, GSM175805,
GSM53073, GSM175804, GSM176362, GSM176363, GSM203776, GSM176364, GSM345147,
GSM176365, GSM199317, GSM176366, GSM176367, GSM306160, GSM176368, GSM176369,
GSM176383, GSM176382, GSM176381, GSM316653, GSM350218, GSM351414, GSM95519,
GSM389788, GSM95522, GSM95523, GSM95524, GSM53063, GSM95525, GSM152709,
GSM176375, GSM199327, GSM176376, GSM95520, GSM345137, GSM176373, GSM203766,
GSM95521, GSM176374, GSM176392, GSM345177, GSM170983, GSM176391, GSM170980,
GSM176390, GSM95509, GSM95508, GSM350228, GSM175828, GSM175829, GSM95513,
GSM80696, GSM175825, GSM95514, GSM80697, GSM53053, GSM175824, GSM170597,
GSM199337, GSM95511, GSM80694, GSM175827, GSM170596, GSM122528, GSM95512,
GSM80695, GSM175826, GSM170595, GSM95517, GSM175821, GSM95518, GSM175820,
GSM95515, GSM80698, GSM175823, GSM95516, GSM80699, GSM175822, GSM306180,
GSM170590, GSM176388, GSM176389, GSM80692, GSM170594, GSM176384, GSM95510,
GSM80693, GSM170593, GSM176385, GSM80690, GSM170592, GSM176386, GSM80691,
GSM170591, GSM176387, GSM203796, GSM170992, GSM345167, GSM350238, GSM175819,
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GSM287453, GSM261127, GSM117649, GSM38386, GSM373559, GSM280917, GSM137994,
GSM277109, GSM287423, GSM277108, GSM277103, GSM277102, GSM277101, GSM277100,
GSM277107, GSM277106, GSM277105, GSM277104, GSM201302, GSM377338, GSM201301,
GSM201300, GSM155920, GSM277110, GSM280947, GSM201304, GSM201303, GSM155923,
GSM155922, GSM155921, GSM38356, GSM155928, GSM155927, GSM287433, GSM155919,
GSM387789, GSM158465, GSM158466, GSM158467, GSM158468, GSM312826, GSM158469,
GSM353885, GSM377348, GSM158471, GSM280937, GSM158470, GSM158473, GSM158472,
GSM158475, GSM158474, GSM335662, GSM38366, GSM287403, GSM102438, GSM353895,
GSM280967, GSM155948, GSM155947, GSM287413, GSM137984, GSM102428, GSM312849,
GSM211022, GSM211012, GSM280957, GSM101301, GSM38346, GSM117610, GSM80725,
GSM272192, GSM80724, GSM272193, GSM80727, GSM327342, GSM272190, GSM80726,
GSM335582, GSM272191, GSM80729, GSM386311, GSM80728, GSM280979, GSM138034,
GSM272295, GSM183260, GSM80730, GSM239824, GSM80731, GSM239825, GSM80732,
GSM272185, GSM239826, GSM80733, GSM80734, GSM272183, GSM80738, GSM335592,
GSM80737, GSM386301, GSM272180, GSM80736, GSM272181, GSM80735, GSM327352,
GSM272182, GSM117587, GSM80739, GSM337309, GSM280989, GSM138044, GSM80740,
GSM272177, GSM80741, GSM286730, GSM272176, GSM183250, GSM272172, GSM80742,
GSM272175, GSM80743, GSM272174, GSM327322, GSM183290, GSM386331, GSM272170,
GSM53113, GSM272171, GSM80749, GSM80748, GSM280999, GSM138054, GSM272169,
GSM134694, GSM272164, GSM272163, GSM272162, GSM272275, GSM272161, GSM286720,
GSM272168, GSM80750, GSM80751, GSM272165, GSM386321, GSM183280, GSM80759,
GSM327332, GSM80758, GSM53103, GSM80757, GSM272160, GSM134690, GSM134691,
GSM134692, GSM134693, GSM272159, GSM134688, GSM272158, GSM134687, GSM134689,
GSM272151, GSM272150, GSM272152, GSM272155, GSM272154, GSM183270, GSM272285,
GSM272157, GSM80761, GSM387799, GSM286710, GSM272156, GSM337339, GSM201279,
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GSM401293, GSM201278, GSM201277, GSM316703, GSM53133, GSM137924, GSM201286,
GSM201287, GSM201284, GSM201285, GSM201282, GSM201283, GSM201280, GSM201281,
GSM119685, GSM119684, GSM119683, GSM119682, GSM179801, GSM201267, GSM119688,
GSM179800, GSM201266, GSM119687, GSM201269, GSM337349, GSM119686, GSM201268,
GSM119681, GSM53123, GSM119680, GSM316713, GSM137912, GSM137910, GSM80701,
GSM80700, GSM138004, GSM201273, GSM138003, GSM201274, GSM119679, GSM138002,
GSM201275, GSM201276, GSM137916, GSM201270, GSM137914, GSM201271, GSM201272,
GSM179810, GSM201299, GSM337319, GSM80706, GSM53153, GSM117577, GSM80707,
GSM80708, GSM316723, GSM80709, GSM80702, GSM80703, GSM80704, GSM80705,
GSM80710, GSM80712, GSM80711, GSM347925, GSM347924, GSM137904, GSM347923,
GSM347922, GSM347921, GSM138014, GSM201289, GSM201288, GSM124996, GSM179820,
GSM337329, GSM80719, GSM80717, GSM80718, GSM53143, GSM80715, GSM352629,
GSM179827, GSM80716, GSM80713, GSM80714, GSM80723, GSM272194, GSM80722,
GSM272195, GSM80721, GSM272196, GSM80720, GSM272197, GSM347916, GSM272198,
GSM272199, GSM347918, GSM347917, GSM162960, GSM201290, GSM162961, GSM201291,
GSM162962, GSM201292, GSM201293, GSM201294, GSM201295, GSM201296, GSM138024,
GSM201297, GSM201298, GSM119649, GSM176025, GSM162954, GSM119648, GSM176026,
GSM359603, GSM162957, GSM119647, GSM176027, GSM272215, GSM170867, GSM162956,
GSM119646, GSM176028, GSM176021, GSM176022, GSM176023, GSM199217, GSM176024,
GSM53173, GSM158991, GSM176029, GSM53170, GSM378838, GSM378837, GSM378836,
GSM378831, GSM119651, GSM378830, GSM170862, GSM119652, GSM179830, GSM176031,
GSM119650, GSM176030, GSM378835, GSM170865, GSM162958, GSM119655, GSM378834,
GSM170866, GSM162959, GSM119656, GSM378833, GSM119653, GSM378832, GSM119654,
GSM119636, GSM176038, GSM119635, GSM176039, GSM272225, GSM119638, GSM176036,
GSM162943, GSM119637, GSM176037, GSM162942, GSM176034, GSM162941, GSM119639,
GSM176035, GSM162940, GSM176032, GSM176033, GSM53163, GSM199227, GSM378826,
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GSM378825, GSM95473, GSM378828, GSM378827, GSM95475, GSM95474, GSM378829,
GSM95477, GSM53167, GSM95476, GSM95479, GSM370399, GSM176042, GSM95478,
GSM176041, GSM378820, GSM119640, GSM176040, GSM179840, GSM119641, GSM378822,
GSM119642, GSM378821, GSM119643, GSM378824, GSM119644, GSM378823, GSM119645,
GSM176000, GSM176001, GSM162931, GSM176002, GSM162930, GSM176003, GSM162933,
GSM176004, GSM162932, GSM176005, GSM162935, GSM119669, GSM176006, GSM162934,
GSM119668, GSM176007, GSM95480, GSM176008, GSM176009, GSM95488, GSM95487,
GSM119670, GSM95486, GSM378819, GSM95485, GSM378818, GSM95484, GSM378817,
GSM95483, GSM378816, GSM95482, GSM378815, GSM95481, GSM378814, GSM378813,
GSM162936, GSM119677, GSM378812, GSM337359, GSM162937, GSM119678, GSM378811,
GSM162938, GSM119675, GSM162939, GSM159101, GSM119673, GSM119674, GSM119671,
GSM95489, GSM119672, GSM179850, GSM176012, GSM176013, GSM199207, GSM176010,
GSM179870, GSM176011, GSM272205, GSM119658, GSM176016, GSM272204, GSM119657,
GSM176017, GSM176014, GSM272202, GSM119659, GSM176015, GSM272201, GSM95490,
GSM176018, GSM95491, GSM176019, GSM53183, GSM281280, GSM95497, GSM95496,
GSM281290, GSM95499, GSM95498, GSM95493, GSM95492, GSM95495, GSM45796,
GSM95494, GSM119664, GSM162928, GSM119665, GSM337369, GSM159111, GSM119666,
GSM119667, GSM119660, GSM176020, GSM179860, GSM119661, GSM162929, GSM119662,
GSM119663, GSM272143, GSM301693, GSM272144, GSM272145, GSM152619, GSM80771,
GSM272146, GSM199257, GSM80778, GSM80777, GSM272140, GSM80776, GSM272255,
GSM272141, GSM272142, GSM272147, GSM179880, GSM272148, GSM272149, GSM159122,
GSM327302, GSM301687, GSM80783, GSM272134, GSM80782, GSM272135, GSM80785,
GSM80784, GSM152609, GSM80787, GSM80786, GSM301680, GSM80789, GSM199267,
GSM80788, GSM350078, GSM272265, GSM162902, GSM272138, GSM272139, GSM179890,
GSM80781, GSM272136, GSM80780, GSM272137, GSM162906, GSM162905, GSM162904,
GSM159132, GSM399579, GSM80779, GSM327312, GSM301677, GSM80799, GSM80798,
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GSM80797, GSM80796, GSM80795, GSM199237, GSM80794, GSM80793, GSM80792,
GSM80791, GSM80790, GSM119628, GSM119629, GSM272235, GSM249790, GSM119626,
GSM119627, GSM119624, GSM119625, GSM119634, GSM119633, GSM119632, GSM119631,
GSM119630, GSM159142, GSM152639, GSM238763, GSM301667, GSM272245, GSM199247,
GSM152629, GSM119617, GSM119618, GSM119619, GSM119615, GSM119616, GSM119621,
GSM119620, GSM119623, GSM119622, GSM159152, GSM301657, GSM152624
7.2 Tables
Table 7.1: GO terms associated with the top 250 differentially expressed soft tissue genes
Anatomic structures 0.860795353 2954 154
Body Regions 0.860795353 2954 154
Physical anatomical entity 0.860795353 2954 154
body system 0.852956551 2603 131
Body tissue 0.837848153 2474 112
Body organ structure 0.744149574 2433 118
Body part 0.906311914 1914 83
Body substance 0.835581871 1916 85
Entire subdivision of organ system 0.742509803 1595 100
Musculoskeletal System 0.742132317 1594 100
Skeletal system 0.742132317 1594 100
SKELETAL SYSTEM: GENERAL 0.742132317 1594 100
TERMS
Skeletal System (Bones of Head, Rib Cage 0.742132317 1594 100
and Vertebral Column)
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SOFT TISSUES, SMOOTH MUSCLE 0.736962657 1571 98
AND CARTILAGINOUS TISSUES
Soft Tissue, Bone and Cartilage 0.736962657 1571 98
soft tissue 0.685021181 1513 98
Disorder by body site 0.741622966 1194 100
Neck, chest, abdomen, and pelvis 0.897100766 1322 73
Disorder of body system 0.741326811 1141 97
Body space structure 0.848075943 1551 62
Body material 0.694239734 1665 70
Body cavities 0.850792747 1537 60
Neck, chest and abdomen 0.897120386 1269 66
Trunk structure 0.859012735 1234 68
Structure of subregion of trunk 0.858528777 1232 66
Chest, abdomen, and pelvis 0.868753539 1193 66
Chest and abdomen 0.871699619 1140 59
Cells 0.913694148 710 90
Neoplasms 0.79627514 910 78
Neoplasm and/or hamartoma 0.79627514 910 78
sex 0.756465161 1457 51
Organ part 0.858393737 1199 53
Unspecified Neoplasms and Tumor Cells 0.79737436 902 75
Malignant Neoplasms 0.815926867 855 74
Malignant tumor of unknown origin or ill- 0.815926867 855 74
defined site
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Malignant neoplasm of other and unspeci- 0.815926867 855 74
fied site otherwise specified
Malignant neoplasm of other and unspeci- 0.815926867 855 74
fied sites
Malignant Neoplasm (Morphology) 0.812252124 835 67
Primary malignant neoplasm 0.811627883 833 66
Upper body structure 0.896343213 1117 44
Upper body part structure 0.896343213 1117 44
Connective Tissue 0.691873179 917 68
Body tissue material 0.691873179 917 68
Skeletal material 0.691873179 917 68
Neoplasm by body site 0.770455134 755 68
Hemic and Immune Systems 0.968525364 681 56
Neoplasms by Site 0.764899866 717 62
Neoplasms by Histologic Type 0.796900372 773 55
Cellular Structures 0.879070575 575 67
Lower body structure 0.799826114 827 51
Lower body part structure 0.799826114 827 51
Abdomen and pelvis 0.80237391 820 50
Entire cell 0.886090444 566 65
Structure of viscus 0.802896481 834 44
Musculoskeletal Diseases 0.647263327 671 62
Connective Tissue Diseases 0.647263327 671 62
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Musculoskeletal and connective tissue dis- 0.647263327 671 62
orders
Abdominal Cavity 0.812552248 767 43
ABDOMEN INCLUDING PERI- 0.812552248 767 43
TONEUM AND RETROPERITONEUM
Abdomen 0.812552248 767 43
Disorder of body cavity 0.725818039 661 49
Fluids and Secretions 0.98873893 526 45
Body Fluids 0.989560932 524 44
Male gender 0.768290336 694 40
Blood 0.99298379 508 41
Female 0.700241563 764 36
Disorder of trunk 0.826006589 546 42
Bone and/or joint structure 0.853841241 487 45
Hematological system 0.907304659 467 44
Hematopoietic System 0.907304659 467 44
Skeletal bone 0.863690184 475 45
Integumentary system 0.827015849 530 42
SKIN AND SKIN APPENDAGES 0.827015849 530 42
INTEGUMENTARY SYSTEM: GEN- 0.827015849 530 42
ERAL TERMS
Immune system 0.906197905 437 42
Structure of lymphoreticular system 0.906197905 437 42
Neoplasms, Glandular and Epithelial 0.906278199 503 32
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Bone Marrow 0.912430297 407 37
Bone Marrow and Erythropoietic Tissues 0.912430297 407 37
Neck and chest 0.860055289 505 31
Gastrointestinal system 0.918517706 466 31
Gastrointestinal tract structure 0.918517706 466 31
DIGESTIVE SYSTEM: GENERAL 0.918517706 466 31
TERMS
Head and neck structure 0.978785357 680 19
Neoplasm of trunk 0.86726834 440 33
Digestive organ structure 0.928308168 442 30
DIGESTIVE ORGANS: GENERAL 0.928308168 442 30
TERMS
DISORDERS OF THE MUSCLES, LIGA- 0.724249863 429 39
MENTS, FASCIAE AND OTHER SOFT
TISSUES
Skeleton 0.782528241 495 31
Epithelioma 0.925849089 486 26
Entire body organ 0.843848235 554 25
Entire anatomical structure 0.843848235 554 25
Bone and Bones 0.789295752 480 30
Carcinoma 0.937877567 459 25
Malignant epithelial neoplasm - category 0.937877567 459 25
Pelvis and lower extremities 0.869981436 455 27
Pelvis 0.875675176 448 26
121
Lower trunk structure 0.875675176 448 26
Structure of abdominal viscus 0.889200394 395 29
Head 0.984123118 634 16
Structure of breast and/or endocrine sys- 0.882905169 431 25
tem
Head part 0.984555368 621 15
Other diseases of blood or blood-forming 0.939489687 274 35
organs
Disorder of cellular component of blood 0.939489687 274 35
Disorder of hematopoietic structure 0.939489687 274 35
Hematological Disease 0.939489687 274 35
Genitourinary system 0.876727537 427 23
Urinary tract 0.876727537 427 23
Urinary system 0.876727537 427 23
URINARY TRACT: GENERAL TERMS 0.876727537 427 23
Structure of thorax, including medi- 0.884483878 376 23
astinum and diaphragm
Upper trunk structure 0.884483878 376 23
Chest 0.884483878 376 23
Digestive System Disorders 0.814596577 333 27
Intra-abdominal digestive structure 0.950259537 319 24
Blood Cells 0.922545955 287 27
Structure of product of conception 0.973690213 486 15
Disorder of abdomen 0.807550896 322 26
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Bone marrow part 0.925127094 257 25
Structure of myelopoietic tissue 0.925127094 257 25
Leukocytes 0.925127094 257 25
Urogenital organ 0.884348608 365 18
Structure of anatomical reproductive sys- 0.884348608 365 18
tem
Genitalia 0.884348608 365 18
Genital system 0.884348608 365 18
Immune System Diseases 0.917118014 207 30
Disorder of pelvis 0.826190109 291 23
Reticuloendothelial System 0.908491689 224 27
Abdominal mass 0.80899537 274 23
Abdominal Neoplasms 0.809412205 273 23
Developmental body structure 0.9814019 435 11
Embryonic Structures 0.9814019 435 11
Gland 0.864800244 301 18
Complex structure derived from epithe- 0.864800244 301 18
lium
Cardiovascular Diseases 0.924081132 222 22
Cultured Cells 0.987418163 152 30
Adenoma AND/OR adenocarcinoma 0.900045077 309 16
ADENOMAS AND ADENOCARCINO- 0.898977891 305 16
MAS
Cell Line 0.988847222 150 29
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Nervous system structure 0.997338868 530 8
Other part of nervous system 0.997338868 530 8
Mononuclear cell (histiocyte, lymphocyte, 0.923247787 207 22
plasma cell)
Reticuloendothelial cell 0.923247787 207 22
Central nervous system part 0.997433424 521 8
Neuraxis 0.997433424 521 8
Brain and spinal cord structure 0.997433424 521 8
Structure of body cavity subdivision 0.879796195 335 14
Pelvic cavity structure 0.879796195 335 14
CLINICAL CLASSIFICATION OF NEO- 0.807428644 232 22
PLASMS OF THE MUSCULOSKELE-
TAL SYSTEM AND SOFT TISSUES
Disorder of soft tissue 0.768224999 233 23
[X]Other soft tissue disorders 0.768224999 233 23
Cranial cavity structure 0.996742397 497 8
Peripheral blood mononuclear cell 0.923089866 204 21
Malignant neoplasm of abdomen 0.852137791 210 22
Brain 0.997067302 488 8
Intracranial structure 0.997067302 488 8
Pelvic genital structure 0.878519688 315 14
Neoplasm, uncertain whether benign or 0.95582066 193 21
malignant
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[X]Malignant neoplasms of lymphoid, 0.967070052 190 21
hematopoietic and related tissue
Hematopoietic Neoplasms 0.967070052 190 21
Neoplasm of hematopoietic cell type 0.967070052 190 21
Disorder of the genitourinary system 0.85773095 241 18
Disorder of hematopoietic morphology 0.966877674 189 20
Malignant adenomatous neoplasm - cate- 0.921305759 282 14
gory
Adenocarcinoma 0.91945118 277 14
peripheral blood 0.948089669 180 19
Structure of respiratory system and/or in- 0.785398275 227 18
trathoracic structure
Intestines 0.954716029 223 15
Lower Gastrointestinal Tract 0.954716029 223 15
Stem cells 0.930699608 179 19
Endocrine system 0.865576316 238 15
Endocrine Glands 0.870520061 236 15
Structure of endocrine system 0.870520061 236 15
Thoracic Diseases 0.883076805 203 17
Respiration Disorders 0.883076805 203 17
DISEASES OF THE SINUSES, NOSE, 0.883076805 203 17
PHARYNX AND LARYNX
skin disorder 0.815144635 185 19
Skin and subcutaneous tissue disorders 0.815144635 185 19
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Disorder of integument 0.815144635 185 19
RESPIRATORY SYSTEM: GENERAL 0.90312674 189 16
TERMS
Respiratory System 0.90312674 189 16
Other female genital tract 0.869372565 277 11
Female genitalia 0.869372565 277 11
Female genitourinary system 0.869372565 277 11
Disorder of digestive organ 0.925218679 165 17
Pelvic organ 0.872254428 270 11
Female internal genitalia structure 0.872649335 268 11
Pelvic cavity female genital structure 0.872649335 268 11
Human material 0.935804891 899 3
Human surgical material 0.935804891 899 3
Human tissue 0.935804891 899 3
Upper female genital structure 0.875670647 260 11
Neuromuscular Diseases 0.853808859 191 15
nervous system disorder 0.853808859 191 15
Neuropathy 0.853808859 191 15
Nervous system and sense organ diseases 0.853808859 191 15
Myopathy 0.853808859 191 15
[X]Other disorders of the nervous system 0.853808859 191 15
Neuromuscular Junction Diseases 0.853808859 191 15
DISORDERS OF PERIPHERAL NER- 0.853808859 191 15
VOUS SYSTEM: GENERAL TERMS
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Disorder of skeletal muscle 0.853808859 191 15
Nerve, plexus and root disorders 0.853808859 191 15
Peripheral Neuropathy 0.853808859 191 15
Breast 0.928091168 195 13
Disorder of digestive tract 0.921074977 157 16
Disorder of immune structure 0.96008056 133 18
Non-infectious disorder of lymphatics 0.96008056 133 18
Lymphatic Diseases 0.96008056 133 18
Lymphatic Vessel Diseases 0.96008056 133 18
Respiratory tract structure 0.914390521 179 14
Telencephalon 0.985696581 422 5
Prosencephalon 0.985696581 422 5
Brain tissue 0.985696581 422 5
Supratentorial brain part 0.985696581 422 5
Embryonic nervous system structure 0.985696581 422 5
Brain part 0.985696581 422 5
Nervous structure of head 0.985696581 422 5
Regional nervous structure 0.985696581 422 5
Nervous structure of head and neck 0.985696581 422 5
Cerebrum 0.985696581 422 5
Neoplasm of intra-abdominal organs 0.820813464 155 16
Skin AND subcutaneous tissue structure 0.936626656 194 11
Integumentary system part 0.936626656 194 11
Soft tissue lesion 0.791637671 156 16
127
Hematologic Neoplasms 0.992818515 151 13
Leukemia (category) 0.992818515 151 13
leukemia 0.992818515 151 13
CLINICAL CLASSIFICATION OF NEO- 0.992818515 151 13
PLASMS OF THE HEMATOPOIETIC
AND IMMUNE SYSTEMS
Thoracic Neoplasms 0.948782839 167 12
Mediastinal Diseases 0.948782839 167 12
[D] Chest mass 0.948782839 167 12
DISEASES OF THE PLEURA, MEDI- 0.948782839 167 12
ASTINUM AND DIAPHRAGM
Thoracic cavity structure 0.806660862 181 13
Immunoproliferative neoplasm 0.960789907 123 16
Lymphoreticular tumor 0.960789907 123 16
[M]Miscellaneous myeloproliferative and 0.960789907 123 16
lymphoproliferative disorders
Hematopoietic neoplasm of uncertain be- 0.960789907 123 16
havior
Immunoproliferative Disorders 0.960789907 123 16
Malignant immunoproliferative neoplasm 0.960789907 123 16
Immunoproliferative morphology 0.960789907 123 16
Lymphoid neoplasm 0.960789907 123 16
Lymphoproliferative Disorders 0.960789907 123 16
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Cerebral hemisphere structure (body 0.984203701 379 5
structure)
Structure of skin and/or surface epithelium 0.929849639 196 10
Primary malignant neoplasm of bone mar- 0.993372685 150 12
row
Upper digestive tract structure 0.914264264 169 11
Structure of lung and/or mediastinum 0.831865487 170 12
Structure of thoracic viscus 0.833626675 169 12
Large Intestine 0.955636743 156 11
Traumatic abnormality 0.865541486 133 14
GENERAL AND COMPRESSION IN- 0.865541486 133 14
JURIES
GENERAL INJURIES 0.865541486 133 14
Injury 0.865541486 133 14
Integumentary system subdivision 0.938580862 188 9
Entire skin 0.938580862 188 9
Skin 0.938580862 188 9
CLINICAL CLASSIFICATION OF NEO- 0.849413338 124 15
PLASMS OF THE DIGESTIVE SYSTEM
Endocrine System Diseases 0.910750297 133 13
GENERAL AND POLYGLANDULAR 0.910750297 133 13
ENDOCRINE DISORDERS
GENERAL AND GROWTH RELATED 0.910750297 133 13
DISORDERS
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Acute leukemia 0.992114711 144 11
Acute leukemia (category) 0.992114711 144 11
Female Reproductive System Disorder 0.830014077 172 11
reproductive system disorder 0.830014077 172 11
Female Genital Diseases 0.830014077 172 11
Primary malignant neoplasm of trunk 0.853404172 126 14
Disorder of skeletal system 0.891154898 104 16
Disorder of immune function 0.893311447 97 16
Lower respiratory tract structure 0.94260856 142 10
Lower respiratory system structure 0.94260856 142 10
Large intestine part 0.954574889 140 10
CNS disorder 0.950732979 126 11
Neck 0.926122775 129 11
Scalp and/or neck structure 0.926122775 129 11
Face and/or neck structure 0.926122775 129 11
Complication 0.863676241 117 13
Poisoning / injury 0.863676241 117 13
POISONINGS: GENERAL TYPES 0.863676241 117 13
Poisoning 0.863676241 117 13
Sequela of disorder 0.863676241 117 13
Bone Marrow Cells 0.919730967 129 11
Colon 0.957816236 134 10
Disorder of head 0.940922395 136 10
Digestive System Neoplasms 0.91056671 108 13
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Neoplasm of digestive organ 0.91056671 108 13
[X]Malignant neoplasm of digestive organs 0.91056671 108 13
Soft Tissue Neoplasms 0.862589352 122 12
Pulmonary structure including vessels and 0.947662442 132 10
lymphoid tissue
Noninflammatory disorder of the female 0.856026394 142 10
genital organs
Pelvic mass 0.856026394 142 10
Genitourinary Neoplasms 0.854429494 141 10
Pelvic Neoplasms 0.854429494 141 10
Gastrointestinal Diseases 0.9385517 116 11
Cerebral hemisphere part 0.987087843 290 4
Skin lesion 0.874163434 108 12
Lung 0.952565902 131 9
Uterus 0.916445334 175 7
UTERUS: GENERAL TERMS 0.916445334 175 7
Endocrine Gland Neoplasms 0.918531693 122 10
Female genital organ part 0.917254244 173 7
Immunologic cell 0.953745764 89 13
Uterus part 0.916187934 172 7
[X]Other specified respiratory disorders 0.900153068 134 9
Other disorders of lung 0.900153068 134 9
Other respiratory system diseases NOS 0.900153068 134 9
Disorder of lower respiratory system 0.900153068 134 9
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DISEASES OF THE LUNG: GENERAL 0.900153068 134 9
TERMS
Lung diseases 0.900153068 134 9
Gonadal structure 0.945116752 126 9
Stomatognathic System 0.942421013 123 9
Mouth and/or pharynx structures 0.942421013 123 9
CLINICAL CLASSIFICATION OF NEO- 0.831083631 124 10
PLASMS OF THE GENITOURINARY
SYSTEM
Soft tissue tumor AND/OR sarcoma 0.894420302 96 12
Sarcoma - category 0.894420302 96 12
Connective and Soft Tissue Neoplasm 0.894420302 96 12
sarcoma 0.894420302 96 12
Leukocytes, Mononuclear 0.959415318 89 12
Brain Diseases 0.96444927 116 9
Tissue membrane 0.858421184 104 11
Upper aerodigestive tract 0.955354786 113 9
Inflammation of specific body systems 0.789088761 91 13
Inflammation of specific body structures or 0.789088761 91 13
tissue
Inflammation of specific body organs 0.789088761 91 13
Inflammatory disorder 0.789088761 91 13
Cerebral cortex 0.988689443 236 4
Layer of cerebrum 0.988689443 236 4
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Malignant neoplasm of pelvis 0.886186182 104 10
Malignant neoplasm of genitourinary or- 0.886186182 104 10
gan NOS
Marrow lymphoid tissue 0.982844922 82 11
Lymphocyte 0.982844922 82 11
Face 0.952046729 103 9
Male Genital Organs 0.908565602 88 11
Male genitourinary tract 0.908565602 88 11
Neoplasms, Nerve Tissue 0.942557141 93 10
Neoplasms, Germ Cell and Embryonal 0.942557141 93 10
Neuroectodermal Tumors 0.942557141 93 10
Hematopoietic precursor cell 0.949869526 131 7
Lobe of brain 0.987886124 218 4
Cerebral lobe 0.987886124 218 4
Animal Structures 0.941326491 109 8
Mammalian Oviducts 0.951279092 107 8
animal Oviduct 0.951279092 107 8
Uterine adnexae structure 0.951279092 107 8
Ovary and/or broad ligament structures 0.947738 103 8
Ovary 0.947738 103 8
Digestive organ part 0.85285045 91 10
Regional musculoskeletal structure 0.871264407 79 11
Skin Neoplasms 0.901783328 93 9
Neoplasm of integumentary system 0.901783328 93 9
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Limb structure 0.910886673 72 11
Primary malignant neoplasm of soft tissues 0.904030962 88 9
Gastrointestinal Neoplasms 0.923123104 86 9
Oral region 0.949576787 94 8
Oral cavity 0.949576787 94 8
Body of uterus 0.941591198 151 5
CLINICAL CLASSIFICATION OF NEO- 0.904218465 87 9
PLASMS OF THE SKIN
Malignant neoplasm of skin 0.904218465 87 9
Primary malignant neoplasm of skin 0.904218465 87 9
Malignant neoplasm of thorax 0.953098002 72 10
Extremity part 0.929292929 66 11
Lymphoid leukemia (category) 0.995833737 84 8
Lymphoblastic Leukemia 0.995833737 84 8
Adult Stem Cells 0.935222713 101 7
Disorder of lower gastrointestinal tract 0.94470788 85 8
Intestinal Diseases 0.94470788 85 8
Propensity to adverse reactions 0.842927076 68 11
Hypersensitivity 0.842927076 68 11
Immune hypersensitivity disorder by 0.842927076 68 11
mechanism
Hypersensitivity disorder 0.842927076 68 11
Adverse reactions 0.842927076 68 11
Bone Diseases 0.972210425 70 9
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Liver and/or biliary structure 0.932231914 59 11
Mammary Neoplasms 0.965571757 69 9
Malignant neoplasm of breast 0.965571757 69 9
Breast Diseases 0.965571757 69 9
Vascular Diseases 0.924512637 108 6
GENERAL VASCULAR DISORDERS 0.924512637 108 6
Carcinoma of the Large Intestine 0.963114694 69 9
Liver 0.931544995 58 11
Mouth region part 0.962988999 88 7
SKELETAL MUSCULAR SYSTEM: 0.985010901 86 7
GENERAL TERMS
Muscle 0.985010901 86 7
Muscle structure 0.985010901 86 7
Types and Parts of Skeletal Muscles 0.985010901 86 7
Skeletal Muscular System (Muscles of 0.985010901 86 7
Head, Neck, Mouth and Upper Extremity)
Skeletal muscle system structure 0.985010901 86 7
Neuroendocrine Tumors 0.95962756 87 7
Regional bone structure 0.872130383 71 9
Skeletal System (Bones of Shoulder Girdle, 0.927519696 59 10
Pelvis and Extremities)
Epithelial Cells 0.858768407 42 15
System disorder of the nervous system 0.973479132 111 5
Lower genitourinary tract structure 0.885750122 67 9
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Structure of soft tissues of head and neck 0.972995275 78 7
Oral soft tissues 0.972995275 78 7
Structure of soft tissues of head 0.972995275 78 7
Lower male genitourinary tract structure 0.890040213 65 9
Back 0.767798133 94 7
Back structure, including back of neck 0.767798133 94 7
Regional back structure 0.767798133 94 7
Genital Neoplasms, Female 0.906491402 92 6
Anogenital region 0.921632318 54 10
Disorder of upper digestive tract 0.932437729 76 7
Mucous Membrane 0.963991525 80 6
Upper extremity part 0.923096036 61 8
Upper Extremity 0.923096036 61 8
Endometrium 0.95604468 93 5
Kidney and/or ureter structures 0.888950617 60 8
Intra-abdominal urinary structure 0.888950617 60 8
Neurodegenerative Disorders 0.978100363 108 4
Kidney 0.892252223 59 8
Retroperitoneal Space 0.929105471 75 6
T-Lymphocyte 0.99042471 70 6
B-cell neoplasm 0.911092675 44 10
Myeloproliferative disease 0.996339917 66 6
Bone Marrow Diseases 0.996339917 66 6
Myeloid Leukemia 0.996339917 66 6
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Leukemia, Myelocytic, Acute 0.996339917 66 6
Skeletal tissue 0.934237452 70 6
Bone Tissue 0.934237452 70 6
Structure of shoulder and/or upper arm 0.923367003 60 7
Shoulder 0.923367003 60 7
Colonic Diseases 0.95768938 57 7
Disorder of large intestine 0.95768938 57 7
Diseases and Syndromes of Colon, Ap- 0.95768938 57 7
pendix and Rectum
Degenerative disorder 0.971820447 98 4
CLINICAL CLASSIFICATION OF NEO- 0.970887741 98 4
PLASMS OF THE RESPIRATORY SYS-
TEM
Respiratory Tract Neoplasms 0.970887741 98 4
Neoplasm of lower respiratory tract 0.970887741 98 4
Lung Neoplasms 0.970887741 98 4
Malignant neoplasm of lung 0.970887741 98 4
Anterior perineum 0.928114094 50 8
External genitalia 0.928114094 50 8
Blast Cell 0.913205095 96 4
Pectoral girdle structure 0.923206641 54 7
Exocrine Glands 0.879361785 65 6
Allergic disorder by body site affected 0.879049525 43 9
Temporal Lobe 0.96914216 117 3
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Autoimmune Diseases 0.928837793 40 9
Infectious and parasitic diseases NOS 0.97870768 85 4
INFECTIOUS AND PARASITIC DIS- 0.97870768 85 4
EASES: GENERAL TERMS
Communicable Diseases 0.97870768 85 4
Epithelium 0.881669888 47 8
Lymphoma, Diffuse 0.91590301 40 9
Malignant lymphoma, diffuse 0.91590301 40 9
Diffuse low grade B-cell lymphoma mor- 0.91590301 40 9
phology
Low grade B-cell lymphoma morphology 0.91590301 40 9
B-cell lymphoma morphology 0.91590301 40 9
Unspecified and Diffuse Lymphomas 0.91590301 40 9
Lymphoma, Non-Hodgkin's 0.91590301 40 9
Lymphoma 0.91590301 40 9
Head and Neck Neoplasms 0.804197324 40 10
Disorder of upper gastrointestinal tract 0.949484821 56 6
Chronic Disease 0.868639252 52 7
[X]Diseases of esophagus, stomach and 0.951535523 55 6
duodenum
Intestinal Neoplasms 0.939129106 55 6
Cancer of Intestines 0.939129106 55 6
Limbic System 0.945704783 109 3
Stomach Diseases 0.95120221 54 6
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Diseases and Syndromes of Stomach and 0.95120221 54 6
Duodenum
Primary malignant neoplasm of intra- 0.909111106 56 6
abdominal organs
Lower urinary tract 0.884958781 57 6
Bladder and outflow structure 0.884958781 57 6
Pelvic cavity urinary structure 0.884958781 57 6
Malignant squamous tumor 0.961447259 78 4
Squamous Cell Neoplasms 0.961447259 78 4
Squamous cell carcinoma - category 0.961447259 78 4
[M]Papillary and squamous cell neoplasms 0.961447259 78 4
Urinary outflow structure 0.899006875 55 6
Breast part 0.982384659 75 4
Colorectal Neoplasms 0.962403491 51 6
Colonic Neoplasms 0.962403491 51 6
Malignant tumor of colon 0.962403491 51 6
Mass of colon 0.962403491 51 6
Rectal Diseases 0.962403491 51 6
Malignant neoplasm of large intestine 0.962403491 51 6
Anorectal disorder 0.962403491 51 6
Neoplasms, Ductal, Lobular, and 0.979846382 58 5
Medullary
Ductal, lobular AND/OR medullary neo- 0.979846382 58 5
plasm
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ovarian neoplasm 0.985859073 70 4
Ovarian Diseases 0.985859073 70 4
Gonadal Disorders 0.985859073 70 4
Neoplasm of uterine adnexa 0.985859073 70 4
Adnexal Diseases 0.985859073 70 4
Stomach and Omentum 0.880863512 52 6
Thyroid and/or parathyroid structures 0.99480563 46 6
Malignant neoplasm of female genital or- 0.979987271 56 5
gan
Malignant neoplasm of other and unspeci- 0.979987271 56 5
fled female genital organs
Male external genitalia structure 0.933642869 41 7
Bone structure of head and/or neck 0.90272065 59 5
Bone structure of cranium 0.90272065 59 5
Bones of cranium and face 0.90272065 59 5
Musculoskeletal structure of head 0.90272065 59 5
Musculoskeletal structure of head and neck 0.90272065 59 5
Bone structure of head 0.90272065 59 5
Pluripotent Stem Cells 0.996533169 53 5
Mesenchymal Stem Cells 0.998486893 66 4
Inflammatory disorder of musculoskeletal 0.89003006 36 8
system
Prostatic and/or seminal vesicle structures 0.891170534 47 6
Minor pelvis 0.891170534 47 6
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Male urinary outflow structure 0.891170534 47 6
Prostate and vas deferens structures 0.891170534 47 6
Prostate 0.891170534 47 6
Male internal genital organ 0.891170534 47 6
Pelvic cavity male genital structure 0.891170534 47 6
GENERAL CONVENIENCE TERMS 0.957050207 131 2
Other mental disorders 0.957050207 131 2
Schizophrenia and Disorders with Psy- 0.957050207 131 2
chotic Features
Mental disorders 0.957050207 131 2
9-72 PSYCHOTIC DISORDERS NEC in 0.957050207 131 2
SNM198
Psychotic Disorders 0.957050207 131 2
Adrenal Glands 0.990503356 50 5
General Cytologic Alterations 0.890608599 45 6
Abnormal cell 0.890608599 45 6
Urologic Diseases 0.810384134 49 6
Urologic Neoplasms 0.810384134 49 6
URINARY TRACT DISEASES: GEN- 0.810384134 49 6
ERAL TERMS
Malignant tumor of urinary system 0.82529203 48 6
Arthritis 0.894450006 33 8
Other and unspecified arthropathies 0.894450006 33 8
Arthropathies NOS 0.894450006 33 8
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DERANGEMENTS OF THE JOINTS 0.894450006 33 8
OTHER THAN VERTEBRAL COLUMN
Mechanical joint disorder 0.894450006 33 8
Thyroid Gland 0.999657493 44 5
Rheumatism 0.91674193 34 7
Malignant melanoma - category 0.977681674 74 3
Nevi and Melanomas 0.977681674 74 3
Melanocytic neoplasm 0.977681674 74 3
melanoma 0.977681674 74 3
Nevus AND/OR melanoma 0.977681674 74 3
Esophageal and/or gastric structures 0.952011911 45 5
Mouth, esophagus and stomach structures 0.952011911 45 5
Leukocyte Disorders 0.939452575 38 6
Structure of digestive system mucous 0.971257448 55 4
membrane
Mediastinum 0.89565277 39 6
Breast Carcinoma 0.969737078 43 5
Primary malignant neoplasm of breast 0.969737078 43 5
frontal lobe 0.962626941 54 4
Extrapyramidal system 0.959566 108 2
Infratentorial brain part 0.949878385 71 3
Brain Stem 0.949878385 71 3
Infratentorial brain structure 0.949878385 71 3
Rheumatoid Arthritis 0.92804053 31 7
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Delayed hypersensitivity disorder 0.92804053 31 7
Secondary inflammatory arthritis 0.92804053 31 7
Arthropathy associated with a hypersensi- 0.92804053 31 7
tivity reaction
Arthropathy associated with another dis- 0.92804053 31 7
order
Cancer of ovary and other female genital 0.98684912 51 4
organs
Malignant neoplasm of ovary 0.98684912 51 4
CLINICAL CLASSIFICATION OF NEO- 0.942647269 35 6
PLASMS OF THE ENDOCRINE SYS-
TEM
Chronic inflammatory disorder 0.865021403 45 5
Degenerative Diseases, Central Nervous 0.982250516 95 2
System
Hereditary AND/OR degenerative disease 0.982250516 95 2
of central nervous system
Embryonic Stem Cells 0.994912283 31 6
B-Cell Lymphomas 0.910409174 29 7
Hippocampus (Brain) 0.970426009 63 3
Hippocampal Formation 0.970426009 63 3
Structure of archicortex 0.970426009 63 3
Cancer; other primary 0.923661035 33 6
Cancer of Head and Neck 0.923661035 33 6
143
Stomach and/or duodenal structures 0.969442212 37 5
Structure of soft tissues of trunk 0.611251251 32 9
Ductal Carcinoma 0.971613624 45 4
Lymphoid system structure 0.924162257 27 7
Lymphoid organ structure 0.924162257 27 7
Lymphatic System 0.924162257 27 7
Lymphoid Tissue 0.924162257 27 7
Stomach 0.967796705 36 5
myometrium 0.995057317 58 3
Smooth muscle (tissue) 0.995057317 58 3
HEART: GENERAL TERMS 0.94233838 36 5
CARDIOVASCULAR SYSTEM: GEN- 0.94233838 36 5
ERAL TERMS
Cardiovascular system 0.94233838 36 5
Cardiovascular structure of trunk 0.94233838 36 5
HEART AND PERICARDIUM 0.94233838 36 5
Heart 0.94233838 36 5
Heart AND pericardium structure 0.94233838 36 5
Regional cardiovascular structure 0.94233838 36 5
Intrathoracic cardiovascular structure 0.94233838 36 5
Neurologic Manifestations 0.769576204 44 5
Cerebral cortex part 0.981008689 85 2
Cerebral gyrus 0.981008689 85 2
Gyrus of brain 0.981008689 85 2
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Squamous cell carcinoma 0.973136228 56 3
Upper respiratory tract 0.945898453 34 5
Pharynx and/or larynx structures 0.945898453 34 5
Ear, nose and throat 0.945898453 34 5
PHARYNX - OROPHARYNX AND HY- 0.945898453 34 5
POPHARYNX
Pharyngeal structure 0.945898453 34 5
Organ dysfunction syndrome 0.988512532 81 2
Bacterial Infections 0.988512532 81 2
Shock 0.988512532 81 2
Bacterial infections - causative organisms 0.988512532 81 2
Systemic Inflammatory Response Syn- 0.988512532 81 2
drome
Systemic infection 0.988512532 81 2
Acute Disease 0.988512532 81 2
Acute disease of cardiovascular system 0.988512532 81 2
Infection by site 0.988512532 81 2
Connective Tissue Cells 0.952872034 24 7
Muscle, Striated 0.961394427 23 7
Skeletal muscle structure 0.961394427 23 7
Mature (peripheral) B-cell neoplasm 0.918352051 28 6
Disorder of basophils 0.9886844 31 5
Basophilic leukemia 0.9886844 31 5
Disorder involving basophils and mast cells 0.9886844 31 5
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Malignant white blood cell disorder 0.9886844 31 5
Acute Basophilic Leukemia 0.9886844 31 5
DISEASES OF THE LIVER AND BIL- 0.910833254 28 6
IARY SYSTEM
Bone structure of face 0.992281879 50 3
Dentition 0.992281879 50 3
Jaw 0.992281879 50 3
Structure of gum and supporting structure 0.992281879 50 3
of tooth
Oral hard tissue structure 0.992281879 50 3
Teeth and Tooth Structures 0.992281879 50 3
Gingiva 0.992281879 50 3
Maxillofacial bone structure 0.992281879 50 3
TEETH, GUMS AND SUPPORTING 0.992281879 50 3
STRUCTURES: GENERAL TERMS
Periodontium 0.992281879 50 3
Structure of teeth, gums, and supporting 0.992281879 50 3
structures
Tooth structure 0.992281879 50 3
Brain stem part 0.968215416 51 3
Midbrain and pons 0.968215416 51 3
Benign Neoplasm 0.580777863 51 5
Tracheobronchial tree part 0.989084098 29 5
Tracheobronchial structure 0.989084098 29 5
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Acute infectious disease 0.989208494 70 2
Cardiovascular Infections 0.989208494 70 2
Septic Shock 0.989208494 70 2
Disorder of neck 0.987936614 28 5
Acute lymphoblastic leukemia - category 0.981072142 28 5
Acute lymphocytic leukemia 0.981072142 28 5
Basal Ganglia 0.957292471 70 2
Basal ganglia and capsules 0.957292471 70 2
Neck Neoplasms 0.991724325 27 5
Layer of adrenal gland 0.993690251 44 3
Endocrine gland part 0.993690251 44 3
Adrenal part 0.993690251 44 3
Adrenal Cortex 0.993690251 44 3
Diseases and Syndromes of Peritoneum, 0.922423086 35 4
Omentum and Mesentery
Peritoneal Diseases 0.922423086 35 4
Primary malignant neoplasm of pelvis 0.757257067 28 6
Uterine Diseases 0.852336909 49 3
Myeloid Cells 0.958760115 26 5
Cell content alteration 0.958760115 26 5
Phagocytes 0.958760115 26 5
Inflammatory disorder of digestive system 0.948365397 43 3
Inflammatory disorder of digestive tract 0.948365397 43 3
Midbrain structure 0.966070632 42 3
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Precursor Cell Lymphoblastic Leukemia 0.99952862 60 2
Lymphoma
Other gastrointestinal cancer 0.91795572 32 4
Tumor of esophagus, stomach and duode- 0.935483871 31 4
num
Nervous system tumor morphology 0.940473634 17 7
Central nervous system tumor morphology 0.940473634 17 7
Neoplasms, Neuroepithelial 0.940473634 17 7
Glioma 0.940473634 17 7
Stomach Neoplasms 0.932511111 30 4
Malignant neoplasm of stomach 0.932511111 30 4
Musculoskeletal structure of limb 0.955653831 19 6
Bronchial 0.987865691 22 5
Organ cavity 0.832953498 26 5
Lower Extremity 0.976372289 18 6
Hematopoietic stem cells 0.994123539 35 3
Cancer of Neck 0.995826078 26 4
[X]Inflammatory polyarthropathies 0.980794838 26 4
Chronic arthritis of juvenile onset 0.980794838 26 4
Chronic polyarticular juvenile rheumatoid 0.980794838 26 4
arthritis
Chronic arthropathy 0.980794838 26 4
Chronic arthritis 0.980794838 26 4
Chronic Childhood Arthritis 0.980794838 26 4
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Chronic disease of musculoskeletal system 0.980794838 26 4
Polyarthropathy 0.980794838 26 4
Adipose tissue 0.974546758 26 4
Primary malignant neoplasm of urinary 0.749115082 27 5
system
Diencephalon part 0.925054759 54 2
Structure of diencephalon 0.925054759 54 2
Airway structure 0.980614618 20 5
Body conduit 0.980614618 20 5
Cervix Uteri 0.907309817 21 5
Normal pregnancy and/or delivery 0.967987732 49 2
Twin Multiple Birth 0.967987732 49 2
Maternal AND/OR fetal condition affect- 0.967987732 49 2
ing labor AND/OR delivery
Abnormal products of conception 0.967987732 49 2
MATERNAL AND FETAL CONDI- 0.967987732 49 2
TIONS AFFECTING LABOR AND
DELIVERY
Hemorrhagic complication of pregnancy 0.967987732 49 2
Complications of pregnancy, childbirth 0.967987732 49 2
and the puerperium
Disorder of labor / delivery 0.967987732 49 2
Disorder of pregnancy 0.967987732 49 2
Pregnancy, Multiple 0.967987732 49 2
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Pregnancy Complications 0.967987732 49 2
Disorder of product of conception 0.967987732 49 2
Delivery AND/OR maternal condition af- 0.967987732 49 2
fecting management
Umbilical Cord Blood 0.98659523 32 3
Cancer of Urinary Tract 0.823079481 23 5
Intestinal Mucosa 0.987446595 47 2
Layers of gastrointestinal wall 0.987446595 47 2
Intestinal wall structure 0.987446595 47 2
Structure of gastrointestinal mucous mem- 0.987446595 47 2
brane
Retroperitoneal mass 0.934945046 33 3
Uterine Neoplasms 0.788099341 39 3
Testis 0.993652492 23 4
Scrotal and testis structures 0.993652492 23 4
Retroperitoneal Neoplasms 0.944369163 32 3
Blood Vessels 0.902209302 20 5
Prostate mass 0.817365812 22 5
Disorder of male reproductive system 0.817365812 22 5
Malignant neoplasm of prostate 0.817365812 22 5
Disorder of the lower urinary tract 0.817365812 22 5
DISEASES OF THE LOWER URINARY 0.817365812 22 5
TRACT: GENERAL CONDITIONS
malignant tumor of male genital organ 0.817365812 22 5
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Prostatic Diseases 0.817365812 22 5
Prostatic Neoplasms 0.817365812 22 5
Genital Neoplasms, Male 0.817365812 22 5
Genital Diseases, Male 0.817365812 22 5
Small Intestine - Duodenum 0.847446994 26 4
Intestines, Small 0.847446994 26 4
SMALL INTESTINE: GENERAL 0.847446994 26 4
TERMS
Benign epithelial neoplasm - category 0.734011111 30 4
Benign adenomatous neoplasm - category 0.734011111 30 4
adenoma 0.734011111 30 4
Lymphoid precursor cell 0.999611825 44 2
lymphoblast 0.999611825 44 2
[X]Malignant neoplasm of thyroid and 0.954295051 23 4
other endocrine glands
Malignant neoplasm of endocrine gland 0.954295051 23 4
Cerebral degeneration presenting primarily 0.995016423 87 1
with dementia
Alzheimer's Disease 0.995016423 87 1
[X]Dementia in other diseases classified 0.995016423 87 1
elsewhere
DEMENTIAS IN THE SENIUM AND 0.995016423 87 1
PRESENIUM
Other cerebral degeneration NOS 0.995016423 87 1
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Degenerative brain disorder 0.995016423 87 1
Delirium, Dementia, Amnestic, Cognitive 0.995016423 87 1
Disorders
Tauopathies 0.995016423 87 1
Dementia 0.995016423 87 1
Dementing Neurological Diseases and Syn- 0.995016423 87 1
dromes
Disease of liver and bile duct 0.904857627 19 5
Malignant neoplasm of liver 0.904857627 19 5
Liver neoplasms 0.904857627 19 5
Liver diseases 0.904857627 19 5
Acute Myeloid Leukemia (AML-M2) 0.986247606 21 4
Structure of soft tissues of abdomen 0.561973276 24 6
EMBRYO AND FETUS 0.868641799 13 7
penis 0.875996016 18 5
Malignant Glioma 0.932550208 14 6
Bronchial Diseases 0.973688928 26 3
Lung Diseases, Obstructive 0.973688928 26 3
Pharyngeal part 0.971269077 26 3
Antibody-Producing Cells 0.982384293 11 7
B-Lymphocytes 0.982384293 11 7
Tongue 0.94076412 20 4
Skin tissue 0.999688663 75 1
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Hereditary and degenerative nervous sys- 0.924063591 27 3
tem conditions
Occipital lobe 0.968327822 38 2
Serous sac 0.798288328 18 5
Serous Membrane 0.798288328 18 5
Bronchi 0.989929172 18 4
Corpus striatum structure 0.981235392 35 2
Lentiform nucleus structure 0.981235392 35 2
Neoplasm Metastasis 0.914861897 25 3
Neoplastic Processes 0.914861897 25 3
Hemorrhage 0.877586295 26 3
Hemorrhage of blood vessel 0.877586295 26 3
Myomatous neoplasm 0.975130493 23 3
Peritoneal sac 0.787801878 17 5
Peritoneal Cavity 0.787801878 17 5
Structure of cavity of serous sac 0.787801878 17 5
Structure of serous cavity 0.787801878 17 5
Peritoneum 0.787801878 17 5
Frontal lobe gyrus 0.982731878 34 2
Lactiferous duct 0.999361019 66 1
Mammary lobe 0.999361019 66 1
Glandular structure of breast 0.999361019 66 1
Duct (organ) structure 0.999361019 66 1
Thyroid lump 0.997053312 22 3
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Malignant neoplasm of thyroid 0.997053312 22 3
thyroid neoplasm 0.997053312 22 3
Thyroid Diseases 0.997053312 22 3
Spinal Cord 0.995085995 33 2
Vertebral column 0.995085995 33 2
BONES OF VERTEBRAL COLUMN 0.995085995 33 2
Structure of vertebral region of back 0.995085995 33 2
Spinal cord, roots and ganglia structure 0.995085995 33 2
Primary malignant neoplasm of gastroin- 0.960565067 34 2
testinal tract
Primary malignant neoplasm of large in- 0.978705979 33 2
testine
Colon Carcinoma 0.978705979 33 2
Primary malignant neoplasm of colon 0.978705979 33 2
Primary malignant neoplasm of intestinal 0.978705979 33 2
tract
Nerve 0.976026532 33 2
Spinal nerve structure 0.976026532 33 2
Nerve part 0.976026532 33 2
Peripheral Nervous System 0.976026532 33 2
Non-Autonomic Spinal Nerves 0.976026532 33 2
Peripheral Nerves 0.976026532 33 2
Extrapyramidal Disorders 0.949830754 22 3
Movement Disorders 0.949830754 22 3
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Other and unspecified extrapyramidal dis- 0.949830754 22 3
eases and abnormal movement disorders
Motion and Coordination Diseases and 0.949830754 22 3
Syndromes
Liver tumor morphology 0.944840743 16 4
Adenocarcinoma of liver 0.944840743 16 4
Primary carcinoma of the liver cells 0.944840743 16 4
Primary malignant neoplasm of liver 0.944840743 16 4
Neoplasm of body of uterus 0.793317267 38 2
Nose and nasopharynx structure 0.988811111 30 2
Endometriosis, site unspecified 0.980633333 30 2
Disorder characterized by pain 0.980633333 30 2
Hypothalamic structure 0.971711111 30 2
Benign neoplasm of trunk 0.936441179 31 2
Benign neoplasm of abdomen 0.936441179 31 2
Metencephalon 0.982821818 29 2
hindbrain 0.982821818 29 2
Regional skeletal muscle structure 0.936436934 12 5
Kidney part 0.885644653 21 3
Pain 0.927266667 30 2
Sensory and Pain Diseases and Syndromes 0.927266667 30 2
Pain Disorder 0.927266667 30 2
Adrenal mass 0.998125331 27 2
Tumors of Adrenal Cortex 0.998125331 27 2
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Adrenal Cortex Diseases 0.998125331 27 2
Adrenal Gland Diseases 0.998125331 27 2
Adrenal Gland Neoplasms 0.998125331 27 2
lymph nodes 0.893914292 12 5
Regional vascular structure 0.95645197 18 3
Serous membrane part 0.80121931 16 4
Omentum 0.80121931 16 4
Ganglia, Sensory 1 25 2
Structure of nervous system ganglion 1 25 2
Ganglia 1 25 2
Leukemia, T-Cell 0.999483221 50 1
Structure of putamen 0.994276206 25 2
Neostriatum 0.994276206 25 2
Temporal lobe gyrus 0.974468337 51 1
Immediate hypersensitivity 0.992372712 25 2
Asthma 0.992372712 25 2
Obstruction of lower respiratory tract 0.992372712 25 2
Respiratory Hypersensitivity 0.992372712 25 2
Respiratory Insufficiency 0.992372712 25 2
Hypersensitivity disease 0.992372712 25 2
Airway Obstruction 0.992372712 25 2
Stomach part 0.972491751 17 3
Region of stomach 0.972491751 17 3
Lower female genital structure 0.971261787 17 3
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Fetus 0.895269355 11 5
GENERAL CONDITIONS OF THE KID- 0.944074567 26 2
NEY AND URETER
Kidney Neoplasms 0.944074567 26 2
Kidney Diseases 0.944074567 26 2
Malignant neoplasm of kidney 0.975720466 25 2
Tumor Cells, Cultured 0.99094323 12 4
Cell Line, Tumor 0.99094323 12 4
Disorder of small intestine 0.989756598 24 2
Inflammatory Bowel Diseases 0.989756598 24 2
Gastritis 0.989756598 24 2
Gastroenteritis 0.989756598 24 2
Thalamic structure 0.967356953 24 2
Musculoskeletal structure of lower limb 0.957256461 12 4
Bone of limb 0.957256461 12 4
Bone structure of lower limb 0.957256461 12 4
Bone and/or joint structure of limb 0.957256461 12 4
Musculoskeletal structure of trunk 0.925833886 12 4
Small intestine part 0.919334771 16 3
Nutrition Disorders 0.912193506 12 4
Developmental Disabilities 0.994223041 44 1
Mental disorder of infancy, childhood or 0.994223041 44 1
adolescence
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Mental disorder usually first evident in in- 0.994223041 44 1
fancy, childhood AND/OR adolescence
Mental Disorders Diagnosed in Childhood 0.994223041 44 1
Developmental mental disorder 0.994223041 44 1
Leiomyomatous neoplasm - category 0.992247945 22 2
Tegmentum Mesencephali 0.983302103 22 2
Midbrain part 0.983302103 22 2
Cerebral Peduncle 0.983302103 22 2
Dermatitis 0.930127142 15 3
Small Intestine - Jejunum and Ileum 0.926390271 15 3
Carcinoma, Papillary 0.941972921 22 2
Cerebellum 1 20 2
Cardiovascular organ part 0.997873754 20 2
Heart part 0.997873754 20 2
Disorder of soft tissue of body cavity 0.996528239 20 2
Disorder of soft tissue of head 0.996528239 20 2
Mouth Diseases 0.996528239 20 2
DISEASES OF THE SALIVARY 0.996528239 20 2
GLANDS AND ORAL CAVITY
Disorder of oral soft tissues 0.996528239 20 2
Circulatory system disease NOS 0.996478405 20 2
Malignant neoplasm of soft tissues of tho- 0.989571913 13 3
rax
Disorder of soft tissue of trunk 0.989571913 13 3
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Skin disorder of breast 0.989571913 13 3
Primary malignant neoplasm of skin of 0.989571913 13 3
chest
Primary malignant neoplasm of soft tissues 0.989571913 13 3
of trunk
Primary malignant neoplasm of soft tissues 0.989571913 13 3
of thorax
Primary malignant neoplasm of skin of 0.989571913 13 3
trunk
Primary malignant neoplasm of chest wall 0.989571913 13 3
Carcinoma, Lobular 0.989571913 13 3
Malignant neoplasm of skin of trunk 0.989571913 13 3
Neoplasm of skin region 0.989571913 13 3
Disorder of body wall 0.989571913 13 3
Primary malignant neoplasm of skin of 0.989571913 13 3
breast
Neoplasm of soft tissues of thorax 0.989571913 13 3
Neoplasm of skin of chest 0.989571913 13 3
Neoplasm of skin of breast 0.989571913 13 3
Neoplasm of skin of trunk 0.989571913 13 3
Disorder of skin AND/OR subcutaneous 0.989571913 13 3
tissue of trunk
Neoplasm of soft tissues of trunk 0.989571913 13 3
Neoplasm of chest wall 0.989571913 13 3
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Hereditary Diseases 0.855280195 11 4
Parkinson Disease 0.976367355 19 2
Basal Ganglia Diseases 0.976367355 19 2
Parkinsonian Disorders 0.976367355 19 2
Carcinoma of genital organs NOS 0.88089712 14 3
Carcinoma of genitourinary organ 0.88089712 14 3
Endocrine tumor morphology 0.947808572 13 3
Noninfectious, erythematous, papular 0.929017618 13 3
AND/OR squamous disease
Cerebral white matter structure 0.996753726 18 2
Corpus Callosum 0.996753726 18 2
White matter structure of brain and spinal 0.996753726 18 2
cord
Child Development Disorders, Pervasive 0.992549487 35 1
Psychoses with origin in childhood 0.992549487 35 1
Autistic Disorder 0.992549487 35 1
[X]Unspecified disorder of psychological 0.992549487 35 1
development
Pervasive Development Disorder 0.992549487 35 1
Endothelial Cells 0.980341194 7 5
MULTIPLE SYSTEM MALFORMA- 0.84513245 10 4
TIONS AND CHROMOSOMAL DIS-
EASES
Congenital Disorders 0.84513245 10 4
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Vascular structure of trunk 0.929865253 12 3
Malignant neuroendocrine neoplasm, neu- 0.988888554 11 3
ral
Embryonal neuroepithelial tumor 0.988888554 11 3
Neuronal and mixed neuronal-glial tumor 0.988888554 11 3
Neuroepitheliomatous neoplasm 0.988888554 11 3
Neuroectodermal Tumor, Primitive 0.988888554 11 3
Bacteria 0.903744201 12 3
Prokaryote 0.903744201 12 3
Musculoskeletal structure of pelvis 0.984070583 11 3
Structure of superior frontal gyrus 0.98377165 33 1
Disorder of lipoprotein AND/OR lipid 0.977235087 11 3
metabolism
Other disorders of metabolism 0.977235087 11 3
Metabolic Diseases 0.977235087 11 3
HYPERALIMENTATION AND OBE- 0.973561384 11 3
SITY
Overnutrition 0.973561384 11 3
Obesity 0.973561384 11 3
Other endocrine/nutritional/metabolic 0.973561384 11 3
disorder
Cranial nerve part 0.943050702 17 2
Cranial Nerves 0.943050702 17 2
Structure of layer of kidney 0.999046118 16 2
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Nerve Tissue 0.999004645 16 2
Spinal nerve root structure 0.999004645 16 2
Peripheral nerve part 0.999004645 16 2
Nerve root structure 0.999004645 16 2
Ganglia, Spinal 0.999004645 16 2
Adrenocortical carcinoma 0.997573822 16 2
Non-Occupational Pulmonary Diseases 0.952362311 11 3
and Syndromes
Amygdaloid structure 0.981668879 16 2
Veins 0.864724705 9 4
Venous system 0.864724705 9 4
VEINS - TYPE AND STRUCTURE 0.864724705 9 4
ARTERIES: TYPE AND STRUCTURE 0.928091782 11 3
Systemic vascular structure 0.928091782 11 3
Systemic arterial structure 0.928091782 11 3
Artery of trunk 0.928091782 11 3
Arteries 0.928091782 11 3
Arterial system 0.928091782 11 3
Head Neoplasms 0.762574454 8 5
Extracellular Fluid 0.918034268 11 3
Extracellular Space 0.918034268 11 3
Posterior root of spinal nerve 0.998629077 15 2
Skin part 0.93563865 8 4
SKIN REGION: GENERAL TERM 0.93563865 8 4
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Skin region 0.93563865 8 4
Skin of trunk, NOS 0.93563865 8 4
Skin of part of trunk 0.93563865 8 4
Skin AND subcutaneous tissue structure of 0.93563865 8 4
trunk
Nervous System Neoplasms 0.854023912 7 5
Central Nervous System Neoplasms 0.854023912 7 5
Intracranial mass 0.854023912 7 5
Brain Neoplasms 0.854023912 7 5
Neoplasms, Intracranial 0.854023912 7 5
Visual Cortex 0.978788889 30 1
Body wall structure 0.807017544 9 4
Salivary Glands 0.933609272 10 3
Cardiac internal structure 0.999668435 14 2
Cardiac chamber structure 0.999668435 14 2
neutrophil 0.998531641 14 2
granulocyte 0.998531641 14 2
Neurosecretory Systems 0.993416067 14 2
Hypothalamus, Middle 0.993416067 14 2
Hypothalamo-Hypophyseal System 0.993416067 14 2
Hypothalamus part 0.993416067 14 2
Pituitary and/or pineal structures 0.993416067 14 2
Pituitary Gland 0.993416067 14 2
Systemic circulatory system 0.86618961 8 4
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Afterbirth 0.852043349 8 4
Structure of middle temporal gyrus 0.969936709 28 1
Layer of temporal lobe 0.969936709 28 1
Cerebral dorsum structure 0.969936709 28 1
Gray matter of temporal lobe 0.969936709 28 1
Acute myeloid leukemia without matura- 0.984111221 9 3
tion
Female perineal structure 0.981205635 9 3
Vulva 0.981205635 9 3
Vulval and/or female perineal structures 0.981205635 9 3
Female external genitalia structure 0.981205635 9 3
Esophagus 0.875529801 10 3
Nipples 0.949280959 9 3
Proximal stomach 0.946816727 9 3
Synovial Membrane 0.841680486 15 2
ARTICULAR SYSTEM - JOINTS 0.841680486 15 2
ARTICULAR SYSTEM: GENERAL 0.841680486 15 2
TERMS
Joint part 0.841680486 15 2
Membrane organ structure 0.841680486 15 2
Joints 0.841680486 15 2
Soft tissue joint component 0.841680486 15 2
Joint Capsule 0.841680486 15 2
Types and Parts of Joints 0.841680486 15 2
164
Articular system 0.841680486 15 2
Cecum 0.907315458 9 3
Primary malignant neoplasm of male gen- 0.935468244 13 2
ital organ
Prostate carcinoma 0.935468244 13 2
Primary malignant neoplasm of prostate 0.935468244 13 2
Childhood asthma 0.992958527 24 1
Exanthema 0.990004418 12 2
Disorder of keratinization 0.990004418 12 2
Cell-mediated cytotoxic disorder 0.990004418 12 2
Cutaneous hypersensitivity 0.990004418 12 2
Acquired disorder of keratinization 0.990004418 12 2
Histologic type of inflammatory skin disor- 0.990004418 12 2
der
Psoriasis 0.990004418 12 2
Other psoriasis 0.990004418 12 2
Skin Diseases, Papulosquamous 0.990004418 12 2
Inflammatory hyperkeratotic dermatosis 0.990004418 12 2
Pain finding at anatomical site 0.945544093 25 1
Ventral Tegmental Area 0.975811796 12 2
Abdominal Pain 0.96174318 24 1
Pain of truncal structure 0.96174318 24 1
Benign neoplasm of other endocrine glands 0.949856417 12 2
and related structures
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Benign tumor of endocrine gland 0.949856417 12 2
Region of cerebral cortex 0.986104886 23 1
Surface of brain 0.986104886 23 1
Structure of entorhinal cortex 0.986104886 23 1
Cerebral medial surface structure 0.986104886 23 1
Parahippocampal Gyrus 0.986104886 23 1
Region of temporal cortex 0.986104886 23 1
Congenital abnormal shape 0.83184376 9 3
CONGENITAL ANOMALIES: GEN- 0.83184376 9 3
ERAL TERMS
Congenital growth alteration 0.83184376 9 3
Deformity 0.83184376 9 3
Other and unspecified congenital anoma- 0.83184376 9 3
lies
Congenital Abnormality 0.83184376 9 3
jejunum 0.929285399 12 2
Nasopharynx 0.998148412 21 1
Parameningeal structure in the context of 0.998148412 21 1
malignancy
Reticuloendotheliosis 0.995397351 10 2
Malignant histiocytic neoplasm 0.995397351 10 2
Histiocytosis 0.995397351 10 2
Histiocytic Disorders, Malignant 0.995397351 10 2
Histiocytosis, Langerhans-Cell 0.995397351 10 2
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Lung Diseases, Interstitial 0.995397351 10 2
Histiocytic neoplasm (morphology) 0.995397351 10 2
Monocytic leukemia 0.995397351 10 2
Histiocytic syndrome 0.995397351 10 2
Dendritic cell neoplasm 0.995397351 10 2
Acute monocytic/monoblastic leukemia 0.995397351 10 2
Langerhans cell histiocytosis - category 0.995397351 10 2
Acute monocytic leukemia 0.995397351 10 2
Entire viscus 0.99423588 20 1
Hollow viscus 0.99423588 20 1
Abdominal organ 0.99423588 20 1
Entire fallopian tube 0.99423588 20 1
Entire pelvic organ 0.99423588 20 1
Entire female internal genital organ 0.99423588 20 1
Entire pelvic viscus 0.99423588 20 1
Entire female genital organ 0.99423588 20 1
Intra-abdominal genital structure 0.99423588 20 1
Uterine Fibroids 0.99154485 20 1
Benign myomatous tumor 0.99154485 20 1
Benign neoplasm of female genital organ, 0.99154485 20 1
site unspecified
Benign neoplasm of body of uterus 0.99154485 20 1
Benign neoplasm of uterus NOS 0.99154485 20 1
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Benign leiomyomatous neoplasm - cate- 0.99154485 20 1
gory
Benign genital neoplasm 0.99154485 20 1
Benign neoplasm corpus uteri NEC 0.99154485 20 1
Thoracic Arteries 0.940551014 7 3
Structure of brachiocephalic artery 0.940551014 7 3
Artery of mediastinum 0.940551014 7 3
Supraaortic branch of thoracic aorta 0.940551014 7 3
Structure of artery of thorax AND/OR ab- 0.940551014 7 3
domen
Branch of thoracic aorta 0.940551014 7 3
Substantia nigra structure 0.977218543 10 2
Midbrain nucleus 0.977218543 10 2
Diffuse high grade B-cell lymphoma 0.97031405 5 4
High grade B-cell lymphoma 0.97031405 5 4
Peripheral and visceral atherosclerosis 1 19 1
Peripheral Vascular Diseases 1 19 1
Multiple Myeloma 1 19 1
Paraproteinemias 1 19 1
Skin Manifestations 1 19 1
Vascular Hemostatic Disorders 1 19 1
Purpura and other hemorrhagic conditions 1 19 1
Other paraproteinemias 1 19 1
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[X]Diseases of arteries, arterioles and cap- 1 19 1
illaries
Blood Protein Disorders 1 19 1
Blood Coagulation Disorders 1 19 1
Gammopathy 1 19 1
Monoclonal Gammapathies 1 19 1
Plasma Cell Neoplasm 1 19 1
White blood cell abnormality 1 19 1
Purpura 1 19 1
Hemorrhagic Disorders 1 19 1
Plasmacytoma - category 1 19 1
Plasma cell myeloma - category 1 19 1
Immunosecretory disorder 1 19 1
Plasma cell myeloma/plasmacytoma 1 19 1
Myeloma cell 1 19 1
Abnormal hematopoietic cell 1 19 1
Abnormal cellular component of blood 1 19 1
Clotting or bleeding disorder NOS 1 19 1
[X]Coagulation defects, purpura and other 1 19 1
hemorrhagic conditions
Plasmacytoma 1 19 1
Malignant immunoproliferative disease 1 19 1
(clinical)
Coagulation and hemorrhagic disorders 1 19 1
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Other peripheral vascular disease 1 19 1
Purpura, Nonthrombocytopenic 1 19 1
Gingival and periodontal disease NOS 0.999160971 19 1
Jaw Diseases 0.999160971 19 1
Inflammatory disorder of jaw 0.999160971 19 1
Inflammatory disorder of head 0.999160971 19 1
Disorder of teeth AND/OR supporting 0.999160971 19 1
structures
Chronic disease of teeth AND/OR sup- 0.999160971 19 1
porting structures
Chronic digestive system disorder 0.999160971 19 1
Disorder of face 0.999160971 19 1
Periodontal Diseases 0.999160971 19 1
Periodontitis 0.999160971 19 1
Neoplasms, Cystic, Mucinous, and Serous 0.920797342 20 1
Cystic, mucinous AND/OR serous neo- 0.920797342 20 1
plasm
Spleen 1 9 2
Base of skull structure 0.997940344 9 2
Structure of organ cavity subdivision 0.997940344 9 2
Intracranial ganglion 0.997940344 9 2
Structure of fossa of cranial cavity 0.997940344 9 2
Structure of middle fossa of cranial cavity 0.997940344 9 2
Structure of cranial nerve ganglion 0.997940344 9 2
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Trigeminal nerve structure 0.997940344 9 2
Structure of trigeminal ganglion 0.997940344 9 2
Parietal Lobe 0.987016808 9 2
Functional disorder of intestine 0.980911398 9 2
DISEASES OF THE GALLBLADDER 0.975725477 9 2
AND BILE DUCTS
Biliary Tract Diseases 0.975725477 9 2
Gall Bladder Diseases 0.975725477 9 2
Endometrial Neoplasms 0.972185333 18 1
Endometrial disorder 0.972185333 18 1
Pontine structure 0.958108058 9 2
Still's disease with juvenile onset and/or 0.990628844 17 1
adult onset
Systemic onset juvenile chronic arthritis 0.990628844 17 1
Endometrioid tumor 0.974073134 17 1
Malignant endometrioid tumor 0.974073134 17 1
Carcinoma, Endometrioid 0.974073134 17 1
ATRIA: GENERAL TERMS 1 8 2
Urethra 1 8 2
Heart Atrium 1 8 2
macrophage 0.999834547 8 2
Structure of medulla of kidney 0.99975182 8 2
Acute Promyelocytic Leukemia 0.999586367 8 2
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Acute myeloid leukemia with recurrent ge- 0.999586367 8 2
netic abnormality
Structure of cortex of kidney 0.9987591 8 2
Vagina 0.998676373 8 2
Structure of pyloric portion of stomach 0.99851092 8 2
Part of pyloric region 0.99851092 8 2
Pylorus 0.99851092 8 2
Oral mucous membrane structure 0.998180013 8 2
Body orifice mucosa 0.998180013 8 2
gastric fundus 0.9975182 8 2
Lymph 0.991727333 8 2
Proteobacteria 0.971376572 8 2
Gram-Negative Bacteria 0.971376572 8 2
Structure of bone (organ) 0.963807081 8 2
Type of bone 0.963807081 8 2
Vestibular nucleus structure 0.963352085 8 2
Pons part 0.963352085 8 2
Structure of vestibular system 0.963352085 8 2
Intracranial nerve structure 0.963352085 8 2
Structure of cranial nerve nucleus 0.963352085 8 2
pontine nuclei 0.963352085 8 2
Special sensory system 0.963352085 8 2
Pontine cranial nerve nucleus 0.963352085 8 2
Fibroblasts 0.960261071 4 4
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Coughing 0.959045289 16 1
T-Cell Lymphoma 0.914160608 4 4
T-cell lymphoma morphology 0.914160608 4 4
T-cell AND/OR NK-cell neoplasm 0.914160608 4 4
Persistent cough 0.953300166 15 1
Congenital chromosomal disease 0.893530774 8 2
Other condition due to autosomal anomaly 0.893530774 8 2
Autosomal hereditary disorder 0.893530774 8 2
Neoplasms, Complex and Mixed 0.893034414 8 2
Larynx and/or tracheal structures 0.998865838 7 2
Trachea 0.998865838 7 2
Musculoskeletal structure of upper limb 0.997259109 7 2
Skeletal muscle structure of upper limb 0.997259109 7 2
monocyte 0.995274325 7 2
Marrow Monocytes and Plasma Cells 0.995274325 7 2
Systemic venous structure 0.988752894 7 2
Type of vein 0.988752894 7 2
Lower extremity part 0.89877686 5 3
sperm cell 1 13 1
Meiotic cell 1 13 1
Germ Cells 1 13 1
Skeletal Muscular System (Muscles of 0.825520661 5 3
Trunk, Perineum and Lower Extremity)
Skeletal muscle structure of trunk 0.825520661 5 3
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Primary malignant neoplasm of endocrine 0.871603421 7 2
gland
Structure of region of lymphatic system 0.808595041 5 3
Structure of peripheral vein 1 6 2
Peripheral vascular system 1 6 2
Venous structure of limb 1 6 2
Saphenous Vein 1 6 2
Vascular structure of lower limb 1 6 2
Structure of pelvic and leg veins 1 6 2
Stromal Cells 1 12 1
Structure of vein of lower extremity 1 6 2
Structure of superficial vein of lower ex- 1 6 2
tremity
Vascular structure of limb 1 6 2
Structure of superficial vein 1 6 2
Heart Ventricle 0.999889771 6 2
White Adipose Tissue 0.999669312 6 2
Subcutaneous Fat 0.999669312 6 2
Subcutaneous Tissue 0.999669312 6 2
Chronic Lymphocytic Leukemia 0.999503968 6 2
Coronary artery 0.998567019 6 2
Mammary gland 0.992504409 6 2
Skin and subcutaneous tissue structure of 0.991407799 4 3
genitalia
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Male perineal structure 0.991407799 4 3
Skin and subcutaneous tissue structure of 0.991407799 4 3
pelvis
Glans penis and/or preputial structures 0.991407799 4 3
Skin structure of anogenital region 0.991407799 4 3
Skin and subcutaneous tissue structure of 0.991407799 4 3
perineum
Male genital organ part 0.991407799 4 3
Penis part 0.991407799 4 3
Structure of soft tissues of perineum 0.991407799 4 3
Soft tissues of pelvis 0.991407799 4 3
Skin structure of lower trunk 0.991407799 4 3
Skin of penis 0.991407799 4 3
Skin structure of male genitalia 0.991407799 4 3
SKIN OF PERINEUM AND GENITALIA 0.991407799 4 3
Skin structure of perineum 0.991407799 4 3
Skin structure of external genitalia 0.991407799 4 3
Skin of pelvis 0.991407799 4 3
Spermatic cord and/or male perineal struc- 0.991407799 4 3
tures
Skin structure of male perineum 0.991407799 4 3
Structure of skin and/or mucosa of anogen- 0.991407799 4 3
ital area
Foreskin of penis 0.991407799 4 3
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Skin of part of pelvic region 0.991407799 4 3
Skin of part of anogenital region 0.991407799 4 3
Skin of part of male external genitalia 0.991407799 4 3
Skin of part of genitalia 0.991407799 4 3
Skin of part of penis 0.991407799 4 3
PLACENTA AND MEMBRANES 0.980434303 6 2
Diffuse non-Hodgkin's lymphoma 0.948777264 4 3
Diffuse Large B-Cell Lymphoma 0.948777264 4 3
Diffuse large B-cell lymphoma - category 0.948777264 4 3
Benign neoplasm of intra-abdominal or- 1 11 1
gans
Benign neoplasm of adrenal gland 1 11 1
Benign neoplasm of adrenal cortex 1 11 1
Adrenal Cortical Adenoma 1 11 1
Benign neoplasm of retroperitoneum 1 11 1
Structure of subthalamic nucleus 0.971152398 11 1
Subthalamic structure 0.971152398 11 1
Neoplasms, Connective Tissue 0.706710744 5 3
Adenocarcinoma, Mucinous 0.954500286 11 1
Large blood vessel structure 0.85587522 6 2
Structure of great blood vessel (organ) 0.85587522 6 2
Type of vessel 0.85587522 6 2
SPECIFIC ENDOMETRIOSES 0.998609272 10 1
Endometriosis of uterus 0.998609272 10 1
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Endometriosis of pelvis 0.998609272 10 1
Cervical 0.997019868 10 1
Globus Pallidus 0.995397351 10 1
Malignant retroperitoneal tumor 0.824018959 6 2
Entire putamen 0.987636364 5 2
Neuroblastoma 0.976066116 5 2
Ewings sarcoma-primitive neuroectoder- 0.976066116 5 2
mal tumor (PNET)
[M]Miscellaneous tumor NOS 0.976066116 5 2
Skin tumor of neural origin 0.976066116 5 2
Oropharyngeal 0.966214876 5 2
Papillary adenocarcinoma 0.964635762 10 1
Anorectal structure 0.954834437 10 1
Lower bowel structures 0.954834437 10 1
Rectum 0.954834437 10 1
Pelvic alimentary structure 0.954834437 10 1
Complex mixed AND/OR stromal neo- 0.944330579 5 2
plasm
Body surface region 0.922049587 5 2
Sense Organs 1 9 1
Nose 1 9 1
Entire skeletal muscle (organ) 0.997136879 3 3
Monozygotic twins 0.994409504 9 1
Neurobehavioral Manifestations 0.990474089 9 1
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Mental Retardation 0.990474089 9 1
Chest wall structure 0.888859504 5 2
Part of chest wall 0.888859504 5 2
Entire nucleus of brain 0.926661518 9 1
Structure of large artery 0.828033058 5 2
Type of artery 0.828033058 5 2
High grade T-cell lymphoma morphology 0.89362405 3 3
Reticulosarcoma 0.89362405 3 3
Thigh structure 1 4 2
Structure of quadriceps femoris muscle 1 4 2
Structure of vastus lateralis muscle 1 4 2
Skeletal muscle structure of thigh 1 4 2
Skeletal muscle structure of hip 1 4 2
Muscle of hip AND thigh 1 4 2
Skeletal muscle structure of perineum 1 4 2
Thigh part 1 4 2
Skeletal muscle structure of lower limb 1 4 2
Entire quadriceps femoris muscle 1 4 2
Hip region structure 1 4 2
Entire vastus lateralis muscle 1 4 2
Skeletal muscle structure of pelvis 1 4 2
Cholelithiasis 0.999669093 8 1
Cholecystolithiasis 0.999669093 8 1
Calculi 0.999669093 8 1
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Biliary calculi 0.999669093 8 1
Multiple Sclerosis 0.999214097 8 1
Autoimmune Diseases of the Nervous Sys- 0.999214097 8 1
tem
Demyelinating Autoimmune Diseases, 0.999214097 8 1
CNS
Demyelinating Diseases 0.999214097 8 1
Demyelinating disease of central nervous 0.999214097 8 1
system
Deficiency anemias NOS 0.989920687 4 2
Anemia 0.989920687 4 2
Refractory anemias 0.989920687 4 2
Refractory anaemia with excess blasts 0.989920687 4 2
Dysmyelopoietic Syndromes 0.989920687 4 2
Other deficiency anemias NOS 0.989920687 4 2
Other anemias NOS 0.989920687 4 2
Red blood cell disorder 0.989920687 4 2
Anemia due to decreased red cell produc- 0.989920687 4 2
tion
Developmental delay (disorder) 0.989741893 8 1
Leukemia, Myelomonocytic, Acute 0.988873263 8 1
Nucleus Accumbens 0.988087359 8 1
[M] Complex mixed and stromal neoplasms 0.983559154 4 2
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Primary malignant neoplasm of retroperi- 0.781884298 5 2
toneum
Waldeyer's ring 0.972488434 4 2
Body region wall 0.972488434 4 2
Structure of lymphatic system of head and 0.972488434 4 2
neck
Lymphatic vessel 0.972488434 4 2
Wall of oropharynx 0.972488434 4 2
Structure of lymphatic vessel of head and 0.972488434 4 2
neck
Tonsil and adenoid structure 0.972488434 4 2
lymphatic system of head 0.972488434 4 2
lateral wall of oropharynx 0.972488434 4 2
Palatine Tonsil 0.972488434 4 2
Low grade B-cell lymphoma 0.964144085 4 2
Uterine Cancer 0.769586777 5 2
Cancer of uterus and cervix 0.769586777 5 2
Virus Diseases 0.95935228 4 2
Specific viral infections 0.95935228 4 2
Firmicutes 0.925644415 4 2
Bacilli class 0.925644415 4 2
Gram-Positive Bacteria 0.925644415 4 2
Extra-embryonic structure 0.781081379 3 3
Bone structure of spine and/or pelvis 1 7 1
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hip bone 1 7 1
Bone structure of ilium 1 7 1
Bone part 1 7 1
Ilium part 1 7 1
Iliac crest structure 1 7 1
Structure of flat bone 1 7 1
Bone structure of pelvic region and/or 1 7 1
thigh
Bony pelvis 1 7 1
Campylobacterales 0.999621946 7 1
Helicobacter 0.999621946 7 1
HCT116 Cells 0.999621946 7 1
Helicobacteraceae 0.999621946 7 1
Epsilonproteobacteria 0.999621946 7 1
Colonic epithelium 0.999621946 7 1
Colonic mucous membrane 0.999621946 7 1
Structure of intestinal epithelium 0.999621946 7 1
Subclass Aerobic-Microaerophilic, Motile 0.999621946 7 1
Curved Gram-Negative Bacteria
[M]Adenocarcinoma, metastatic, NOS 0.872559563 8 1
Pancreas 0.865251157 4 2
Congenital hypergammaglobulinemia 0.982987571 7 1
Job's Syndrome 0.982987571 7 1
Congenital immunodeficiency disease 0.982987571 7 1
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Qualitative abnormality of granulocyte 0.982987571 7 1
Disorder of neutrophils 0.982987571 7 1
Immunologic Deficiency Syndromes 0.982987571 7 1
Non-malignant white cell disorder 0.982987571 7 1
Chemotactic disorder 0.982987571 7 1
Autosomal recessive hereditary disorder 0.982987571 7 1
Phagocyte Bactericidal Dysfunction 0.982987571 7 1
Abdominal bloating 0.973772506 7 1
Flatulence, eructation, and gas pain 0.973772506 7 1
[D]Gas pain (abdominal) 0.973772506 7 1
Pain of digestive structure 0.973772506 7 1
Metastatic Carcinoma 0.951420065 7 1
Hela Cells 1 3 2
medulloblastoma 1 6 1
Primary malignant neoplasm of thyroid 0.999614198 6 1
gland
Papillary thyroid carcinoma 0.999614198 6 1
Primary malignant neoplasm of neck 0.999614198 6 1
Structure of deltoid muscle 0.99928351 6 1
Structure of skeletal muscle of shoulder 0.99928351 6 1
Carcinoma, Transitional Cell 0.998126102 6 1
Transitional Cell Neoplasm 0.998126102 6 1
[M]Transitional cell papilloma or carci- 0.998126102 6 1
noma NOS
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Upper urinary tract structure 0.998126102 6 1
Upper genitourinary tract structure 0.998126102 6 1
Papillary serous cystadenocarcinoma 0.992504409 6 1
Entire substantia nigra 0.984032596 3 2
Gastrointestinal Hemorrhage 0.968065191 3 2
Maintenance chemotherapy; radiotherapy 0.964891975 6 1
Chemotherapy Regimen 0.964891975 6 1
Upper gastrointestinal disorders 0.944169144 3 2
Neoplasms, Muscle Tissue 0.916969497 3 2
Malignant myomatous tumor 0.916969497 3 2
Superior mediastinum 0.909150975 3 2
Osseous AND/OR chondromatous neo- 0.843078956 3 2
plasm
Amniotic Fluid 1 5 1
Pneumocyte 0.999867769 5 1
Macrophages, Alveolar 0.999867769 5 1
Mononuclear phagocyte system 0.999867769 5 1
Colonic Diseases, Functional 0.998942149 5 1
Irritable Bowel Syndrome 0.998942149 5 1
Renal collecting system structure 0.997487603 5 1
Renal pelvis 0.997487603 5 1
Complex epithelial neoplasm 0.926479339 5 1
Hereditary disorder by system 0.685827552 3 2
Cancer of Head 1 4 1
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Skin and subcutaneous tissue structure of 0.998182419 4 1
chest
Skin structure of breast 0.998182419 4 1
Anterior chest wall structure 0.998182419 4 1
Structure of soft tissues of thorax 0.998182419 4 1
Skin of chest 0.998182419 4 1
Skin structure of nipple 0.998182419 4 1
Skin structure of upper trunk 0.998182419 4 1
Structure of surface region of thorax 0.998182419 4 1
Skin of anterior surface of thorax 0.998182419 4 1
Skin of anterolateral surface of thorax 0.998182419 4 1
Nipple part 0.998182419 4 1
Skin of part of front of thorax 0.998182419 4 1
Skin of part of breast 0.998182419 4 1
Skin of part of thorax 0.998182419 4 1
Skin of part of anterolateral surface of tho- 0.998182419 4 1
rax
Precursor B-cell neoplasm 0.997769332 4 1
Precursor B-cell lymphoblastic leukemia 0.997769332 4 1
Precursor B-lymphoblastic 0.997769332 4 1
leukemia/lymphoblastic lymphoma
Other and unspecified gastrointestinal dis- 0.991242564 4 1
orders
Constipation 0.991242564 4 1
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Squamous epithelial cell 0.983972241 4 1
Adenocarcinoma of pelvis 0.982650364 4 1
Primary malignant neoplasm of kidney 0.982650364 4 1
Renal glomerular disease 0.982650364 4 1
RENAL GLOMERULAR AND TUBU- 0.982650364 4 1
LOINTERSTITIAL DISEASES
Renal Cell Carcinoma 0.982650364 4 1
Malignant tumor of kidney parenchyma 0.982650364 4 1
Adenosquamous carcinoma 0.943985459 4 1
Neoplasm of cerebrum 0.419337077 3 3
Transitional epithelial cell 0.894828156 4 1
Primary malignant neoplasm of intratho- 0.593436846 3 2
racic organs
Primary malignant neoplasm of lung 0.593436846 3 2
Primary malignant neoplasm of respira- 0.593436846 3 2
tory tract
Tongue part 0.883179114 4 1
Tongue surface region 0.883179114 4 1
Papilla of tongue 0.883179114 4 1
Dorsum of tongue 0.883179114 4 1
Systemic artery of trunk 0.882187707 4 1
Aorta 0.882187707 4 1
Synovial Fluid 1 3 1
Lactobacillales 1 3 1
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Streptococcaceae 1 3 1
Streptococcus 1 3 1
Synovial fluid mononuclear cell 1 3 1
ileum 1 3 1
Diffuse low grade B-cell lymphoma 1 3 1
Marginal Zone B-Cell Lymphoma 1 3 1
Catalase-negative Gram-positive coccus 1 3 1
Facultative anaerobic bacteria 1 3 1
Fastidious bacteria 1 3 1
Gram-Positive Cocci 1 3 1
Fastidious bacterium 1 3 1
Cocci 1 3 1
mucosa-associated lymphoid tissue lym- 1 3 1
phoma
Rhinovirus infection 0.9994494 3 1
Abnormal coordination 0.9994494 3 1
Dyskinetic syndrome 0.9994494 3 1
Ataxia 0.9994494 3 1
RNA Virus Infections 0.9994494 3 1
Picornaviridae Infections 0.9994494 3 1
Joint and/or tendon synovial structure 0.99867856 3 1
Synovial joint structure 0.99867856 3 1
Structure of synovial tissue of joint 0.99867856 3 1
Rectum and sigmoid colon 0.997467239 3 1
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Table 7.2: GO terms associated with the top 250 differentially expressed soft tissue genes





























platelet-derived growth factor binding
collagen fibril organization




Entire entorhinal cortex 0.996476159 3 1
Hemoptysis 0.980839115 3 1
Respiratory tract hemorrhage 0.980839115 3 1
Myositis 0.971038432 3 1
Polymyositis 0.971038432 3 1
Dermatomyositis 0.971038432 3 1
Rheumatic and Collagen Muscle Diseases 0.971038432 3 1
and Syndromes
Dermatomyositis, Childhood Type 0.971038432 3 1

















































multicellular organismal metabolic process
extracellular matrix part




structural constituent of cytoskeleton
response to inorganic substance
osteoblast differentiation














































































response to abiotic stimulus
extracellular region
extracellular space






response to hormone stimulus
response to endogenous stimulus












response to external stimulus
anatomical structure development
response to chemical stimulus
developmental process
response to stress
Table 7.3: GO terms associated with the top 250 differentially expressed brain genes.
















































anion transmembrane transporter activity
neuron projection morphogenesis







































































Table 7.4: GO terms associated with the top 250 differentially expressed blood genes.










































alpha-beta T cell receptor complex
respiratory burst




T cell receptor complex
regulation of antigen receptor-mediated signaling
pathway




defense response to Gram-positive bacterium
response to fungus
cellular defense response
nucleotide receptor activity, G-protein coupled
purinergic nucleotide receptor activity, G-protein
coupled
non-membrane spanning protein tyrosine kinase
activity
































































positive regulation of cell activation
leukocyte activation
response to other organism
external side of plasma membrane
positive regulation of immune system process
cell activation
regulation of lymphocyte activation
regulation of cell activation
regulation of leukocyte activation
inflammatory response
regulation of immune system process
behavior












































response to external stimulus
integral to plasma membrane

















Table 7.5: GO terms associated with the DNA replication / cell cycle SCGS expression module










































































establishment of organelle localization
chromosome localization
establishment of chromosome localization
regulation of cell cycle
microtubule-based process
mitotic cell cycle checkpoint
organelle localization
DNA metabolic process










































attachment of spindle microtubules to chromo-
some
regulation of mitotic cell cycle
establishment of mitotic spindle localization
DNA-dependent DNA replication
mitotic metaphase plate congression
establishment of spindle localization
spindle localization
mitotic chromosome movement towards spindle
pole
positive regulation of chromosome segregation
positive regulation of attachment of spindle mi-
crotubules to kinetochore




regulation of cell cycle process
positive regulation of organelle organization
DNA replication
'de novo' IMP biosynthetic process
positive regulation of mitotic
metaphase/anaphase transition














































regulation of attachment of spindle microtubules
to kinetochore




positive regulation of mitosis
spindle assembly




DNA-dependent DNA replication initiation
positive regulation of cell cycle
mitotic cell cycle G2/M transition DNA damage
checkpoint
protein localization to kinetochore
maintenance of DNA repeat elements
positive regulation of helicase activity
mitotic cell cycle G2/M transition checkpoint
cytoskeleton organization
response to DNA damage stimulus
somatic diversification of immune receptors via so-
matic mutation



















































G2/M transition of mitotic cell cycle
RNA 3'-end processing
establishment of mitotic spindle orientation
regulation of helicase activity
establishment of spindle orientation
centrosome organization
determination of adult lifespan
regulation of G2/M transition of mitotic cell cycle
negative regulation of DNA recombination
microtubule organizing center organization
positive regulation of cell cycle process
cellular component organization
nucleic acid metabolic process
cellular response to stimulus
DNA unwinding involved in replication
regulation of chromosome segregation
multicellular organismal aging
positive regulation of histone modification
mitotic cell cycle spindle checkpoint
nucleobase, nucleoside, nucleotide and nucleic
acid metabolic process
cellular response to stress
DNA conformation change











































regulation of nuclear division
maintenance of protein location in cell
purine nucleoside monophosphate biosynthetic
process
purine ribonucleoside monophosphate biosyn-
thetic process
spindle checkpoint
G1/S transition of mitotic cell cycle
positive regulation of cellular component organi-
zation
maintenance of protein location
DNA geometric change
DNA duplex unwinding
nitrogen compound metabolic process
maintenance of location in cell
regulation of organelle organization
gene silencing
mismatch repair
G2/M transition DNA damage checkpoint
purine nucleoside monophosphate metabolic pro-
cess
purine ribonucleoside monophosphate metabolic
process














































regulation of mRNA stability involved in response
to stress
neural plate mediolateral regionalization





paraxial mesoderm structural organization
regulation of chromosome condensation
cellular response to iron ion
cellular response to iron(III) ion
somatic recombination of immunoglobulin genes
involved in immune response
somatic diversification of immunoglobulins in-
volved in immune response
mitotic metaphase/anaphase transition
ribonucleoside monophosphate biosynthetic pro-
cess












































negative regulation of macromolecule metabolic
process
cell proliferation
immunoglobulin production involved in im-
munoglobulin mediated immune response
chromatin silencing
chromosome condensation
negative regulation of cellular component organi-
zation
ribonucleoside monophosphate metabolic process
somatic recombination of immunoglobulin gene
segments
regulation of DNA recombination
negative regulation of gene expression, epigenetic
regulation of gene expression, epigenetic
DNA repair
negative regulation of metabolic process
negative regulation of organelle organization
somatic diversification of immunoglobulins
DNA damage response, signal transduction result-










































branched chain family amino acid biosynthetic
process
response to iron(III) ion
DNA methylation on cytosine within a CG se-
quence
DNA methylation on cytosine
regulation of histone phosphorylation
lateral mesoderm morphogenesis
lateral mesoderm formation
lateral mesodermal cell differentiation
lateral mesodermal cell fate commitment
lateral mesodermal cell fate specification
regulation of lateral mesodermal cell fate specifi-
cation
mesendoderm development
positive regulation of histone H3-K4 methylation
neural plate regionalization
regulation of vitamin D receptor signaling path-
way
spindle assembly involved in mitosis

















































somatic diversification of immune receptors via
germline recombination within a single locus




somatic diversification of immune receptors
stem cell differentiation
negative regulation of protein metabolic process
maintenance of chromatin silencing
miRNA metabolic process
miRNA catabolic process
positive regulation of mRNA 3'-end processing
S-adenosylmethioninamine metabolic process
lateral mesoderm development
positive regulation of mRNA processing
centrosome separation
negative regulation of histone H3-K9 methylation
neural plate pattern specification
heart formation
regulation of microtubule cytoskeleton organiza-
tion
negative regulation of cellular metabolic process
DNA recombination
















































regulation of nervous system development





DNA replication, synthesis of RNA primer
methylation-dependent chromatin silencing
positive regulation of histone methylation
regulation of mRNA 3'-end processing
regulation of mesodermal cell fate specification
negative regulation of MHC class II biosynthetic
process
regulation of histone H3-K9 methylation
hemopoietic stem cell differentiation
regulation of mitotic spindle organization
vitamin D receptor signaling pathway
mesenchyme morphogenesis
regulation of microtubule-based process
positive regulation of cytoskeleton organization
growth
response to drug
negative regulation of protein modification pro-
cess


















































regulation of cell development
response to abiotic stimulus
endocardial cushion development
mesodermal cell fate specification
positive regulation of receptor biosynthetic pro-
cess
otic vesicle formation
negative regulation of histone methylation
intra-S DNA damage checkpoint
kinetochore assembly
regulation of histone H3-K4 methylation
CRD-mediated mRNA stabilization
cellular response to vitamin D
cellular response to fatty acid
cellular response to oxygen levels
cellular response to hypoxia
otic vesicle development
otic vesicle morphogenesis
regulation of spindle organization
establishment or maintenance of cell polarity
response to organic cyclic substance
cellular process
cellular macromolecule metabolic process
regulation of cellular protein metabolic process













































regulation of cyclin-dependent protein kinase ac-
tivity
response to UV
regulation of cellular metabolic process
histone modification










positive regulation of SMAD protein nuclear
translocation















































positive regulation of cellular protein metabolic
process
forebrain development
response to ionizing radiation
regulation of ubiquitin-protein ligase activity in-
volved in mitotic cell cycle
regulation of protein localization
cellular metabolic process










ventricular cardiac muscle cell development
positive regulation of cardiac muscle cell prolifer-
ation
regulation of SMAD protein nuclear translocation
cellular response to organic cyclic substance
immunoglobulin mediated immune response

















































positive regulation of protein metabolic process
dorsal/ventral axis specification





regulation of cell fate specification
response to organic nitrogen
cellular localization
negative regulation of cell cycle
regulation of protein metabolic process
mesodermal cell fate commitment
postreplication repair
double-strand break repair via nonhomologous
end joining
regulation of gene expression by genetic imprint-
ing
mRNA polyadenylation
regulation of receptor biosynthetic process
negative regulation of histone modification
nose development
regulation of MHC class II biosynthetic process
















































cellular response to metal ion
genetic imprinting
male sex differentiation
regulation of ubiquitin-protein ligase activity
phosphoinositide-mediated signaling
mRNA cleavage
MHC class II biosynthetic process
mesodermal cell differentiation
ventricular cardiac muscle cell differentiation
regulation of cellular component organization
regulation of ligase activity
negative regulation of biological process




response to dietary excess
mitotic chromosome condensation
mitotic cell cycle spindle assembly checkpoint
branched chain family amino acid catabolic pro-
cess
positive regulation of collagen metabolic process













positive regulation of developmental process
response to stress
Term











































activation of adenylate cyclase activity by sero-
tonin receptor signaling pathway
protein amino acid nitrosylation
peptidyl-cysteine S-nitrosylation
positive regulation of cell fate specification
formaldehyde catabolic process
peripheral nervous system neuron axonogenesis
small molecule metabolic process
cofactor biosynthetic process
cellular amino acid metabolic process
mRNA metabolic process
mitotic spindle elongation














































D-amino acid catabolic process









regulation of translational initiation
regulation of exocytosis
tRNA aminoacylation for protein translation
amino acid activation
tRNA aminoacylation




peptidyl-diphthamide biosynthetic process from
peptidyl-histidine
peptidyl-cysteine methylation
D-amino acid metabolic process
















































small molecule catabolic process
organic acid metabolic process
cellular ketone metabolic process
coenzyme metabolic process
rhythmic process
outer mitochondrial membrane organization
negative regulation by host of viral transcription
peripheral nervous system neuron development
response to nitrosative stress
mitochondrial outer membrane translocase com-
plex assembly
translational initiation
cellular amine metabolic process
cell proliferation in hindbrain
cell proliferation in the external granule layer
granule cell precursor proliferation
negative regulation of translational initiation in
response to stress
peripheral nervous system neuron differentiation
ethanol metabolic process
ethanol oxidation
serotonin receptor signaling pathway













































negative regulation of viral transcription
monohydric alcohol metabolic process
mammary gland epithelial cell differentiation
cellular amino acid catabolic process
modulation by host of viral transcription
regulation of retinal cell programmed cell death
response to redox state
modulation of transcription in other organism in-
volved in symbiotic interaction




cellular amino acid and derivative metabolic pro-
cess
folic acid and derivative biosynthetic process
NAD biosynthetic process
peptidyl-histidine modification
regulation of translational initiation in response
to stress
tetrahydrofolate metabolic process
retinal cell programmed cell death












































cellular macromolecular complex assembly
cell migration involved in sprouting angiogenesis
regulation of cell fate commitment
nicotinamide nucleotide biosynthetic process
regulation of granule cell precursor proliferation
positive regulation of granule cell precursor pro-
liferation
negative regulation of cAMP metabolic process
negative regulation of cAMP biosynthetic process
regulation of cell fate specification
regulation of translation in response to stress
G-protein signaling, coupled to cAMP nucleotide
second messenger
gliogenesis
negative regulation of cyclic nucleotide metabolic
process
negative regulation of cyclic nucleotide biosyn-
thetic process
negative regulation of nucleotide biosynthetic pro-
cess














































positive regulation of Rac GTPase activity
prophase
modification by host of symbiont morphology or
physiology
ncRNA metabolic process
regulation of adenylate cyclase activity
amine metabolic process
RNA splicing, via transesterification reactions
with bulged adenosine as nucleophile
nuclear mRNA splicing, via spliceosome
regulation of cyclase activity
regulation of lyase activity
acetyl-CoA biosynthetic process from pyruvate
branched chain family amino acid catabolic pro-
cess
regulation of acetyl-CoA biosynthetic process
from pyruvate





















































positive regulation of blood vessel endothelial cell
migration
negative regulation of translational initiation
regulation of viral transcription
regulation of cardiac muscle tissue growth
regulation of cardiac muscle tissue development
regulation of cardiac muscle cell proliferation
cellular metabolic process
RNA splicing, via transesterification reactions
acetyl-CoA biosynthetic process
C21-steroid hormone biosynthetic process
folic acid and derivative metabolic process
regulation of cofactor metabolic process
regulation of coenzyme metabolic process
cellular macromolecular complex subunit organi-
zation
regulation of cAMP biosynthetic process
oligodendrocyte development
regulation of calcium ion-dependent exocytosis
viral genome expression
viral transcription
pyridine nucleotide biosynthetic process
regulation of heart growth
cAMP biosynthetic process
















regulation of cell cycle
microtubule-based movement
negative regulation of protein secretion
interaction with symbiont
tRNA metabolic process
G-protein signaling, coupled to cyclic nucleotide
second messenger
Term































purine nucleoside metabolic process
purine ribonucleoside metabolic process
tRNA export from nucleus
response to light intensity
bis(5'-nucleosidyl) oligophosphate biosynthetic
process
diadenosine polyphosphate biosynthetic process
diadenosine tetraphosphate metabolic process
diadenosine tetraphosphate biosynthetic process























































chromatin silencing at telomere
glycyl-tRNA aminoacylation
isoleucyl-tRNA aminoacylation
C-terminal protein amino acid methylation
formate metabolic process
peptide or protein carboxyl-terminal blocking
tRNA 3'-end processing
ribonucleoside metabolic process
nucleobase, nucleoside and nucleotide metabolic
process
internal protein amino acid acetylation
bis(5'-nucleosidyl) oligophosphate metabolic pro-
cess
diadenosine polyphosphate metabolic process
myelination in the central nervous system
















































positive regulation of hair follicle development
nucleoside metabolic process
G-protein signaling, coupled to cGMP nucleotide
second messenger
regulation of gonadotropin secretion
negative regulation of gonadotropin secretion
embryonic cleavage
regulation of follicle-stimulating hormone secre-
tion
negative regulation of follicle-stimulating hor-
mone secretion
regulation of hair follicle development
hemopoietic stem cell differentiation
multicellular organism growth
myelin assembly
negative regulation of activin receptor signaling
pathway























































positive regulation of cGMP metabolic process
nucleotide-excision repair, DNA incision
cellular metabolic process
signal peptide processing
folic acid and derivative biosynthetic process
erythrocyte maturation
regulation of translational initiation in response
to stress
positive regulation of epidermis development
tetrahydrofolate metabolic process
small molecule metabolic process
nucleoside biosynthetic process
cGMP-mediated signaling
purine nucleoside biosynthetic process
ribonucleoside biosynthetic process
regulation of translation in response to stress
regulation of endocrine process
purine ribonucleoside biosynthetic process
UV protection
peptidyl-asparagine modification
protein amino acid N-linked glycosylation via as-
paragine
hair follicle maturation



















































establishment of tissue polarity
protein amino acid glycosylation
macromolecule glycosylation
glycosylation
regulation of activin receptor signaling pathway
erythrocyte development
cellular biosynthetic process
cellular macromolecule metabolic process
folic acid and derivative metabolic process





cellular aromatic compound metabolic process
activin receptor signaling pathway
biosynthetic process
response to light stimulus














































negative regulation of macromolecule biosynthetic
process
hair follicle morphogenesis
cellular amino acid and derivative metabolic pro-
cess
negative regulation of cellular biosynthetic process
endoplasmic reticulum unfolded protein response
cellular response to unfolded protein
chordate embryonic development
negative regulation of biosynthetic process
embryo development ending in birth or egg hatch-
ing
nucleotide-excision repair, DNA damage removal
Wnt receptor signaling pathway, calcium modu-
lating pathway















































antigen processing and presentation of peptide or
polysaccharide antigen via MHC class II
regulation of leukocyte mediated cytotoxicity
negative regulation of leukocyte mediated cyto-
toxicity
regulation of cell killing
negative regulation of cell killing
gamma-delta T cell differentiation
regulation of gamma-delta T cell differentiation
positive regulation of gamma-delta T cell differ-
entiation
regulation of gamma-delta T cell activation
positive regulation of gamma-delta T cell activa-
tion
leukocyte mediated cytotoxicity
negative regulation of leukocyte mediated immu-
nity
negative regulation of lymphocyte mediated im-
munity
positive regulation of humoral immune response











































gamma-delta T cell activation
positive regulation of humoral immune response
regulation of humoral immune response mediated
by circulating immunoglobulin
regulation of lymphocyte mediated immunity
antigen processing and presentation
positive regulation of B cell mediated immunity
positive regulation of immunoglobulin mediated
immune response
cell killing
regulation of leukocyte mediated immunity
regulation of humoral immune response
biological regulation
regulation of biological process
regulation of natural killer cell mediated immu-
nity
regulation of natural killer cell mediated cytotox-
icity
positive regulation of leukocyte mediated cytotox-
icity
negative regulation of immune effector process
regulation of cellular process
response to stimulus
positive regulation of cell killing




































negative regulation of immune system process
regulation of B cell mediated immunity
regulation of immunoglobulin mediated immune
response
immune effector process
natural killer cell mediated immunity
natural killer cell mediated cytotoxicity
regulation of immune effector process
positive regulation of adaptive immune response
based on somatic recombination of immune recep-
tors built from immunoglobulin superfamily do-
mains
negative regulation of immune response
lymphocyte mediated immunity
positive regulation of adaptive immune response
positive regulation of T cell differentiation
positive regulation of leukocyte mediated immu-
nity
positive regulation of lymphocyte mediated im-
munity
osteoclast proliferation
CD4-positive, CD25-positive, alpha-beta regula-
tory T cell differentiation




































regulation of natural killer cell cytokine produc-
tion
positive regulation of natural killer cell cytokine
production
detection of hormone stimulus
detection of endogenous stimulus
regulation of CD4-positive, CD25-positive, alpha-
beta regulatory T cell differentiation
positive regulation of CD4-positive, CD25-
positive, alpha-beta regulatory T cell differenti-
ation
glycoprotein transport
positive regulation of membrane potential
diapedesis
dichotomous subdivision of terminal units in-
volved in lung branching
positive regulation of lymphocyte differentiation
regulation of alpha-beta T cell activation
humoral immune response mediated by circulat-
ing immunoglobulin
elevation of cytosolic calcium ion concentration
leukocyte mediated immunity
regulation of biological quality







































cytosolic calcium ion homeostasis
negative regulation of T cell mediated cytotoxicity
negative regulation of natural killer cell mediated
immunity
Arp2/3 complex-mediated actin nucleation
positive regulation of regulatory T cell differenti-
ation
negative regulation of natural killer cell mediated
cytotoxicity
regulation of B cell receptor signaling pathway
defense response to virus
positive regulation of immune effector process
calcium ion transport into cytosol
alpha-beta T cell activation
cytosolic calcium ion transport
regulation of T cell differentiation
regulation of adaptive immune response based on
somatic recombination of immune receptors built
from immunoglobulin superfamily domains
regulation of localization
regulation of adaptive immune response
desensitization of G-protein coupled receptor pro-











































positive regulation of cholesterol biosynthetic pro-
cess
regulation of regulatory T cell differentiation
regulation of transcription, mitotic
positive regulation of transcription, mitotic
regulation of transcription from RNA polymerase
II promoter, mitotic
positive regulation of transcription from RNA
polymerase II promoter, mitotic
induction of apoptosis
induction of programmed cell death
regulation of lymphocyte differentiation
chemical homeostasis
regulation of innate immune response
negative regulation of T cell mediated immunity
regulation of osteoblast proliferation
heterotypic cell-cell adhesion
positive regulation of cholesterol metabolic pro-
cess
production of molecular mediator of immune re-
sponse
leukocyte differentiation
cellular calcium ion homeostasis











































negative regulation of nitric oxide biosynthetic
process
regulatory T cell differentiation
positive regulation of antigen receptor-mediated
signaling pathway
immunoglobulin mediated immune response
calcium ion homeostasis
B cell mediated immunity
cellular metal ion homeostasis
positive regulation of T cell activation
positive regulation of T cell mediated cytotoxicity
activation of transmembrane receptor protein ty-
rosine kinase activity
negative regulation of cholesterol storage




positive thymic T cell selection
positive regulation of isotype switching to IgG iso-
types
phospholipid homeostasis














































positive regulation of intracellular protein kinase
cascade
humoral immune response
regulation of T cell mediated cytotoxicity
G-protein coupled receptor internalization
cAMP catabolic process
negative regulation of interferon-gamma produc-
tion
negative thymic T cell selection
negative regulation of innate immune response




initiation of signal transduction
signal initiation by diffusible mediator
signal initiation by protein/peptide mediator
positive regulation of MAPKKK cascade
regulation of cholesterol esterification
intracellular lipid transport
myeloid dendritic cell differentiation
positive T cell selection
negative T cell selection









































regulation of isotype switching to IgG isotypes
cellular di-, tri-valent inorganic cation homeosta-
sis
defense response
regulation of immune response
T cell differentiation
negative regulation of adaptive immune response
negative regulation of adaptive immune response
based on somatic recombination of immune recep-
tors built from immunoglobulin superfamily do-
mains
cyclic nucleotide catabolic process
positive regulation of steroid biosynthetic process
amyloid precursor protein catabolic process
positive regulation of CD4-positive, alpha beta T
cell differentiation
regulation of cholesterol biosynthetic process
positive regulation of isotype switching
regulation of mitochondrial membrane permeabil-
ity
isotype switching to IgG isotypes
positive regulation of cell differentiation
di-, tri-valent inorganic cation homeostasis
positive regulation of apoptosis















































positive regulation of cell death
T cell mediated cytotoxicity
diuresis
phospholipid efflux
low-density lipoprotein particle remodeling
positive regulation of DNA recombination
cellular cation homeostasis
positive regulation of lymphocyte activation
myeloid dendritic cell activation
desensitization of G-protein coupled receptor pro-
tein signaling pathway
positive regulation of cytokine production in-
volved in immune response
positive regulation of epithelial cell migration
negative adaptation of signaling pathway
adaptation of signaling pathway
protein destabilization














































negative regulation of peptidyl-tyrosine phospho-
rylation
B cell receptor signaling pathway
intracellular transport
positive regulation of signal transduction
maintenance of location
positive regulation of signaling process
negative regulation of cytokine-mediated signal-
ing pathway
positive regulation of T cell mediated immunity
renal water homeostasis
nucleoside monophosphate catabolic process
regulation of cholesterol storage
regulation of alpha-beta T cell proliferation
decidualization
regulation of cholesterol metabolic process
adaptive immune response based on somatic re-
combination of immune receptors built from im-
munoglobulin superfamily domains
positive regulation of leukocyte activation
G-protein signaling, coupled to cyclic nucleotide
second messenger
trophectodermal cell differentiation










































negative regulation of macrophage derived foam
cell differentiation
cholesterol storage
regulation of CD4-positive, alpha beta T cell dif-
ferentiation
regulation of isotype switching
regulation of B cell differentiation
multicellular organismal water homeostasis
adaptive immune response
regulation of T cell activation
negative regulation of response to stimulus
positive regulation of cell activation
positive regulation of natural killer cell mediated
immunity
epithelial cell migration
regulation of epithelial cell migration
negative regulation of lipid storage
high-density lipoprotein particle remodeling
retrograde transport, endosome to Golgi
cytoplasmic sequestering of transcription factor
positive regulation of natural killer cell mediated
cytotoxicity
regulation of antigen receptor-mediated signaling
pathway























































positive regulation of production of molecular me-
diator of immune response
negative regulation of protein binding
alpha-beta T cell proliferation
leukocyte proliferation
regulation of lipid metabolic process
establishment of localization in cell
regulation of T cell mediated immunity
amyloid precursor protein metabolic process
negative regulation of insulin secretion




regulation of cell differentiation
regulation of homeostatic process
reverse cholesterol transport
T cell selection
positive regulation of steroid metabolic process








































protein import into nucleus
cyclic-nucleotide-mediated signaling
homeostatic process
regulation of intracellular protein kinase cascade
nuclear import
negative regulation of peptide secretion
glycoprotein catabolic process
water homeostasis
positive regulation of actin filament polymeriza-
tion
positive regulation of alpha-beta T cell differenti-
ation
cytoplasmic sequestering of protein
response to corticosterone stimulus
epithelial tube branching involved in lung mor-
phogenesis
regulation of metabolic process
negative regulation of protein modification pro-
cess
hemopoietic or lymphoid organ development
blastocyst formation
regulation of cytokine production involved in im-
mune response
































placenta blood vessel development
cyclic nucleotide metabolic process
CD4-positive, alpha beta T cell differentiation
transport
intracellular protein kinase cascade
signal transmission via phosphorylation event
positive regulation of developmental process
negative regulation of protein import into nucleus
negative regulation of G-protein coupled receptor
protein signaling pathway
protein transport
protein localization in nucleus
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